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Genomic imprinting plays a vital role in normal mammalian growth and development. Normal 
expression of imprinted genes is highly dependent on parental-specific methylation at the 
differentially-methylated regions known as imprinting control regions.  Imprinting control 
regions often regulate the parental-specific expression of a number of nearby imprinted 
genes. Abnormal expression of these imprints is caused by chromosomal anomaly or an 
epimutation such as loss of methylation at the imprinted control region. Using human and 
mouse model systems I investigated the mechanisms behind imprinting and imprinting- like 
disorders. 
Firstly, I utilised the chromosomally stable human fibroblast cell line hTERT-1604 with a long-
term depletion of the maintenance methylation enzymes DNMT1 and UHRF1. I present data 
showing that the long-term knockdown of DNMT1 results in an interesting cross-talk between 
the gametic and somatic DMRs at a subset of imprinted clusters. Further to this, I show the 
depletion of UHRF1 results in loss of imprinting with the inability to recover upon the rescue 
of the WT protein.  
I also took the opportunity to use publicly available datasets and a bespoke in-house Galaxy 
workflow to score abnormal methylation variability across patient samples and described a 
methylation index to detect epimutations in imprinting disorders. Not only was it able to 
detect the same epimutations as the wet-lab technique that was previously used to diagnose 
the patient samples, but the methylation index also detected epimutations in patient samples 
that were not previously diagnosed at the molecular level.  
Finally, with the help of CRISPR-generated mouse models, I was able to describe a novel role 
for the PHD domain of Uhrf1 in the maintenance of genomic imprinting during embryonic 
development. Furthermore, I also contributed to the literature in support of Uhrf1’s role in 
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Chapter 1- General Introduction  
Genomic imprinting is the epigenetic phenomenon in which genes are expressed in a parent 
of origin manner.  Epigenetics is the term given to the study of heritable alterations to 
genomic DNA that affect expression without changing the DNA sequence.  These epigenetic 
regulators include chromatin and histone modifications and DNA methylation. While some 
sources include long non-coding RNAs (lncRNA) and microRNAs, these act at post-
transcriptional levels and are not heritable through cell division and so are not regarded as 
epigenetic controllers by most researchers. The parental-specific expression seen at 
imprinted loci is largely controlled by the presence of imprinting control regions. These 
regions are differentially methylated regions that have been shown to have a functional 
effect. As the differentially methylated regions play an important role in the regulation of 
imprinted genes, this thesis will focus on the mechanistic action behind these regions. 
However, in this introduction, I will cover the basics behind methylation such as the 
establishment and maintenance of methylation as well as how aberrant methylation patterns 
can lead to imprinting disorders. This thesis will be investigating the changes of methylation 
seen at Differentially methylated regions (DMRs) with different models utilizing wet-lab 
techniques and publicly available datasets. Understanding the mechanisms that drive 
methylation at these DMRs and how they react to different models will help to understand 
the imprinted disorders related to these DMRs.  
1.1 Addition, maintenance and loss of DNA methylation patterns 
DNA methylation is the main contributor to the parental specific expression seen in imprinted 
genes through silencing or expression of imprinted genes through methylation or lack of 
methylation at differential methylated regions (DMRs) (Barlow and Bartolomei, 2014). DNA 
methylation was first discovered in 1925 in tubercle bacillus, though it was not until 1975 
when it was found to regulate gene expression (Holliday and Pugh, 1975; Johnson and Coghill, 
1925). Methylation is the addition of a methyl group to the 5’ carbon, primarily at a cytosine 
and guanine dinucleotide (CG). The methyl group is transferred to the 5’ carbon position of 
the cytosine base from the universal donor S-adenosyl methionine (SAM) (Gibney and Nolan, 





be methylated (Larsen et al., 1992). It is believed that the lack of CGs in the human genome 
could be credited to the inefficiency of the base excision repair (BER) pathway (Walsh and Xu, 
2006). This comes about due to the hypermutability of CG sites in which the methylcytosine 
can deaminate to thymine resulting in a thymine guanine (TG) dinucleotide (Bird, 1980; 
Coulondre et al., 1978). When the TG mutation is not repaired this will transition into an 
adenine guanine dinucleotide and lead to loss of the CG site (Walsh and Xu, 2006). This is 
thought to have led, over time, to the loss of CG dinucleotides in most of the genome of 
organisms with cytosine methylation, but the preservation of CpG islands, where the cytosine 
is never methylated.  Though CG methylation is the most predominant and most investigated 
form of methylation, it is important to note non-CG methylation occurs in some abundance 
in stem cells, oocytes and brain cells, though it can be found in low quantity in other somatic 
tissues (He and Ecker, 2015). Non-CpG methylation includes methylation at the cytosine of 
the following dinucleotides CpA, CpT and CpC, of which CpA is the most abundant (Jang et al., 
2017). Interestingly, non-CpG methylation shows a spatial correlation with CpG methylation, 
while also showing a strong correlation with the expression of the de novo DNA 
methyltransferase (DNMT) DNMT3A (Ziller et al., 2011).   
Methylation at the CG sites is the most abundant, though non-CG methylation also exists at a 
lower amount. However, non-CG methylation is not fully clear and is highly debated in the 
literature, some studies showed that non-CG methylation is relatively low at promoter 
regions and that increased levels of non-CG methylation results in repression of the gene. 
Furthering this increased levels of non-CG methylation at the promoter of peroxisome 
proliferator-activated receptor γ coactivator 1α gene was seen in type 2 diabetes patients 
which were also seen to have lower levels of expression of the gene (Barrès et al., 2009). 
However, it may not only be non-CG methylation at promoter regions that play a functional 
role as it was observed that methyl-CpG binding protein 2 (MeCP2) a protein involved in the 
neurological disorder Rett syndrome, was able to bind to gene body non-CG methylation. 
Investigating this,  a study observed that mutations in MeCP2 resulted in misregulation of 
non-CG methylation at genes known to acquire increased levels of non-CG methylation after 





1.1.1 Methylation Distribution  
The term CG island (CGI) is used for a region of at least 200 bases that is dense with CG sites 
(at least 50% CG rich) (Bird, 1986; Gardiner-Garden and Frommer, 1987). The regions within 
2kb on either side of a CGI are termed as CpG “Shores”, while the region that extends from 
2kb upstream and downstream from the shore is termed the CpG “Shelf”, while finally, any 
CpGs found anywhere else in the genome are classed as being in “open sea” (Borchiellini et 
al., 2019; Irizarry et al., 2009). Around 60% of promoter regions at genes within the human 
genome have a CGI present (Costello and Plass, 2001). CG islands are usually hypomethylated 
apart from about 3% of CGIs that are hypermethylated during development resulting in 
repression of the genes in which they are present (Illingworth et al., 2010). The 
hypermethylation at these genes is important for regulation during development and includes 
genes on the inactive X chromosome, imprinted genes and a subset of tissue-specific genes 
(Jones, 2012). Despite being obvious target regions for methylation, CGIs appear to be 
protected from methylation. At imprinted loci, histone modifications and transcription factors 
are believed to be a possible reason why these subsets of CGIs remain unmethylated. One 
well-investigated transcription factor that is associated with methylation is CTCF, which binds 
to unmethylated regions. Studies have shown that the loss of CTCF leads to hypermethylation 
at CGIs that are normally unmethylated (Engel et al., 2006; Schoenherr et al., 2003). 
Methylation of H3K4 is frequently observed at regions that facilitate transcription,  for 
example, H3K4me3 has been shown to protect from methylation as it has been observed in 
at CGIs that are known to remain unmethylated in sperm (Bernstein et al., 2002; Henckel et 
al., 2012). Due to the nature of CGIs, they are effective regions to study for gene regulation 
in specific cell lineages and epigenetic biomarkers, while CpG shelves and shores are used for 
environmental effects on DNA methylation due to their susceptibility to external factors 
(Borchiellini et al., 2019).  
Methylation found at the promoter region of a gene is mostly consistent with the subsequent 
repression of the gene (Klose and Bird, 2006).  However, gene body methylation which is 
usually found on the exons of long transcripts away from 5’ and 3’ ends is commonly found 
at constitutively expressed genes such as housekeeping genes and rarely found at genes with 





methylation was important for regulating intragenic promoters of the SHANK3 locus and its 
mouse homologue, suggesting a role of gene body methylation in repressing intragenic 
promoter expression. There is a clear contradiction between gene body methylation and 
promoter methylation which is referred to as the methylation paradox (Jones, 1999). Jjingo 
et al., (2012) contradicting the study by Maunakea et al., (2010) showed the relationship 
between transcription and gene body methylation is non-monotonic and that role of 
intragenic promoter repression was an epiphenomenal by-product that cannot explain the 
majority of methylation found at gene bodies and that gene-body methylation is due to the 
accessibility of DNA during transcription. The contradiction between gene body and promoter 
methylation is still not fully understood, however, the current consensus suggests gene body 
methylation facilitates gene transcription, as reductions are associated with concomitant 
decreases in transcript level (Irwin et al., 2014; Maunakea et al., 2010). Research on gene 
body methylation is important due to the association between aberrant methylation at gene-
body in a variety of cancers (Arechederra et al., 2018).  
Distal control regions, better known as enhancers, are known regulatory regions that are 
established to control gene expression outside gene promoters and were first discovered in 
1981 (Banerji et al., 1981). Enhancers are known to regulate genes through their interaction 
with promoters at various distances due to chromatin looping, allowing them to be in close 
spatial proximity. In line with gene body methylation, enhancers correspond with cell-specific 
expression. (Ordoñez et al., 2019). While discovered around 40 years ago, there is still a lot of 
movement in this area with recent investigations describing coalescence of genes and several 
regulatory elements and super-enhancers which are characterised by their high occupancy 
for transcription factors (Schoenfelder and Fraser, 2019).  This cell-specific gene expression 
regulation seen with enhancers is partly due to epigenetic regulation, with hypomethylation 
at the enhancers resulting in transcription factor binding and subsequent expression while 
hypermethylation is a common observation at inactive enhancers (Wiench et al., 2011). DNA 
methylation is not the only epigenetic regulator known to regulate enhancers, for example, 
enhancers are enriched with H3K27ac and H3K4me1 modifications which are associated with 
chromatin accessibility (Sur and Taipale, 2016). Epigenetic regulation at enhancers is 





Meissner et al., 2008; Rönnerblad et al., 2014). Aberrant methylation at enhancers 
contributes to cancer progression and patient mortality (Bell et al., 2016).  
Another control region found in mammals is an imprinting control region (ICR). ICRs are 
differentially methylated regions (DMRs) usually found at imprinting clusters that are seen to 
control allele-specific gene expression of several genes in a large region. The establishment 
of the imprinting mark is well-reviewed by Hanna and Kelsey (2014). ICRs control a subset of 
genes known as imprinted genes, they carry out this function due to a parental-specific 
methylation pattern leading to monoallelic expression (Edwards and Ferguson-Smith, 2007). 
Interestingly the DMRs that are maternally methylated are usually found at promoter regions 
while paternally methylated DMRs are usually found at intragenic regions  (Bartolomei and 
Ferguson-Smith, 2011). The dosage control of imprinted genes carried out by the ICR is 
essential for many biological functions such as endocrine and metabolic functions, placental 
development and function, brain development and behaviour and foetal growth (Farhadova 
et al., 2019). Though methylation is the main driving factor of parental specific transcription 
it should be noted that histone modifications also show consistency with DMR methylation. 
H3 lysine-64 tri-methylation (H3K64me3), histone H3 lysine-9 trimethylation (H3K9me3), H4 
lysine-20 trimethylation (H4K20me3) and H4 arginine-3 symmetrical dimethylation 
(H4R3me2s) is common at the DNA methylated allele, whereas enrichment of H3 lysine-4 di- 
and/or trimethylation (H3K4me2/H3K4me3) and acetylation of H3 and H4 at lysine residues 
is consistent with the unmethylated allele (Sanli and Feil, 2015)- these will be discussed in 
more detail later in this section.  
1.1.2 De novo DNA methylation enzymes  
DNA methyltransferases (DNMT) DNMT3A and DNMT3B are important regulators of de novo 
methylation. These were first discovered in mouse embryonic stem cells (mESC), which 
continued to methylate invading viral sequences even with the loss of DNA Methyltransferase 
1 (DNMT1) (Lei et al., 1996; Okano et al., 1998). DNMT3A and DNMT3B regulate de novo 
methylation during gametogenesis and embryonic development, in which unmethylated CG 
sites become methylated. De novo methylation during embryonic development is not well 





it has currently not been fully explained why (Edwards et al., 2017; Garrick et al., 1998). 
Growing oocytes and spermatogonia express DNMT3L which is a co-factor that forms a 
complex with DNMT3A and DNMT3L, the addition of DNMT3L allows DNMT3A and DNMT3B 
to bind to H3K4me0 and subsequently results in de novo methylation  (Bourc’his and Bestor, 
2004; Bourc’his et al., 2001; Ooi et al., 2007). DNMT3A was also shown to be important for 
establishing methylation at non-CpG sites such as cytosine, thymine (CpT) and cytosine, 
adenine (CpA) dinucleotides (Ramsahoye et al., 2000).  Dnmt3c is a de novo methyltransferase 
that is only found in mouse which protects the male germline from transposon activity by 
methylating evolutionarily young retrotransposons and is required for male fertility (Barau et 
al., 2016; Zeng and Chen, 2019).  
DNMT3A is expressed in two isoforms known as DNMT3A1 and DNMT3A2, both isoforms 
contain the PWWP and ADD domain which interact with H3K36me3, while only the latter 
interacts with unmethylated H3K4 (Dhayalan et al., 2010; Otani et al., 2009; Zeng and Chen, 
2019). DNMT3A2 is the shorter isoform lacking the N-terminal before amino acid 223. 
However, while smaller it is the more predominant isoform that is responsible for de novo 
DNA methylation in embryonic stem cells (ESC) and was associated with euchromatin (Chen 
et al., 2002). In comparison, the DNMT3A1 is mostly expressed in differentiated cells and 
associates with heterochromatic regions and interacts with DNA through its N-terminal region 
(Chen and Chan, 2014; Suetake et al., 2011). Following this DNMT3B is highly isoformic with 
over 30 different variants, though some do not contain the catalytic domain, the inactive 
isoforms while associated with DNA methylation their mechanisms are still largely clouded. 
However, some studies have shown roles in modulating de novo methylation and their ability 
to act as an accessory protein in the absence of DNMT3L in somatic cells (Duymich et al., 2016; 








Figure 1.1: De novo methylation enzymes. Protein structure for the de novo DNA methyltransferases (DNMT) 3A, 3B and 3C. 
The DNMT3 enzyme family has overlapping catalytic domains and regulatory regions. The catalytic domain contains catalytic 
motifs (I-X) which are preserved in DNMT3A, 3B and 3C. Numbers represent the number of amino acids found in the mouse 
protein. PWWP,  proline-tryptophan-tryptophan-proline domain; ADD, ATRX-DNMT3-DNMT3L domain. Edited from “DNA 
Methylation Reprogramming during Mammalian Development” “https://creativecommons.org/licenses/by/4.0/” (Zeng and 
Chen, 2019).  
1.1.3 Maintenance DNA methylation enzymes 
Methylation patterns are inherited during mitotic replication of DNA in somatic cells: DNMT1 
is recruited to hemimethylated DNA where it maintains methylation (Jeltsch and Jurkowska, 
2014; Wigler et al., 1981). In Dnmt1 KO mouse models it was observed that unlike Dnmt3a, 
Dnmt1 did not affect non-CpG methylation (Arand et al., 2012).  The DNMT1 C-catalytic 
domain contains two sub-domains- the target-recognition domain (TRD) and the 
methyltransferase domain (Song et al., 2012).  The TRD domain is important for recognising 
hemimethylated cytosines (Gujar et al., 2019). The N-terminal regulates protein interaction 
through multiple functional domains such as the replication foci targeting sequence (RFTS) 
domain (also known as replication foci domain)  which localises DNMT1 to the replication 
fork, the CXXC zinc finger domain that recognises unmethylated CpG DNA and the paired 
bromo-adjacent homology (BAH) domain (Callebaut et al., 1999; Leonhardt et al., 1992; 
Pradhan et al., 2008; Zeng and Chen, 2019). DNMT1 contains an autoinhibitory loop which is 
an interposed stretch of acidic amino acids between the CXXC and BAH1 domain that is 
present at the DNMT1 active site (Song et al., 2011). This Auto-inhibitory loop along with the 
RFTS binding with the enzyme Ubiquitin Like With PHD And Ring Finger Domains 1 (UHRF1) 
that binds to hemimethylated DNA may explain the faithfulness of DNMT1 and 





domain blocks the active site of DNMT1, the RFTS is then displaced when DNMT1 forms the 
complex with UHRF1 and hemimethylated DNA (Edwards et al., 2017).   
UHRF1 is a protein that is involved with the maintenance of DNA methylation, UHRF1 
colocalises and interacts with DNMT1 at the replication fork (Sharif et al., 2007). The Ubiquitin 
Like (UBL) domain of UHRF1 was able to interact with the RFTS domain of DNMT1 allowing 
the two to bind, this binding was also seen to be essential for DNMT1 enzymatic activity (Li et 
al., 2018). As mentioned previously UHRF1 binds to hemimethylated DNA, it carries out this 
function through its Su(var)3-9, Enhancer of zeste and Trithorax (SET) and Really interesting 
new gene (RING) finger-associated (SRA) domain (Avvakumov et al., 2008). Furthering this the 
SRA domain is also known to interact with the RFTS domain of DNMT1 and increase its activity 
by 5-fold without the SRA DNA binding (Bashtrykov et al., 2014; Zeng and Chen, 2019). UHRF1 
can recognise the histone marks H3R2 and H3K9me3/2 through the cooperation of the plant 
homeodomain (PHD) and tandem tudor domain (TTD) domains, with the PHD domain having 
a more dominant role (Arita et al., 2012). UHRF1 has an autoinhibitory mechanism in which a 
polybasic region (PBR) between the SRA and RING domains acts as a competitive inhibitor 
to  H3K9me2/3 binding to the PHD domain, this is inhibition is prevented through the binding 
of phosphatidylinositol 5-phosphate binding to BRP resulting in a rearrangement of the 
domains (Gelato et al., 2014).  The RING finger of UHRF1 is important for H3 ubiquitination 
due to its functionality as an E3 ubiquitin ligase (Citterio et al., 2004). The protein structure of 








Figure 1.2: DNA maintenance methylation enzymes. Protein structure for the maintenance enzymes DNA methyltransferase 
1 and ubiquitin−like with plant homeodomain and interesting new gene finger domains 1 (UHRF1). DNMT1 regulatory region 
and the catalytic domain is labelled. The catalytic domain contains catalytic motifs (I-X). Numbers represent the number of 
amino acids found in the mouse protein. PBD, proliferating cell nuclear antigen (PCNA)-binding domain; NLS, nuclear 
localization signal; RFTS, replication foci targeting sequence; CXXC, a cysteine-rich zinc finger domain; BAH, bromo-adjacent 
homology domain; (GK)n, glycine/lysine repeats; UBL, ubiquitin-like domain; TTD, tandem Tudor domain; PHD, plant 
homeodomain; SRA, Su(var)3-9, Enhancer of zeste and Trithorax (SET) and RING finger-associated; RING, really interesting 
new gene domain. Edited from “DNA Methylation Reprogramming during Mammalian Development” 
“https://creativecommons.org/licenses/by/4.0/” (Zeng and Chen, 2019).  
1.1.4 Development of the early mouse embryo  
In order to understand better the context in which DNA methylation changes occur during 
development, it seemed useful to provide a brief summary here of embryogenesis in the 
mouse. The first interval in mouse embryo development is preimplantation, this interval is 
where the inseminated oocyte implants to the uterine wall and establishes pregnancy. This 
interval lasts for 4.5 days containing a total of seven cleavage divisions, in which the late 
blastocyst consisting of three distinct cell lineages the trophectoderm (TE), inner cell mass 
(ICM) and primitive endoderm (PrE) is implanted on to the uterus wall (Mihajlović and Bruce, 
2017). Upon fertilisation, the sperm is rapidly demethylated prior to the first cleavage while 
the oocyte methylation is gradually lost during division steps as described in Figure 1.3. The 
first two cleavage divisions lasts approximately 20 hours, which is considerably longer than 
the later divisions which only last around 12 hours (Artus and Cohen-Tannoudji, 2008). The 
zygote is not transcriptionally active until a small burst of activation by the end of the 1 cell-
stage, this is then followed by a major activation upon completion of the 2 cell-stage this 
process is known as zygote genome activation (ZGA) (Schultz, 1993). Until ZGA the zygote 
relies on maternal mRNA, which is then mostly degraded by the end of the second cell-stage 





McConnell, 2004). A second major wave of activation occurs in the zygote at 4 cell-stage, this 
activation peaks at the 8 cell-stage and involves the translation of genes involved in 
morphological changes during late preimplantation development (Hamatani et al., 2004; 
Hamatani et al., 2006). It is around this time that demethylation of the oocyte is completed 
(Figure 1.3), there is also a final wave of transcript activation resulting in expression of genes 
involved in cavitation and cell-fate and lineage segregations resulting in the transition to 
blastocyst. The late blastocyst then leaves the zona pellucidae and implantation occurs at E4.5 
(Wang and Dey, 2006).  
At implantation (E4.5) the embryo has reestablished methylation levels through de novo 
synthesis which will then be maintained by Dnmt1 (Figure 1.3).  The epiblast begins to 
proliferate into the blastocyst cavity due to the physical block imposed by the implantation 
site (Copp, 1979). Simultaneously the proamniotic cavity is being formed, the formation of 
the cavity is believed to be due to apoptotic signals from the visceral endoderm causing cell 
death (Coucouvanis and Martin, 1995). The PrE gives rise to the parietal endoderm and the 
visceral endoderm which play important roles in the development of the yolk sac as they 
make up the visceral and parietal yolk sacs components respectively of the mouse yolk sac 
(Xenopoulos et al., 2012). The development of the proamniotic cavity, parietal endoderm and 
the visceral endoderm and cell proliferation of the epiblast lead to the morphological changes 
observed in the pre-gastrula at E5.5 to E6.0 prior to gastrulation (Kojima et al., 2014). 
Gastrulation begins usually at E6.5 once the threshold number of epiblast cells have been 
reached, however, reaching the threshold before E6.5 earlier, as can be seen in double-sized 
embryos, does not initiate gastrulation any earlier, suggesting a chronological control. 
However, if the required number of epiblast cells has not been reached by E6.5 due to cell 
loss or disruption of proliferation,  gastrulation is delayed until sufficient numbers of epiblast 
cells have been reached (Tam and Behringer, 1997).  
Gastrulation (E6.5-E7.5) is the phase that results in specific morphologic transformation 
through cell proliferation and differentiation and morphogenetic movements. During the 
Gastrulation stage, primordial germ cells begin to be specified bringing about the full circle of 
genomic reprogramming with complete widespread demethylation across the genome and 





mark (Figure 1.3). Epithelial-to-mesenchymal transition is an important process for 
gastrulation in which epiblasts changes to mesenchymal cells at the primitive streak, resulting 
in the three primary germ layers (a transient embryonic structure made of epiblast cells that 
have started mesenchymal transition but still connected to the epiblast) (Nakaya et al., 2013). 
The epiblasts cells that undergo epithelial-to-mesenchymal transition at the proximal end of 
the embryo, become part of either the definitive endoderm germ layer or form a new tissue 
germ layer known as the mesoderm, while those that remain in the epiblast become the 
ectoderm with the mesoderm and endoderm contributing to many of the adult tissues 
(Acloque et al., 2009). Immediately after gastrulation begins early organogenesis (E8.0–E8.5): 
during this time the neural plate and heart tube begin to form (Cao et al., 2019a). In the next 
few days of organogenesis (E9.5–E13.5), the embryo begins to take its distinctive shape in 
which the head, limbs, heart and spinal cord can be identified (Mitiku and Baker, 2007). The 
remaining phase in embryo development following organogenesis is fetal growth and 
development and finally birth (Ko, 2001).  
1.1.5 DNA demethylation  
DNA demethylation is the process in which the 5-methylcytosine (5-mC) is converted to a 
cytosine, this can occur through two processes which can be passive and active 
demethylation. Passive demethylation occurs when DNA methylation is lost during the 
synthesis of a new DNA strand (Rougier et al., 1998). Active demethylation is when 
methylation is lost outside DNA synthesis, the exact mechanism is not fully elucidated, 
however, it is known that the ten-eleven translocation (TET) enzymes are involved (Bhutani 
et al., 2011; Paroush et al., 1990; Tahiliani et al., 2009).  TET was found to have a hydroxylating 
activity to convert 5-mC to 5-hydroxymethylcytosine (5-hmC) (Tahiliani et al., 2009). Later the 
TET enzymes were found to be able to further convert 5-hmC to 5-formylcytosine (5-fC) then 
finally 5-carboxylcytosinen (5-caC) (Ito et al., 2011). The derivatives 5-fC and 5-caC are 
pathways for the thymine DNA glycosylase pathway (TDG) along with the BER pathway 
completes the demethylation of 5-mC to an unmethylated cytosine (Maiti and Drohat, 2011; 





The TET enzymes carry out their hydroxylating activity by utilising the important co-factors 
Fe(II) and α-ketoglutarate (Wu and Zhang, 2014). The Tet enzymes have different expression 
levels through development to somatic tissues in mice. Tet3 is highly expressed in oocyte and 
preimplantation embryos until the blastocyst stage in which Tet1 and Tet2 show the highest 
expression. During differentiation to the germ layers, Tet2 and Tet3 expression is up-
regulated or remains unchanged. Then finally in adult somatic tissue, Tet2 and to some extent 
Tet3 show high levels of expression (Rasmussen and Helin, 2016). Tet3 appears to play an 
irreplaceable role in embryonic development as the mouse KO model of Tet3 results in 100% 
embryonic lethality, while Tet1 and Tet 2 mouse KO models resulted in no developmental 
phenotype (Dawlaty et al., 2011; Gu et al., 2011; Quivoron et al., 2011). Interestingly the 
Double KO (DKO) of Tet1 and Tet2 is still tolerable in mice, though results in hypermethylation 
and compromises imprinting (Dawlaty et al., 2013).  The same lab then carried out a triple KO 
(TKO) of the Tet enzymes in mESCs, this resulted in misregulation of genes, increased 
promoter methylation, loss of 5-hmC and impaired ESC differentiation further confirming the 
role of the Tet enzymes and 5-hmC in development and gene regulation (Dawlaty et al., 2014).  
The oxidised modifications of 5-mC (5-hmC, 5-fC and 5-caC) have been increasingly 
investigated over the years and are important in many biological functions (Shi et al., 2017). 
5-hmC is the most abundant oxidised derivative of 5-mC found at  3-5% of cytosine species in 
the human genome, while the more oxidised modifications are only found at 0.002–0.02% of 
all cytosine species (Dietzsch et al., 2018). Genomic regions in mESCs, 5-hmC and the more 
oxidised derivatives (5-fC and 5-cac) are found separately (Wu and Zhang, 2017). 5-hmC was 
discovered in 1952 shortly after the discovery of 5-mC (Wyatt and Cohen, 1952). Though 5-
hmC is the result of the hydroxylating activity of the TET enzymes, it is important to note that 
increased expression of the TET enzymes does not correlate with the increased levels of 5-
hmC suggesting that TET activity may be controlled by other factors (Szulwach et al., 2011). 
5-hmC is found primarily at gene bodies of transcribed genes, however, 5-hmC can be variable 
across different tissues with similar gene expression suggesting that 5-hmC is dependent on 
tissue type (Nestor et al., 2012). Though the function of the gene body enrichment of 5-hmC 
is still to be determined (Lio and Rao, 2019), aberrant 5-hmC can be seen in tumorgenesis, 
stress response and neurological and psychiatric disorders (Chouliaras et al., 2013; Dong et 





1.1.6 Methylation reprogramming 
Methylation reprogramming occurs during gametogenesis and again throughout embryonic 
development, Widespread demethylation first occurs in the primordial germ cells (PGCs) 
during gametogenesis, this is the first drop of methylation as seen in Figure 1.3B. During this 
time the diploid PGC’s undergoes demethylation removing all previous methylation marks 
including imprinting (Hajkova et al., 2002). Before the primordial germ cells can become 
sperm or oocyte, dependent on the sex, methylation is then reestablished which includes the 
imprinting marks known as gametic DMRs (gDMRs) (Figure 1.3), most of which are maternally 
methylated and are then protected from any further reprogramming and retained as a life-
long mark (Guibert et al., 2012; Lees-Murdock et al., 2003; Proudhon et al., 2012). However, 
an exception to this is transient DMRs which are protected during gametogenesis though are 
susceptible to reprogramming during embryonic development leading to tissue-specific 
gDMRs (Proudhon et al., 2012; Rutledge et al., 2014). The next reprogramming occurs during 
fertilisation: almost immediately after fertilisation occurs, as observed by the different degree 
of gender-specific methylation as seen in Figure 1.3B, the sperm is rapidly demethylated 
before the first round of division occurs, while the oocyte methylation occurs passively over 
several divisions (Oswald et al., 2000). As mentioned previously the gDMRs are protected 
from demethylation during embryonic development, this is due to the binding of two Krüppel-
associated box containing zinc finger proteins (ZFP), ZFP57 and ZFP445, though other 
effectors may also be involved (Ferguson-Smith, 2011; Takahashi et al., 2019). ZFP57 and 
ZNF445, when bound to a gDMR by targeting UHRF1, maintain methylation and H3K9me3 
histone modifications (Strogantsev et al., 2015; Takahashi et al., 2019). Repetitive DNA and a 
subset of single-copy genes also avoid DNA demethylation during embryonic development 
(Borgel et al., 2010; Guibert et al., 2012; Lane et al., 2003; Lees-Murdock et al., 2003). After 






Figure 1.3: DNA methylation reprogramming throughout development. (A) Methylation reprogramming at gametic 
differentially methylated regions (gDMR) throughout development. Primordial germ cells (PGC) (Diploid) contain the 
methylation imprints as inherited from the parents. As PGCs undergo gametogenesis methylation gDMR marks are lost. As 
the PGC matures towards their respective germ cell depending on gender they become haploid and the methylation marks 
are established. After fertilisation, the zygote is formed and begins embryonic development, as it progresses through the 
pre-implantation phase gDMR methylation is maintained. Progressing through embryonic development, imprint gDMRs 
continue to be maintained and even transcribed and a monoallelic fashion. PGC formation and gametogenesis occurs during 
post-implantation beginning the reprogramming loop from the gametogenesis stage. Black arrows represent transcription 
from the allele. (B) DNA methylation reprogramming genome-wide and imprints during embryonic development in mice. 
The timescale in the graph overlap with the events from figure 1.3A. At the beginning of gametogenesis in PGCs widespread 
methylation erasure occurs, however, as the PGCs mature towards their respective germ cell methylation is re-established 
this occurs at birth for sperm and later in life for oocyte (Puberty). Upon fertilisation another genome-wide (Solid) DNA 
methylation erasure event occurs genome-wide, however, the imprinted gDMRs (dashed) are protected. As the embryo 
develops through pre-implantation methylation is gradually re-established genome-wide. Upon implantation, the inner cell 
mass (ICM) is known to carry more methylation than the trophectoderm (TE). Reprinted from “The role of imprinted genes 





1.1.7 Environmental factors and DNA methylation 
DNA methylation is a very stable epigenetic regulator, though it should be noted that it is 
susceptible to changes through environmental and genetic factors (Hannon et al., 2018). The 
effect of environmental factors varies depending on age, sex and tissue (van Dongen et al., 
2016). It was noticed that the ageing process leads to overall hypomethylation in the genome 
(Heyn et al., 2012). With this in mind, studies then looked further into methylation as a 
predictor of age (Bocklandt et al., 2011). The Horvath clock predicts the age of an individual 
by the methylation pattern depending on the tissue which leads to the concept of DNA 
methylation age (DNAmAge) (Horvath, 2013). Several studies went on to show that increase 
of DNAmAge compared to actual age resulted in a term denoted as accelerated ageing (AA) 
which results in a higher risk of mortality or disease, with an increase of 1-year DNAmAge 
there was an increased risk of cancer (Jylhävä et al., 2017; Zheng et al., 2016a).  
DNAmAge can be affected by environmental factors. One environmental factor that has been 
shown to cause AA is diet. A study investigating the association of socio-economic impact with 
epigenetic differences found that those on the lower end of the socioeconomic scale were 
seen to  have methylation associated with AA that they contributed to the higher 
consumption of red meat (McClelland et al., 2016).  Smoking is a further factor known to 
cause hypomethylation, these marks of methylation from smoking persist even after an 
individual quits smoking (Shenker et al., 2013). Studies have even shown that the effects on 
methylation can be seen in several tissues and can even be seen in newborns related to 
maternal smoking during pregnancy (Joubert et al., 2012). However, interestingly though 
smoking has been shown to have profound effects on methylation and age-related disease 
the literature is conflicting if there is a correlation between AA and smoking (Beach et al., 
2015; Gao et al., 2016; Marioni et al., 2015).  
Training and exercise have been observed to have beneficial effects that can be correlated 
with changes of methylation at promoters and enhancers of loci related to the health-
enhancing phenotype (Lindholm et al., 2014). Further to this, it was seen that folic acid 
supplementation during the second and third trimester resulted in changes of methylation 





an important role in neurodevelopment in offspring (Caffrey et al., 2018). Furthering this 
study the authors showed that in the same cohort the children in which their mothers took 
folic acid supplementation had higher emotional intelligence and resilience (Henry et al., 
2018).  
1.2 Functional roles for DNA methylation  
DNA methylation plays many essential roles in mammalian development, this includes 
inactivation of the X chromosome, silencing of repetitive element activity, silencing of the 
germ-line genes and cell differentiation. Ageing and the direct environment are well known 
to correlate with changes in methylation. Methylation plays an important role in the normal 
regulation of several gene classes, which I will outline in this section;  likewise, aberrant 
methylation can lead to various diseases such as cancer and imprinting disorders. 
1.2.1 Inactivation of the X chromosome  
 In mammals, there are two sex chromosomes X and Y, with males having XY and females 
containing XX. The X chromosome contains ∼1100 genes, whereas the Y contains ∼100 genes, 
this would lead to a genetic imbalance in Females (Heard and Disteche, 2006; Pinheiro and 
Heard, 2017). To compensate for the extra X chromosome, females inactivate the X 
chromosome to prevent transcription, in a process known as X inactivation (Lyon, 1961). X 
inactivation occurs during ESC differentiation after implantation.  X inactivation is regulated 
by the X inactivation centre which contains the lncRNA known as X inactive-specific transcript 
(Xist) (Brown et al., 1991). Xist is expressed from the inactive X chromosome where it coats 
the chromosome leading to the subsequent enrichment of repressive histone marks and 
methylation (Heard et al., 2001). The Xist lncRNA appears to be regulated by methylation as 
it was shown that in Dnmt1 KO mESCs and embryos that methylation at the promoter of the 
active X chromosome is required for stable repression (Panning and Jaenisch, 1996).  It should 
be noted that the selection of the chromosome to be inactivated appears to be completely 
random (Takagi et al., 1982). In addition to regulating Xist, DNA methylation is important for 
repressing CGI-containing genes on the Xi (Gendrel et al., 2012; Grant et al., 1992; Lock et al., 





inactivation. Some genes escape x-inactivation: studies vary but 8-15% genes on the inactive 
x chromosome are reported as consistently expressed while another 10-32% of genes are 
variable depending on the individual and tissue. It is currently unclear if the escaped genes 
avoid the silencing signal or are reactivated after silencing (Posynick and Brown, 2019). In 
comparison x-inactivation in mouse has fewer genes escaping, ranging from 3-7% depending 
on the strain and tissue (Balaton et al., 2015). Genes that escape x-inactivation are found 
throughout the x chromosome however, they are most prevalent at regions homologous 
between sex chromosome, known as the pseudoautosomal regions (PAR) (Berletch et al., 
2011). The escaped genes have been associated with the disease phenotype in a female 
monosomy disorder known as Turner’s syndrome. The PAR genes CSF2RA and SHOX, in 
particular, have been suggested to be involved in the placental defects and short stature 
disease phenotypes respectively (Clement-Jones, 2000; Urbach and Benvenisty, 2009).  
1.2.2 Silencing of ‘selfish’ DNA 
There are many types of repetitive elements in the human genome which makes up 66-69% 
of the human genome (de Koning et al., 2011). The ‘selfish’ DNA term is used for transposable 
elements, of which there are two types. Class 1 also known as Retrotransposons makes up 
42% of the human genome and rely on their mRNA being reverse transcribed and then 
reincorporated randomly back into the genome (Finnegan, 2012; Lander et al., 2001). Class 2 
also known as DNA transposons use the ‘cut and paste’ mechanism which involves the DNA 
transposon being cut out and reincorporated randomly back into the DNA sequence (Smit and 
Riggs, 1996). Transposable elements can have detrimental effects by causing loss of gene 
activity (Hancks and Kazazian 2012). Methylation plays an important role in maintaining 
transposon elements in a repressed state and it has even been speculated that the evolution 
of methylation was primarily to repress the transposable elements (Yoder et al., 1997). Loss 
of methylation has been shown to derepress long interspersed nuclear element-1 (LINE 1) in 
human ESCs using a DNMT inhibitor 5’Aza-dC as well as in mice deficient in DNMT1, 
respectively (Walsh et al., 1998; Woodcock et al., 1997). Though transposable elements are 
usually detrimental they also play a role in genomic evolution as a source of genetic variation, 
as some genes contain transposon-like elements that are important for correct regulation and 





variation caused by transposable elements has also been associated with the establishment 
of several imprinted genes in humans such as RTL1 (Grothaus et al., 2016). Transposition 
events usually result in inverted or truncated copies of the transposable elements that are 
inactive and accumulate in the genome. 
LINE1 is an active and the most abundant non–long terminal repeat retrotransposable 
element in mammals making up 20% of the genome in human and mouse (Sassaman et al., 
1997; Yang and Wang, 2016). Studies suggest that there are up to 3000 intact copies of LINE1 
in mouse and up to 100 copies in human (DeBerardinis et al., 1998; Mandal and Kazazian, 
2008). LINE1 retrotransposable activity is carried out through its two open reading frames 
(ORF1 and ORF2). ORF1 encodes nucleic acid chaperone activity while ORF2 is required for 
reverse transcriptase and endonuclease activity (Feng et al., 1996; Martin et al., 2005; 
Mathias et al., 1991). LINE1 also contains a 5’ and 3’ untranslated region (UTR), the 3’ UTR is 
punctuated by a poly(A) tail, while the 5’ end functions as an internal promoter containing a 
CpG island which is usually methylated to silence expression (Beck et al., 2011).  
Human endogenous retroviruses (HERVs) are a type of Long terminal repeat (LTR) 
retrotransposon which are remnants of ancient retroviruses that are largely immobile and 
inactive and are inherited in a Mendelian fashion (Jern and Coffin, 2008). While most HERVs 
are inactive, there remains a small number of “young” HERV which are almost intact and can 
be transcribed nearly in full. Additionally, despite most HERVs loss of retrotransposon activity 
and function, the LTR may still contain functional regulatory regions which can then act as 
alternative promoters for nearby genes (Cohen et al., 2009). Thus, repression of both full-
length and truncated HERV by DNA methylation is crucial to the organism. DNA transposons 
only make up 3% of all elements and are highly diverse with 120 families which are 
categorised into 5 superfamilies, however, these DNA transposable elements are now mostly 






1.2.3 Germline silencing  
Genome-wide studies relatively recently uncovered an additional subset of genes that were 
heavily methylated at their promoters in somatic tissue leading to their subsequent 
repression, while in the germline these promoters were hypomethylated and subsequently 
expressed (Meissner et al., 2008; Weber et al., 2005). During embryonic development 
repression of the germline genes is one of the most robust and coordinated methylation 
mechanisms (Smith and Meissner, 2013).  Dnmt3b is found at the promoter sites of the germ-
line specific genes, where it establishes methylation during ESC differentiation at 
implantation in mouse embryos at E6.5 (Borgel et al., 2010). DNMT3B is recruited by the 
transcription repressor E2F6 to the promoter site of the germ-line specific genes (Velasco et 
al., 2010). Leseva et al (2013) showed for a group of germ-line specific genes that the absence 
of E2f6 resulted in aberrant reactivation. The overexpression of Dnmt3b and subsequent 
hypermethylation at the promoter site of Stag3 was not sufficient to silence Stag3 expression 
either in E2f6 deficient  mouse embryonic fibroblasts (Leseva et al., 2013). DNMT1 plays an 
important role in maintaining the methylation at the germline promoters, as Dnmt1-null 
mouse somatic cells failed to methylate the promoter regions which subsequently resulted in 
the upregulation of germline genes in somatic tissues (Maatouk et al., 2006). Failure to 
repress germ-line genes in somatic tissue can have detrimental effects, though the expression 
is normal during the germ-line, the abnormal expression has been identified in many different 
tumour types (Simpson et al., 2005). 
1.2.4 Genomic Imprinting  
Genomic imprinting was first discovered in 1960 in Sciara but was referred to as a controlling 
element in sex chromosome behaviour, it wasn’t until the early to mid-1980s that imprinted 
genes were suspected to be present in the mammalian genome (Crouse, 1960; McGrath and 
Solter, 1983; Surani and Barton, 1983; Surani et al., 1984). It has been well established that 
imprinted genes play an essential role in embryo and placental biology. They also play an 
important role in congenital function and metabolism, with aberrant regulation of Imprinted 
genes leading to imprinting disorders, congenital conditions and an increased risk of cancer 
(Peters, 2014). There have been over 100 imprinted genes identified in mammals (Luedi et 





and predominantly expressed in the placenta. Paternal expressed imprinted genes usually 
promote growth while maternal expressed imprinted genes usually inhibit growth (Renfree 
et al., 2013). How Imprinted genes came to be is not fully understood but there are two major 
theories in literature which include the predominant Kinship theory and the maternal-
offspring coadaptation theory (O’Brien and Wolf, 2017). However, the evolution of imprinting 
is not within the scope of this thesis.   
Imprinting DMRs can be established in both the germline and after fertilisation in somatic 
tissues, which are known as germline DMRs (gDMR) or somatic DMRs (sDMR) respectively as 
described in Figure 1.4 (Pervjakova et al., 2016). The first observation of an sDMR was at the 
promoter region of the mouse Igf2r which was seen to have paternal methylation outside the 
germline in mouse (Stöger et al., 1993). A further DMR that was observed to be established 
outside the germline is located at the maternally expressed Cdkn1c gene in mouse in which 
the promoter region was also paternally methylated (Bhogal et al., 2004). The best-described 
model for an ICR is the regulation of the H19/Igf2 genes in mouse. The ICR at the H19 gene is 
usually methylated on the maternal allele and unmethylated on the paternal allele leading to 
maternal expression of H19 and paternal expression of the Igf2. A paternally methylated 
sDMR was seen to be important for further silencing of the paternal expression of the H19 
gene, shown in Figure 1.5 (Bartolomei et al., 1993; Ferguson-Smith et al., 1993). However, it 
should be noted that the same group went on to show that deletion of the gDMR does not 
result in the loss of methylation at the sDMR suggesting that once established the sDMR is 






Figure 1.4: Schematic diagram describing the establishment of imprinting gDMRs and sDMRs in mice. During 
gametogenesis DNA methylation undergoes reprogramming, it is here that the gametic DMRs (gDMR) are established and 
maintained as a lifelong mark. On the formation of a zygote, methylation undergoes a second round of reprogramming: 
however, the imprinted gDMRs are protected during this phase. It is the embryonic stage of methylation reprogramming 









Figure 1.5: Schematic diagram describing the ICR and sDMR functionality at the H19/Igf2. On the Maternal Allele, the ICR 
and sDMR are unmethylated, this opens the CTCF binding site, allowing CTCF to bind and prevent the upstream enhancers 
from interacting with Igf2. Therefore, the enhancers instead interact with H19 resulting in the expression of H19 and 
repression of Igf2. On the paternal allele, the ICR and sDMR are methylated, this blocks the CTCF binding site preventing 
CTCF binding. This allows the enhancers to interact with Igf2, leading to its subsequent expression, while the sDMR is 
important for the silencing of H19. Legend describes all symbols found within the figure. 
The environment plays an important role in altering methylation and has been even known 
to alter the methylation at Imprinted genes. One environmental factor that can affect 
Imprinted genes is maternal nutrition, as maternal nutrition is critical for foetal development 
it is widely explored across many systems (Kappil et al., 2015). Maternal folate status has 
shown to have an inverse relationship with DNA methylation at a tested set of imprinting 
DMRs (Hoyo et al., 2014). Further to this, it was seen that maternal smoking during pregnancy 
and paternal drinking would affect the methylation at imprinting DMRs such as MEG3 in the 
offspring and H19 in the sperm respectively (Markunas et al., 2014; Stouder et al., 2011). 
Assisted reproduction technologies (ART) have also been seen to have a large impact on 
genomic imprinting. A population study in Japan showed an association between ART and 
imprinting disorders such as BWS and SRS, further to this widespread disruption of the 
imprinting gDMRs was also observed after the use of ART (Hiura et al., 2012). However, 
Deangelis, Martini and Owen (2018) have suggested that the risk of imprinting disorders in 
ART is low and screening is unwarranted due to studies being unable to differentiate if the 
risk of imprinting disorders is due to the fertility treatment or rather the fertility issues in the 






ESCs and PGCs are the building blocks to essentially all cell types, during differentiation 
remarkable changes in morphology and function can be seen usually largely determined by 
distinct gene expression. This distinct expression usually involves the silencing of self-renewal 
specific genes and the expression of tissue-specific genes (Hackett et al., 2012). De novo 
DNMTs establish the tissue-specific methylation patterns that lead to cell differentiation 
during embryonic implantation (Wu and Sun, 2006). Further to this double knockout (DKO) 
mouse ESCs are unable to undergo differentiation in vitro, further confirming the importance 
of methylation in tissue-specific stem cells and/or differentiated cells (Okano et al., 1999). It 
is possible to induce pluripotency in differentiated cells to give induced pluripotent stem cells 
(iPSCs) which closely resemble the epigenetics of normal ESCs including DNA methylation 
after continuous passaging (Nishino et al., 2011). The imprinting status of most imprints is 
conserved through induced pluripotency, though if imprinting is lost it can not be fixed 
through continuous passage (Hiura et al., 2013).  
Reprogramming of somatic tissue to iSPCs has a large impact with benefits for both clinicians 
and researchers while minimising ethical conflicts. However, the efficiency of reprogramming 
is low (0.1-3%) with a high financial cost (Gomes et al., 2017). This low efficiency can be partly 
attributed to the epigenetic memory of the source cells, that is partially explained by 
incomplete DNA promoter methylation (Kim et al., 2010; Ohi et al., 2011). Supporting this 
Mikkelsen et al., (2008) showed that treatment with the DNMT 1 inhibitor 5-aza-2′-
deoxycytidine (AZA) resulted in higher cell death at early treatment stages, but a four-fold 
increase of embryonic-stem-cell like colonies at later stages which led the author to suggest 
that demethylation of 1 or more loci is important for late-stage reprogramming. A further 
method to increase the efficiency of cell reprogramming is treatment with vitamin C: by 
alleviating cell senescence, promoting H3K36me2/3 demethylation through Jhdm1a/1b and 
preventing loss of imprinting at the Dlk1/Dio3 loci through blocking Dnmt3a binding (Esteban 
et al., 2010; Stadtfeld et al., 2012; Wang et al., 2011). Interestingly loss of function studies of 
Dnmt3a and 3b showed that de novo methylation is dispensable when inducing pluripotency 





1.3 DNA methylation changes associated with Disease  
1.3.1 DNA methylation and disease Functionality  
As discussed previously correct DNA methylation regulation is important as it may lead to 
disorders due to misregulation of genes required for normal bodily function. As mentioned 
previously deviations from the normal DNAmAge can lead to diseases such as cancer, 
diabetes, cardiovascular disease and neurological disorders (Fransquet et al., 2019). In this 
section, the epigenetic changes in a number of diseases will be discussed.  
Cancer initiation, promotion and progression is the result of global genetic and epigenetic 
abnormalities (Hanahan and Robert A, 2017). DNA methylation is often associated with 
regulating the processes contributing to the neoplastic transformation such as Genome-wide 
hypomethylation resulting in activation of retrotransposons and cancer-testis antigen (CTA) 
genes (Jasek et al., 2019). Retrotransposal elements and CTA genes have been shown to have 
the ability to stimulate oncogenic pathways involved with angiogenesis, cell proliferation, 
metastasis and immortality as well as inhibiting tumour suppressor pathways involved with 
apoptosis, controlling growth inhibition signals and genome integrity (Van Tongelen et al., 
2017). A further study by Greißel et al., (2015) showed loss of methylation at the LINE-1 
elements in high-grade carotid artery stenosis. LINE-1 hypomethylation was also observed in 
a study of 292 myocardial infarction cases and a longitudinal analysis of ischaemic heart 
disease and stroke showed hypomethylation at the LINE-1 elements was associated with 
higher risk and subsequent mortality, further supporting hypomethylation at the involvement 
of the LINE-1 element in CVD (Baccarelli et al., 2010; Guarrera et al., 2015).   
Epigenetic alterations have been seen in metabolic disorders such as type 2 diabetes (T2DM) 
(Bansal and Pinney, 2017). Methylation was first associated with diabetes in candidate gene 
studies which showed patients with T2DM had increased methylation at the promoters of the 
peroxisome proliferator-activated receptor γ and peroxisome proliferator-activated receptor-
gamma coactivator-1 alpha genes (Barrès et al., 2009; Ling et al., 2008). Interestingly loss of 





mediate susceptibility to diabetes through the aberrant expression of  CDKN1C, KCNQ1 and 
KCNQ1OT1 during development (Travers et al., 2013).  
1.3.2 Imprinting Disorders 
Imprinting disorders, as mentioned previously occur due to aberrant regulation of imprinted 
genes. Imprinting disorders are characterized by overlapping clinical features such as 
abnormal development, growth and metabolism usually caused by molecular disturbances 
affecting the imprinted genes. A list of imprinting disorders and their respective affected gene 
can be seen in Table 1.1. Imprinting disorders can be caused by four main molecular changes 
which include uniparental disomy (UPD), genetic mutations at the imprinted loci, 
chromosomal rearrangements and epimutation. However, the phenotypic changes that occur 
are usually dependent on the affected allele (Eggermann et al., 2015b). UPD is when both 
chromosomes are inherited from the same parent and causes an imbalance of imprinted 
genes on the affected chromosome. UPD is known to be associated with almost every known 
imprinted disorder (Eggermann et al., 2015a). Genetic mutations are known to be the cause 
of a few imprinting disorders, the Imprinted gene CDKN1C when mutated is known to cause 
the imprinting disorders Silver-Russell syndrome (SRS) and Beckwith-Wiedemann syndrome 
(BWS) (Brioude et al., 2013; Hatada et al., 1996). Chromosomal rearrangements such as 
deletions, duplications and translocations can alter regions important for the regulation of 
imprinted genes or the imprinted gene itself, these rearrangements would then cause the 
aberrant expression of the respective gene and therefore lead to an imprinting disorder 
related to the imprinted gene affected. One example is the deletion of the ICR at the 11p15.5 
region which is often referred to as ICR 2, the deletion of this ICR on the maternal 
chromosome is associated with BWS  (De Crescenzo et al., 2013). Epimutations account for 
50% of cases for imprinting disorders, this occurs when methylation at the imprinting DMRs 
are abnormal (Eggermann et al., 2015b).  
Loss of imprinting has been seen to cause increased tumorigenesis in mice, in humans the 
imprinting region H19/IGF2 has been known to be aberrantly expressed in several cancers  
(Lim and Maher, 2010). A further Imprinted gene RTL1 which is present at the DLK1 imprinting 





et al., 2013). As well as cancer, imprinted genes also have been linked to psychiatric disorders 
such as autism spectrum disorders (Fradin et al., 2010). In mice the paternally expressed 













(Wang et al., 2020) 












• Pre- and postnatal overgrowth 
• Macroglossia 
• pinna abnormalities 
Silver-Russell syndrome 








 Chr 7 
Maternal • clinodactyly 
• relative macrocephaly 
• ear anomalies 
• skeletal asymmetry 
• Pre- and postnatal growth 
restriction 
• short stature 
• triangular face 
upd(20)mat Syndrome 
(Hjortshøj et al., 2020) 
N/A UPD(20)mat Chr 20 Maternal • Pre- and postnatal 
growth restriction 
• feeding difficulties 
Transient Neonatal Diabetes 
Mellitus 
(Touati et al., 2019)  
601410 PLAGL1 DMR 
LOM 
UPD(6)pat  
6q24 Paternal • renal abnormalities 
• developmental delay 
• congenital heart diseases 
• hypothyroidism 
• Prenatal growth restriction 
• transient diabetes 
• hyperglycemia without 
ketoacidosis 
• umbilical hernia  
Prader-Willi syndrome 




15q11 Maternal • intellectual disability 
• Behavioural problems 
• risk of developing 
psychosis 
• Hypogonadism 
• Pre- and postnatal growth 
restriction 
• hypotonia 
• feeding difficulties 
• hyperphagia  
Angelman syndrome 




15q11 Paternal • neurological problems 
• hyperactivity 
• attention deficit 




(Ogata and Kagami, 2016) 
608149 UPD(14)pat 
IG-DMR GOM 
MEG3 DMR GOM 




• developmental delay 
• Prenatal overgrowth 
• protruding philtrum 
• polyhydramnios 





Table 1.1: Overview of known imprinted disorders clinical features and molecular abnormalities. Uniparental disomy (UPD) is shown which chromosome is affected by number in brackets 
and whether is maternal or paternal by mat/pat respectively. Recent reviews or relevant studies when reviews were not available are cited below each imprinting disorder. DMR, differentially 
methylated region; GOM, gain of methylation; LOM, Loss of methylation; pat, paternal; mat maternal; Chr, chromosome. 
Pseudohypoparathyroidism Ib 








20q13 Paternal • postnatal growth 
restriction 
• rounded face 
• brachydactyly 
• ectopic ossifications 
• Intellectual disability 
• renal resistance to Parathyroid 
hormone 
• absence of any features of 
Albright's hereditary 
osteodystrophy 
• mild resistance to Thyroid-
stimulating hormone 
Precocious puberty syndrome 
(Abreu et al., 2013; Dauber et 
al., 2017) 






 • Precocious puberty in 
girls younger than 9 
• Precocious puberty in boys 
younger than 8 
Temple syndrome 
(Prasasya et al., 2020; Temple 
et al., 1991) 
616222 UPD(14)mat 
IG-DMR LOM 
14q32   Maternal • muscular hypotonia 
• precocious puberty 
• feeding difficulties 
• Pre- and postnatal growth 
restriction 
• small hands and feet 
 
Birk-Barel Syndrome 
(Barel et al., 2008) 
612292 KCNK9 mutations 8q24  • feeding problems 
• dolichocephaly 
• short philtrum 
• congenital hypotonia 
• variable cleft palate 
• delayed development 
Schaaf-Yang syndrome 
(Schaaf et al., 2013) 
615547 MAGEL2 
mutations 
15q11  • infantile feeding 
problems 
• distal joint contractures 
• gastroesophageal reflux 
• chronic constipation 
• intellectual disability 
• developmental delay 
• autism spectrum disorder 
• neonatal hypotonia 





1.3.3 Mutations in DNA methyltransferase genes and disease 
 As shown throughout this chapter the regulation of the methylome is essential for normal 
biological function throughout the body, therefore it is not surprising that mutations in any 
of the three DNMT’s are associated with disease states.  
A syndrome called immunodeficiency, centromere instability and facial anomalies-1 (ICF-1) 
(OMIM 242860) is caused by loss-of-function mutations at DNMT3B (Xu et al., 1999). The 
mutations are found mostly located within the catalytic domain leading to abnormal DNA 
binding, SAM utilisation, SAM binding and homo-oligomerization (Moarefi and Chédin, 2011). 
Missense and splice site mutations do occur in the N-terminal in some ICF patients, leading 
to an inactive truncated protein (Jiang et al., 2005). ICF is an extremely rare autosomal disease 
that was first described in 1978, with only around 50 cases reported worldwide up to 30 years 
later (Ehrlich et al., 2006; Hulten, 1978). ICF patients suffer from recurrent severe infections 
usually resulting in death before adulthood due to agammaglobulinemia caused by peripheral 
terminal B-cell blockage (Blanco-Betancourt et al., 2004). ICF most typical feature is 
chromosome instability at chromosomes 1, 9 and 16 due to gains and losses of chromosome 
arms due to loss of methylation at classic satellites 2 and 3. This loss of methylation is 
observed in all cells, however, the chromosome instability is only present in specific cell types 
(Edwards et al., 2017). Further loss of methylation is also observed at a subset of the germline 
genes promoters MAEL and SYCE1, CpG islands on the inactive x-chromosome, SST1 (a family 
of microsatellites), subtelomeric regions and D4Z4 DNA repeats (Velasco and Francastel, 
2019). Velasco et al., (2014) suggest that the hypomethylation of MAEL and SYCE1 and 
subsequent derepression of these germ-line genes may act as specific and robust biomarkers 
for the diagnosis of ICF.  
DNMT1 mutations are associated with two neurodegenerative adult-onset disorders, 
Hereditary Sensory Neuropathy with dementia and hearing loss type 1E (HSAN1E) (OMIM 
614116) 10 and Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy (ADCA-DN) 
(OMIM  604121) (Klein et al., 2011; Winkelmann et al., 2012). HSAN1E to date has been 
associated with 9 mutations located frequently within exon 20 while only 4 mutations have 





parts of the RFTS domain (Norvil et al., 2019). With both diseases being linked to mutations 
in the RFTS domain of DNMT1, it is not surprising that they have many overlapping clinical 
features, such as cognitive decline by late ’40s, sensorineural hearing loss, mild to severe 
neuropathy and similar age-onset of disease and life expectancy. One exception is the 
prominence of narcolepsy associated with ADCA-DN that is only found in some cases of 
HSAN1E (Baets et al., 2015). A study utilising whole-genome bisulphite sequencing, showed 
genome-wide hypomethylation, at most CpG islands, promoters, exons, L1, L2, Alu and 
satellite repeats and simple repeat sequences. Imprinted genes were most affected with 
more hypomethylated CpGs than in other genes. However, some regions did appear to be 
hypermethylated (Sun et al., 2014). Kernohan et al., (2016) showed a similar trend using the 
450k array in ADCA-DN patients and suggested that the DNMT1 mutations cause similar 
methylation profiles in both disorders with hypomethylation at repetitive elements and site-
specific hypermethylation at specific gene promoters and CpG islands.  
DNMT3A mutations are associated with a number of disorders such as germ-line mutations 
in Tatton-Brown-Rahman syndrome (TBRS) (OMIM 615879) and microcephalic dwarfism 
(MD), while somatic mutations are observed in Acute Myeloid Leukemia (AML) (OMIM 
601626) ( (Heyn et al., 2019; Ley et al., 2010; Lin et al., 2018; Tatton-Brown et al., 2014). TBRS 
is an overgrowth syndrome that arises due to mutations in the germline with 40 different 
variants found in any of the three functional domains. TBRS presents with facial 
abnormalities, tall stature and intellectual disability (Norvil et al., 2019). Genome-wide 
profiling of 15 TBRS patients observed accelerated epigenetic ageing with hypomethylation 
at genes associated with development, differentiation, morphogenesis and malignancy 
predisposition pathways, this was seen to be most severe in the patient with the 
R882H  mutation that is seen in >20% of AML cases (Jeffries et al., 2019). R882H mutations 
result in 80% reduction of DNMT3A activity in the mutant enzyme, which is also known to 
inhibit the WT from forming tetramers which represent the most active form of DNMT3A 
(Russler-Germain et al., 2014). AML patients suffering from mutations in R882H in the MTase 
domain are seen to have genome-wide hypomethylation at specific CpGs predominantly at 
homeobox genes (Qu et al., 2014). The R882H mutations in AML patients have also been 
observed to be predictive of a poorer prognosis, with AML R882H patients having an inferior 





common occurring DNMT3A mutation in AML, it should be noted that 15-20% of DNMT3A 
mutations in AML cases are outside the R882H codon, but rather they contain insertions, 
truncations or single-copy deletions mutations, however, these mutations are less 
investigated in the literature (Bruno et al., 2019). A recent study by Heyn et al., (2019) 
described two PWWP gain of function germ-line mutations W330R and D333N in 
microcephalic dwarfism. Using the Infinium® MethylationEPIC BeadChip (EPIC) array 
hypermethylation was observed at Polycomb-regulated regions associated with 
developmental genes. The increase of methylation was found in conjunction with the 
depletion of H3K27me3 and H3K4me3. This led the authors to believe that the PWWP 
mutation impaired the Polycomb repressive complex 2 (PRC2) binding (Heyn et al., 2019).  
1.3.4 The Infinium HumanMethylation BeadChip Array and RNA-seq 
The use of genome-wide technology has helped researchers to gain a greater understanding 
into epigenetic regulators, such as RNA-seq, Methylation BeadChip array (450k and EPIC), 
ever since the human genome project, the technological advances within genomics has 
exploded, accelerating a change in biology and medical research fields. With the introduction 
of the 1000 genome project and HapMap, researchers were provided with an extensive 
catalogue of human variation, opening the door to more in-depth investigations with 
genome-wide association studies (GWAS) (Altshuler et al., 2010; Auton et al., 2015). 
Epigenome-wide association studies (EWAS) have also flourished over recent years, in 
particular following the introduction of the Illumina Infinium methyl-seq (reduced 
representation/whole genome bisulphite sequencing), histone/chromatin enrichment with 
and transcriptome analysis (RNA-seq) to name a few (Chaitankar et al., 2016; Sandoval et al., 
2011). Utilising the genomewide technologies mentioned above-allowed researchers to 
understand epigenetic changes from environmental effects to disorders (Barletta et al., 1997; 
Lindholm et al., 2014). This has been especially progressive for imprinting disorders leading 
to the discovery of novel DMRs and imprinted genes as well as candidate imprinted regions 





1.4 Summary and Hypothesis 
Genome-wide methylation NGS utilises sodium bisulphite treatment of DNA, this treatment 
converts unmethylated cytosines to thymine which is ultimately converted to uracil, which 
can be then quantified (Altshuler et al., 2010). Illumina Infinium methylation BeadChip arrays 
utilise a probe-based fluorescent system that hybridises to bisulphite treated DNA, resulting 
in a signal. There are two types of probes: Type I probes use a paired system -one binds to the 
methylated locus and the other unmethylated locus; while type II only contains 1 probe which 
binds to both the methylated and unmethylated locus (Zhou et al., 2017). Illumina Infinium 
Methylation BeadChip arrays have a high level of reproducibility and reliability with probes 
covering RefSeq genes, promoter CpG islands and covers all known imprinting clusters in both 
the HumanMethyation450 (450K) and MethylationEPIC (850K) arrays (Carmona et al., 2017). 
RNA-seq is a type of high throughput sequencing technology (sequences multiple DNA 
molecules in parallel), it utilises cDNA synthesised directly from an RNA sample to provide the 
transcriptional status at a specific time at when it was extracted.  RNA-seq is carried out in 3 
stages, library preparation to manipulate the RNA to be compatible with sequencing, 
sequencing and finally analysing with bioinformatic tools (Qian et al., 2014).  
It is clear that methylation plays a major role in genomic imprinting and genomic imprinting 
like disorders. However, there is still much left unknown about the mechanism of how these 
regions and their related genes are regulated. Imprinting disorders have a unique mechanism 
such as parental specific methylation controlling monoallelic expression, as well as being 
protected from the genomewide demethylation during reprogramming of the zygote. 
Understanding the imprinted genes and regions fully will allow for more accurate diagnosis 
and may help pave the way for effective treatments for imprinting disorder patients. This 
thesis will aim to expand our understanding behind genomic imprinted and retrotransposable 
regions. Firstly, we hypothesise that the 450k array can be used to characterize and ‘score’ 
genomic imprinted genes to differentiate between normal and abnormal levels of 
methylation to identify DMR disturbances. To answer this I will utilise publicly available 
datasets and analyse them using R studio and use galaxy to create a methylation index for 
normal methylation variability of the genomic imprinted regions and test against datasets for 





widespread loss of methylation caused by the depletion of DNMT1 in the hTERT-1604 cell line 
will disrupt the regulation of the imprinted regions. To test this we aim to investigate the 450k 
array datasets generated by the Walsh lab using genome coordinates for imprinted DMRs 
found in the literature and confirm the changes of methylation using pyrosequencing 
technology, qPCR will then be used to confirm any consequent functional changes. The third 
and final hypothesis is that the point mutation in the PHD domain of Uhrf1 will result in the 
abrogation of the H3K binding and subsequent aberrant epigenetic regulation of the genomic 
retrotransposable and imprinted elements. We aim to investigate the retrotransposable and 
imprinted elements through the use of wet-lab experiments designed to analyse the 
methylation and transcriptional status of these elements in PHD mutant homozygotic 















Chapter 2. General Materials and Methods 
2.1 Tissue Culture  
The adherent fibroblast hTERT immortalised human lung fibroblast-1604 (hTERT-1604) 
(Ouellette, 2000) and the adherent HT29 and HCT116 epithelial colon cancer cell lines was 
cultured in high glucose 4.5g DMEM media (Gibco, Paisley, UK) supplemented with 10% fetal 
bovine serum (Gibco, Paisley, UK) and 2x NEAA (Gibco, Paisley, UK).  Previous members of the 
CPW laboratory generated the respective DNMT1 and UHRF1 stable knockdowns in hTERT-
1604s using a pSilencer construct (Ambion, Huntingdon, UK) with integrated DNMT1/UHRF1 
targeting shRNA.  For selection of shRNA cells, media was supplemented with 150μg/ml 
hygromycin B (Invitrogen, Paisley, UK) and culture was carried out the same as wild type 
hTERT-1604s; hygromycin B treatment was halted at least 48hours before any experimental 
procedure.  Conditions for all cell culture was 37°C, 5% CO2 in a humidified incubator. 
Downstream analysis was carried out on cells at passage #22-24. 
2.2 Cell passaging 
Cell passaging was carried out at ~70-80% confluency when media was removed and x2 
washes was carried out with PBS (Oxoid Ltd). Cells in a 90mm tissue culture plate (Iwaki) were 
deattached with 1ml 1x trypsin-EDTA (Gibco, Paisley, UK) incubation at 37⁰C; time of 
treatment required for disassociation of the was reliant on the cell line in use. FBS 
supplemented media was used to end treatment. Cells were pelleted in a universal tube by 
centrifuging for 5 minutes at 1200rpm; the supernatant was then removed and the pellet was 
gently agitated to unclump cells.  The pellet was resuspended in 5ml of complete media; a 
haemocytometer counting chamber (Neubauer) was utilised to count the cells. The volume 
of cells used for passaging was formulated based on the number of cells counted to ensure 
culturing consistency; media was added to a total of 10ml media.  Additional components (5-






2.3 Preparation of cell stocks 
Cells were frozen down when ~70-80% confluent.  Trypsanisation and cell counting was 
carried out as explained previously, 5 cell stocks could be created from cells at 70-80% 
confluency in a 90mm plate. The volume required for 5x106 cells was centrifuged at 1200rpm 
for 5min in a universal tube to form a pellet; the supernatant was removed and the pellet was 
gently agitated to unclump cells then resuspended in 2.5ml of media.  2.5ml ice-cold freezing 
solution (80% FBS; Invitrogen, Paisley, UK, 20% DMSO; Sigma-Aldrich, Dorset, UK) was added 
dropwise to the cell/media mix whilst agitating the cell solution to ensure even distribution 
of the freezing solution.  The cell solution was then split into 5x1ml individual cryovials 
(Davidson & Hardy Ltd, Belfast, UK) and immediately, transferred into a Mr Frosty™ Freezing 
Container (ThermoFisher, Loughborough, UK) and stored in a -20⁰C freezer overnight. The 
cryovials were placed at -80⁰C for at least 24hr and retained at -80⁰C for short term storage 
or transferred to the liquid nitrogen facility within the University’s cryostorage for long term 
storage.  
2.4 DNA extraction and Bisulphite conversion 
Cell pellets were resuspended in 500μl of lysis buffer [50 mM Tris pH 8, 0.1 M EDTA (both 
Sigma-Aldrich) incubated overnight with rotation at 55°C, 0.5% SDS, 0.2 mg/ml proteinase K 
(Roche, West Sussex, UK)]. The phenol/chloroform/isoamyl alcohol (25:24:1 pH8, Sigma-
Aldrich) extraction method was utilised to isolate the DNA. Once extracted UV absorbance 
measurements at 260/280 and 260/230 nm using a Nanodrop UV spectrophotometer were 
used to quantify and examine the quality of DNA (Labtech International, Ringmer, UK). 
250/500ng of DNA depending on the quantity of DNA available was used for bisulphite 
conversion with the EZ DNA Methylation Kit (Zymo, Cambridge, UK) according to the 







2.5 Bisulfite PCR 
Amplification was carried out using the PyroMark PCR kit (Qiagen, Crawley, UK) with 2 μl 
bisulphite-converted DNA, 12.5 μl MasterMix, 2.5 μl CoralLoad Concentrate, 1.25 μl each 
primer (10 μM) and 5.5 μl nuclease-free water (Qiagen, Crawley, UK) using the following 
conditions: 15 min at 95 °C followed by 45 cycles of 94 °C for 30 s, 56 °C for 30 s, 72 °C for 30 
s and a final elongation step of 72 °C for 10 min. Primers were designed in-house using the 
PyroMark Assay Design software 2.0 before synthesis (Metabion, Germany) some assays were 
ordered pre-designed from Qiagen (Crawley, UK) were as described.  
2.6 Agarose gel electrophoresis 
Gel electrophoresis is used to determine the success of the PCR by the presence of a band at 
the expected size. 1μl of the produce was mixed with 5μl of loading dye (20% glycerol, 0.05% 
orange G; both from Sigma-Aldrich, Dorset, UK) before being separated through a 1% agarose 
gel by electrophoresis. 1% Gel prepared by heating 100ul 1x TAE buffer with 1g agarose 
electrophoresis grade powder (Apollo Scientific, Cheshire, UK) and 2ul GelRed Nucleic Acid 
Gel Stain, 10,000X in DMSO (Cambridge Bioscience, Cambridge, UK) until clear then left to set 
in a cast.  1x TAE buffer was made using a 50x concentrated stock which consisted of 2M Tris-
base, 0.05M EDTA (Sigma-Aldrich, Dorset, UK), 1M acetic acid (VWR, Lutterworth, UK). To 
estimate the size of the product, samples were run alongside the 100bp ladder (Invitrogen, 
Paisley, U.K).  Agarose gels were imaged by UV transillumination on the Bioview UV light 
(Biostep, Jahnsdorf, Germany).   
2.7 Pyrosequencing 
A pyro PCR product was generated as seen in the bisulphite PCR above, however, a primer 
contained a biotin label which is dependent on the read direction of the assay.  The pyro PCR 
was then analysed using Pyromark™ Q24 pyrosequencer (Qiagen, Crawley, UK).  To the PCR 
product, 2μl beads (GE Healthcare, Chalfon St. Giles, UK), 40μl binding buffer (Qiagen, 
Crawley, UK) and 18μl nuclease-free water (Qiagen, Crawley, UK) was added.  Samples were 
placed on a shaker for 5min at 1400rpm allowing for attachment of the sepharose beads to 





ethanol (5 sec), denaturation solution (5 sec) (0.2M NaOH; Sigma-Aldrich, Dorset, UK) and 1x 
wash buffer (10 sec) (Qiagen, Crawley, UK), the PCR products were then released onto a 
PyroMark™ Q24 plate (Qiagen, Crawley, UK) which contained 0.3µM sequencing primer in 
25µl annealing buffer (Qiagen, Crawley, UK) at the pyromark workstation.  The pyromark was 
placed on a heat block at 80°C for 2min and left to cool at RT for >5min, allowing the 
sequencing primer to anneal to the pyro PCR product. The pyromark Q24 cartridge was then 
loaded with enzyme and substrate solutions and nucleotides from PyroMark Gold Q24 
Reagents  (Qiagen, Crawley, UK)  following the manufacturers' instructions. Both the samples 
and cartridge was placed into the Pyromark™ Q24 pyrosequencer (Qiagen, Crawley, UK) and 
samples were sequenced. The results were viewed using the associated PyroMark™ Q24 
software, v.2.0.6 (Qiagen, Crawley, UK). 
2.8 Pyrosequencing Statistical analysis 
The mean methylation across all CpG sites analysed in the assay was calculated for each CpG 
assay.  The standard deviation (SD) was calculated and the standard error of the mean (SEM) 
was calculated using the SD.  In some assays the methylation value for each of the CpG sites 
able to be assessed by the assay was used for the SD and SEM; this is indicated in the figure 
legend when this was the case.  Significance was carried out using the non-parametric Mann–
Whitney U test.  
2.9 RNA extraction, cDNA synthesis and RT-qPCR 
RNA was extracted using the RNeasy kit (Qiagen, Crawley, UK), according to the 
manufacturer’s instructions. cDNA synthesis was carried out with 250/500ng RNA used in 
combination with 0.5 μg random primers (Roche, West Sussex, UK), 40 U RNaseOUT 0.5 μM 
dNTPs (Invitrogen, Paisley, UK) 1× RT Buffer (Fermentas, Cambridge, UK) and RevertAid 
reverse transcriptase (Fermentas, Cambridge, UK) made up to a final volume of 20 μl using 
RNase-free water (Qiagen, Crawley, UK). Reactions were carried out in a thermocycler with 
conditions—25 °C for 10 min, 42 °C for 60 min and 70 °C for 10 min. One microlitre cDNA per 
well on a 96-well plate (Roche) was used for RT-qPCR with SYBR Green reagent and the 
remaining cDNA was stored at −80 °C. RT-qPCRs was performed using a LightCycler 480 





for both human and mouse studies as indicated in the figure legend. Relative expression was 
calculated by the ΔΔCT method [40]. Each RT-qPCR contained 1× buffer, 0.4 mM dNTPs, 50 
μM primers, 0.01 U Taq DNA polymerase (Invitrogen, Paisley, UK) and nuclease-free water 
(Qiagen, Crawley, UK). The general thermocycler conditions are as follows—94 °C for 3 min, 
followed by 30 cycles of 94 °C for 30 s, 63 °C for 1 min, 72 °C for 1 min with a final elongation 
step of 72 °C for 4 min.  
2.10  qPCR Statistical analysis  
Gene expression was significance was determined by two-tailed, unpaired t-test function on 
excel.  SD was calculated using the mean fold changes in >1 experiment which in turn was 
used to determine SEM. In some experiments only 1 triplicate value was used for the SD and 
SEM; this is indicated in the figure legend when this was the case.  
2.11 R processing  
Gene Expression Omnibus (GEO) dataset files were downloaded and processed using the 
RnBeads (Assenov et al., 2014) methylation analysis package (v1.0.0) through the GSE dataset 
identifier. In some cases, iDATs were downloaded manually for the GEO datasets and then 
processed with RnBeads in the same manner. Processing of the data included quality control, 
filtering out of probes containing SNPs and checking for hybridisation performance. The data 
was then normalised using the SWAN method in minfi (Aryee et al., 2014) after background 
subtraction with methylumi.noob. The data was then extrapolated from RnBeads as a bed file 
with methylation as absolute β levels and uploaded to USEGalaxy where it was subjected to 
the in-house workflow and subsequent analysis in SPSS.  
2.12 UseGalaxy Workflow  
The online bioinformatic software usegalaxy.org allows for the creation of online workflow 
tools. The Walsh lab designed a workflow for extracting the data at a list of genes or locations 
from processed beadchip array datasets uploaded as bed files containing absolute β levels of 
methylation. This workflow extracts the methylation value at each probe at the region or gene 





max which is then used to work out the standard error of mean and significance. In some 
figures, the individual probes were taken and statistical analysis was carried out using SPSS 



















Chapter 3. Determination of the potential utility of Methylation BeadChip arrays in the clinical 
diagnosis of imprinting disorders 
3.1 Introduction  
3.1.1 Clinical Diagnosis of imprinting disorders 
As established throughout this thesis, imprinting disorders are a group of congenital disorders 
defined by molecular aberrations at imprinted genes/regions. The molecular disturbances 
observed in imprinting disorders are not the only feature shared among these disorders, 
many imprinting disorders also share similar clinical features involved in growth, metabolism 
and development. Due to the broad phenotype spectrum among imprinting disorders and the 
overlap of clinical features can result in patients being mis- and/or underdiagnosed due to a 
lack of efficient diagnostics and clinical management (Eggermann et al., 2015c). When 
imprinting disorders are suspected, the first test carried out would usually be a DNA 
methylation analysis of the ICR (Paulsen and Ferguson-Smith, 2001). This is due to the 
methylation disturbances at the ICR due to single-locus imprinting disturbances (SILD), copy 
number variance (CNV), or UPD. DMRs are regions in which allele-specific methylation occurs, 
a quantitative analysis of DNA methylation at imprinted DMRs carried out by Woodfine, 
Huddleston, and Murrell 2011 suggested DMRs established in the germ-line were quite stable 
and would normally fall within a range of 35-65% in healthy individuals. It is also important to 
consider the methylation differences between gDMRs and sDMRs, as gDMRs typically display 
very high levels of DNA methylation on the methylated allele (90–100%) and very low levels 
of DNA methylation on the unmethylated allele (0–10%). In contrast, significantly more 
variations in DNA methylation patterns are observed at secondary DMRs (Nechin et al., 2019).  
Unlike the more common methylation control elements observed in the genome which are 
normally hypermethylated or hypomethylated as described in the density plot in Figure 3.1. 
Figure 3. 1 is a bimodal graph with the probe density on the Y-axis and beta methylation value 
across the bottom. The first peak represents the number of hypomethylated probes, while 
the second peak represents the number of hypermethylated probes in both the healthy and 





methylated probes. As imprinted DMRs are intermediately methylated it is no surprise that 
the SRS patients display a decrease of intermediately methylated probes and an increase of 
hypermethylated probes due to their disturbances at a subset of DMRs.  
Figure 3.1: Density plot comparing the methylation distribution across probes from the Infinium 450k beadchip array in 
blood samples from SRS patients and healthy 
controls. In normal conditions density plots will 
present with the peaks showing here in which 
highly methylated probes are largest in density 
(Red), followed by lowly methylated probes 
(Blue), then a low density of intermediate probes 
(Green). Imprinted regions would fall under 
intermediately methylated probes due to having 
methylation levels around 50%. Therefore, it is 
understandable that the disruption of the 
imprinted regions caused by Silver-Russell 
Syndrome (SRS) patients would result in a 
decrease of intermediately methylated probes 
and an increase in highly methylated probes. 
Generated by Gareth Pollin (2020) using the 





Methylation-specific PCR and southern blots were frequently used for the diagnosis of 
imprinting disorders. However, due to the labour intensity of the southern blot and 
qualitative-only data limitation of both methods, they have over time been replaced with 
methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) (Algar, 
2019). MS-MLPA is carried out by the hybridisation of two gene-specific adjacent probes to 
the sample DNA, it utilises methylation-sensitive enzymes to digest the DNA along with DNA 





Figure 3.2. This is advantageous over the other methods as it is simple and several tests can 
be run simultaneously. Subsequent results are 1) quantitative; 2) return data which includes 
methylation at either one, two, or none of the alleles depending on the disturbance and finally 
3) can show CNV, CNV analysis would have been previously ran separately along with the 
methylation-specific PCR and southern blots (Nygren et al., 2005). In patients with UPD, 
diagnosis is usually carried out by genotyping of microsatellite markers at the chromosome 
suspected to be affected in comparison to the two parental chromosomes, also single 
nucleotide polymorphism (SNP) arrays may be used as a diagnostic tool for UPD (Altug-Teber 
et al., 2005; Chen et al., 2019; Wilson et al., 2008). Diagnostic tests for imprinting disorders 
usually focus on one locus/region, with the two commonest being chromosomes 11 and 15 
which I will talk about first. With the increase in studies using genome-wide technologies, 
however, it is being observed that many imprinting disorders are not restricted to the disease-
specific regions but rather additional genetic and epigenetic disturbances can be seen at other 
imprinted loci and DMRs throughout the genome (Eggermann et al., 2014) and I will discuss 





Figure 3.2: Experimental protocol for methylation-specific multiplex ligation-dependent probe amplification. (A) Each 
probe is designed with a target sequence for a restriction site of a methylation-sensitive endonuclease, a nonhybridizing tail 
containing and universal primer sequences (X and Y). A “stuffer sequence” is added to either probe to modulate the length. 
(B) The left and right probes will hybridize adjacently to the target sequence, after this ligation with the methylation-sensitive 
endonuclease is carried out but only cutting probes that have bound to unmethylated strands, leaving the methylated bound 
probes intact. The intact probes are then amplified using fluorescently labelled primers complementary to the primer 
sequences on the probes. Fragments are usually analysed by measuring signals from both digested and undigested samples, 
comparison of these two samples it is possible to determine the DNA methylation levels. reprinted from “DNA methylation 





3.1.2 Chromosome 11 Imprinting disorders 
The short arm on chromosome 11 (11p15) contains two very distinct imprinted clusters 
controlled by their respective ICRs. These two ICR’s show opposite parental methylation and 
play an irreplaceable role in growth and development. The H19 maternally methylated DMR 
(also known as ICR1) controls the expression of the H19/IGF2 loci and some nearby genes, the 
mechanism in how it controls expression at this region is explained in the General 
Introduction chapter. The KvDMR (also known as ICR2, KvLQT1-A andLIT1) is the contrasting 
paternal DMR, controls a cluster of genes around the KCNQ1 and CDKN1C loci as well as 
nearby genes (Begemann et al., 2012). The KvDMR is not well understood in contrast to the 
H19 DMR, though recent studies have shown a strong requirement for maternal transcription 
of the KNCQ1 gene. Disruption of transcription of the KNCQ1 gene has been shown to 
correlate with a failure to establish methylation at the KvDMR (Beygo et al., 2019a; Valente 
et al., 2019). Aberrant expression of the maternal or paternal genes at these ICRs can lead to 
maternal Silver-Russell Syndrome (SRS) and paternal Beckwith Wiedemann syndrome (BWS) 
imprinting disorders respectively (Õunap, 2016).  
SRS is a Pre- and postnatal growth restriction disorder with many clinical features, it was first 
described by Silver et al., (1953) and later by Russell (1954). Azzi et al (2015) suggested the 
most recent clinical scoring system in which they list 6 of the most common SRS phenotypes: 
if the patients match 4+ of the items then they likely have SRS, +2 SRS is suspected and less 
than 2 they do not have SRS with a sensitivity of 98%. This list includes (1) prenatal growth 
retardation; (2) postnatal growth retardation; (3) relative macrocephaly at birth; (4) 
protruding; (5) body asymmetry; (6) feeding difficulties. The SRS phenotype has been 
observed together with disturbances at different loci throughout the genome, with 
approximately 40% of cases occurring due to hypomethylation at the H19 DMR with a subset 
of these patients suffering from MILD (7-9%) (Eggermann et al., 2016). The other primary 
cause of SRS cases is due to mUPD 7 (10%). Rare cases of SRS has also been observed in some 
patients with mUPD of chromosome 16 and 20, partial deletions on chromosomes 1, 11, 12 
and 15 were also observed in rare cases of SRS  (Azzi et al., 2015; Fokstuen and Kotzot, 2014). 
Due to the complex nature of this disease, 30-40% of patients are diagnosed based on clinical 





BWS is a heterogeneous disease compared to SRS and is its polar opposite in terms of growth 
and molecular disturbances (Galerneau, 2018). BWS is primarily an overgrowth syndrome but 
linked with many other clinical features, it was first described in 1963 and 1964 by Beckwith 
and Wiedemann respectively (Beckwith, 1963; Wiedemann, 1964). A study on a set of Chinese 
BWS patients observed that 48.1% of cases were linked to loss of methylation at the 
maternally methylated KvDMR, while 11.1% of patients were associated with 
hypermethylation at the paternally methylated H19 DMR, 33.3% of patients suffered from 
upd(11)pat and finally, 7.5% of patients were seen with CDKN1C mutations (Luk, 2017). 
Diagnosis of BWS is made through the help of a clinical scoring system, a recent consensus 
statement defined a criterion using cardinal and suggestive features awarding 2 and 1 points 
respectively. Patients with >4 points are sufficient to be diagnosed with BWS while patients 
with >2 are recommended to have genetic testing and further investigation, those with <2 do 
not require genetic testing (Brioude et al., 2018). Unlike SRS only 13-15% of BWS patients are 
diagnosed based on clinical symptoms with no molecular disturbance (Õunap, 2016). 
3.1.3 Chromosome 15 Imprinting Disorders  
The PWS/AS region on chromosome 15  (15q11–13) is controlled by an imprinting centre (IC) 
pair which includes the PWS-IC and AS-IC, both the ICRs control a number of imprinted genes 
most of which are paternally expressed (Chamberlain and Lalande, 2010a). The PWS-IC 
contains a DMR and is found at the promoter region of the SNURF/SNRPN loci, the AS-IC does 
not contain a DMR and is found 35kb downstream from the PWS-IC. Though not imprinting 
control regions, the MKRN3 and NDN promoter regions contain maternally methylated DMRs 
(Horsthemke and Wagstaff, 2008; Matsubara et al., 2019). There is strong evidence that the 
AS-IC drives maternal methylation at the PWS/AS region, recently it was reported that the AS-
IC overlaps with oocyte-specific transcription start sites in which the transcripts involved may 
play an important role in maternal-specific methylation at PWS/AS region (Beygo et al., 2020; 
Lewis et al., 2015; Matsubara et al., 2019). Molecular defects at the PWS/AS imprinting region 
are observed in patients with PWS and AS, in which aberrant expression of the imprinted 
genes is seen (Rabinovitz et al., 2012).  PWS was first described in 1956 by Andrea Prader it 
presents with clinical features such as hypotonia, hypogonadism, obesity and central nervous 





recommend patients for genetic testing, is split into different age groups, gradually increasing 
the number or severity of the common features involved with PWS. Genetic testing is 
suggested from birth to 2 years old if hypotonia with poor suck is observed while the criteria 
for 13 years of age through to adulthood includes common features like intellectual 
disabilities, excessive eating and hypothalamic hypogonadism and/or typical behaviour 
problems. Further criteria exist for 2-6 and 6-12-year-olds (Gunay-Aygun et al., 2001). The 
molecular defects in PWS is much more defined than the previously discussed imprinting 
disorders. About 70% of cases occur due to a regional paternal chromosomal deletion at 
15q11-q13, while roughly 25% of cases are caused by maternal disomy of chromosome 15 
and the remaining individuals have either epimutations or microdeletions at the PWS-IC 
(Butler et al., 2016). Interestingly the molecular defects do not cause different combinations 
or addition/removal of clinical features, though patients with 15q11-q13 maternal 
duplications appear to have more severe behaviour and psychological problems (Butler et al., 
2004). 
AS is a rare neurogenetic disorder first described by Harry Angelman in 1965, similar to PWS 
it presents with intellectual disability, though no other clinical features overlap (Angelman, 
1965). The diagnosis of AM involves a criteria list of clinical features leading to suspicion, 
however, it can only be effectively diagnosed with molecular testing (Williams et al., 1995; 
Williams et al., 2006).  Similarly, to PWS about 75% of AM patients contain a regional 
chromosomal deletion at 15q11-q13 but instead on the maternal chromosome. Interestingly 
parental UPD is associated with a small percentage (1-2%) of AM patients (Buiting et al., 
2016). A further 1-3% can be caused by imprinting defects, either aberrant methylation or 
loss of the AS-IC, leading to loss of maternal imprinting. 10% of patients are associated with 
mutations at UBE3A, the majority of which are premature stop codons and the remaining 
patients are observed to have no identifiable defect (Beygo et al., 2019b). Only two paternally 
imprinted genes are present at the PWS/AS imprinted region, which are UBE3A and ATP10A: 
while UBE3A plays a role in cell cycle regulation, the function of ATP10A is currently not yet 





3.1.4 Multilocus imprinting disorder 
How MLID (Multilocus imprinting disturbances) occurs has not yet been established, however, 
it has been observed to be dependent on the tissue and the imprinting disorder. MLID has 
currently been investigated in syndromes such as BWS, SRS, transient neonatal diabetes 
mellitus (TNDM1) and Pseudohypoparathyroidism Ib (PHP1b) (Eggermann et al., 2015b). 
MLID was first observed by Mackay et al (2008) in TNDM patients with mutations within the 
ZFP57 gene resulting in variable but stable mosaicism of hypomethylation. The TNDM 
patients with the ZFP57 mutation present with classical TNDM as well as other, 
heterogeneous features, most notably developmental delay and congenital heart disease. 
The authors observed the first instance in which a global heritable global imprinting disorder 
that was compatible with life. A follow-up study by Boonen et al., (2013) further investigated 
the implication of TNDM1 patients with a mutation in ZFP57, the authors observed consistent 
loss of methylation at the PEG3 and GRB10 DMRs, some patients were also displaying a 
combination of congenital abnormalities and/or developmental delay along with the 
phenotype associated with TNDM1 as noted in the previous study by the same lab. A further 
study showed two patients with TNDM1, both patients had hypomethylation at the PLAGL1 
DMR which was expected, but were also observed with hypomethylation at the KvDMR 
(Arima, 2005). 
 In BWS aberrant methylation is expected to be at the KvDMR and/or H19 imprinted regions, 
though one study has associated MLID in up to 30% of BWS patients with hypomethylation at 
the KvDMR, although is less common in BWS patients with H19 hypermethylation (Sanchez-
Delgado et al., 2016a). NLRP family members NLRP2, NLRP5 and NLRP7 have also been 
associated with MLIDs in a term described as ‘maternal-effect’ mutations. As mentioned in 
the previous chapter, maternal NLRP2 germ-line mutation is associated with BWS in offspring 
with loss of methylation at the KCNQ1OT1 and MEST DMRs (Meyer et al., 2009). NLRP5 is the 
most recent of the NLRP family to be involved with MLIDs: maternal NLRP5 mutations led to 
the loss of imprinting for a number of genes in various combinations, with some of the 
offspring displaying BWS- and SRS-like phenotypes (Docherty et al., 2015). NLRP7 is the most 
investigated of the NLRP family members involved with MLIDs: maternal NLRP7 mutations 





hydatidiform mole, which shows normal biparental chromosomes but complete loss of 
maternal imprinted DMRs (Begemann et al., 2018; Mahadevan et al., 2014; Murdoch et al., 
2006). These maternal effect genes have been investigated using mouse models, however, 
they have not provided insight into the mechanisms behind MLID as mutations at these genes 
result in early embryo lethality or cause limited imprinting alterations in the progeny 
(Mahadevan et al., 2017; Sparago et al., 2019; Tong et al., 2000).  
3.1.5 Uniparental disomy  
Many different models have been used in an attempt to understand genomic imprinting such 
as samples from imprinting disorder patients, UPD at a single chromosome or genome-wide 
UPD, in vitro mutations and/or treatment of cell lines, hydatidiform moles and uniparental 
embryonic stem cells (Allen et al., 1994; Barletta et al., 1997; Court et al., 2014; Devriendt, 
2005; Ding et al., 2015; Elalaoui et al., 2014; Quenneville et al., 2011; Sharp et al., 2010). UPD 
is the inheritance of chromosome(s) from a single parent, it is observed in almost all types of 
imprinting disorders and was first described by Engel in 1980 (Eggermann et al., 2015b; Engel, 
1980). UPD can be either isodisomy, in which the chromosome pair is a duplicate from one 
parent or heterodisomy in which the pair is heterozygous, but still from the same parent. UPD 
can arise due to 1) gamete complementation, 2) hetero-chromosomal substitution, 3) post-
fertilization errors, 4) monosomy rescue causing chromosome duplication and 5) trisomic 
rescue followed by chromosomal loss (Engel, 1993; Spence et al., 1988). Genome-wide UPD 
is a very rare occurrence with under 20 cases being described in the literature since 2017 and 
only 3 of these cases being genome-wide maternal UPD. As expected, mUPD is observed with 
a maternal bias for methylation and expression of cognate imprinted genes. Interestingly 
these patients present with an SRS-like phenotype (Bens et al., 2017; Strain et al., 1995; 
Yamazawa et al., 2010). Genome-wide pUPD is against prediction as androgenetic embryos 
would be expected to incorrectly develop to an embryoblast and instead become a 
hydatidiform mole (Devriendt, 2005). Despite this, a handful of patients with genome-wide 
pUPD have been described in the literature, they observe a methylation and expression bias 
towards paternally imprinted genes and present with BWS-like phenotypes (Morales et al., 





3.1.6 The inefficiency of imprinting disorder testing 
The majority of genomic imprinting syndromes rely on molecular tests to confirm the 
condition. While this may be appropriate for PWS, which is well-characterised with 3-4 
abnormalities all focused within one region, it is just not enough for the remaining imprinting 
disorders. Many of the imprinting conditions especially SRS have a proportion of clinically 
diagnosed patients in which no underlying molecular defect could be found using standard 
tests such as MS-MLPA. This is disadvantageous to the patient as many imprinting syndromes 
have varying phenotypes depending on the molecular disturbance that is causing the 
disorder. Diagnosis based on clinical features could lead to a misdiagnosis of the patient and 
therefore preventing the patient from receiving the suitable treatment. With the increased 
use of genome-wide methylation tools, MLID is being seen as a common occurrence among 
many imprinting disorders and presents with varying phenotypes, combining the known 
clinical features involved within their respective imprinting disorders and additional 
phenotypes in some cases. Current diagnostic tests lack the power to accurately identify 
patients with imprinting disorders and the full extent of their molecular defects without 
multiple tests especially with the increased observation of MLIDs. The Illumina bead chip 
array has been described as a promising tool for molecular diagnostics (Grafodatskaya et al., 
2016). Due to the increased occurrences of MLID and variable phenotypes liked with the 
disturbances it is imperative that a diagnostic test for imprinted disorders has the capacity to 
diagnose disturbances outside the disease-causing region. With this in mind, the genome-
wide bead chip array would be a strong candidate. However, before the bead chip array can 
be utilised in such manner a set of normal ranges for each DMR will need to be correctly 
defined to be able to conclude what constitutes as a gain or loss of methylation at imprinted 
DMRs (Monk et al., 2018). 
3.1.7 Characterisation of imprinted DMRs using Infinium arrays  
A study by Hernandez et al (2018) previously characterized the imprinted regions using the 
850k array and identified imprinted status at new genes using UPD patient data. The authors 
also went on to characterize normal and abnormal levels of methylation by comparing the 





carried out in this thesis. To carry this out Hernandez et al (2018) used ± 1SD from the control 
data as their statistical cut-off.  
In the previous chapter, we observed that the methylation data at a subset of imprinted DMRs 
were non-normally distributed in human blood 450k datasets. With this mind, we believed it 
to be better to use the median along with the IQRs to create a statistical cut-off for normal 
ranges of methylation for each DMR. Further to this, we will also compare these cut-offs 
against numerous imprinted disorder patient datasets for PWS, AM, SRS and BWS to detect 
abnormal methylation in patient datasets rather than just UPD patients as seen in the 
Hernandez study. Due to the lack of 850k datasets for imprinting disorder patients, we will 
carry out this study using 450k array datasets. 
 The overall aim of this chapter is to characterise normal ranges of methylation in the 450K 
array using the median and IQRs. The normal ranges will then be tested for the ability to 
detect molecular defects at imprinted regions in order to provide a more powerful diagnostic 
tool for describing multiple molecular defects and the presence of MLID in one test.   
3.2 Aims and objectives  
Aims 
Can we use the 450k array to: 
1. Identify normal methylation at imprinted regions 
2. Categorise a set of testable DMRs  









1. Score methylation at 2-3 well-characterised imprinted regions in the blood  
2. Test normal range for these imprints in several tissues to assess variability among 
somatic tissue 
3. Apply this to all known imprints to see how many can be scored like this 
4. Define a criterion for normal variability at DMRs in 100 blood control samples 
5. With the use of a defined criterion is it possible to score abnormal methylation defects 
to diagnose Angelman syndrome, Prader–Willi syndrome, Silver Russell syndrome and 
Beckwith Wiedemann syndrome patient 450k samples? 
3.3 Methods 
R-studio was used to generate bed files of 450k array data sets to be uploaded and analysed 
using USE-GALAXY as described in chapter 2. Normal somatic tissue 450 datasets used in this 
chapter was blood (GSE55491), saliva (in house dataset), muscle, liver and brain (GSE52578). 
Genome-wide UPD patient samples for maternal and paternal methylation controls 
(GSE52578). 100 healthy blood samples were used to create a normal reference range 
(GSE73103). Finally, imprinting disorder datasets used in this chapter was Angelman 
syndrome (GSE78956), Prader-Willi syndrome (GSE78956), Beckwith-Wiedemann syndrome 
(GSE78956 and GSE95488) and finally Silver-Russell Syndrome (GSE55491). These datasets 
while all very detailed and furthered our understanding of imprinting disorders, they use 
extremely complex bioinformatic approaches which would not be applicable to a diagnostic 
setting without highly experienced training. Further from this, only Bens et al (2016) describe 
what they believed to be abnormal changes of methylation but this may not be a suitable 







3.4.1 Establishing testable DMRs 
To test the 450k array a detailed collection of imprinted DMRs was assembled using the 
literature, as gDMRs are more stably kept as lifelong marks they make up the majority of the 
list along with some sDMRs that have been relatively well described (Table 1). This list as 
generated using the genome location as defined by Court et al (2011) and Woodfine et al 
(2011). While both studies thoroughly investigated imprinting DMRs, Woodfine et al (2011) 
carried out investigations by validating 50 pyrosequencing assays for imprinting DMRs across 
numerous somatic tissues. However, a shortcoming of this paper is that it did not confirm the 
methylation bias on the alleles with other methods.  Court et al (2014) furthered the 
investigations into genomic imprinting DMRs with the use of genome-wide methylation 
infimum bead chip array on a number of somatic tissues and genome-wide UPD patients.  
Using this approach Court et al was able to show several novel regions with parental specific 
methylation, though they did not investigate normal variation at the imprinted DMRs and had 
a small number of somatic tissues as controls. Using these two papers a list of coordinates 
was generated to investigate normal variability of imprinting DMRs across a large pool of 
samples. Then using this variability to create a methylation index (MI) to identify epimutations 
to diagnose potential imprinting disorders.  The initial list was produced based on the 
establishment of the DMR and a selection of novel DMRs which showed promise. Some DMRs 
in the original formulation of the list showed methylation bias but only contained 1-5 probes 
lowering its statistical power, however, are described to be disturbed in some imprinting 
disorders so all DMRs with low probe coverage were kept as to not discriminate, though this 
















Source ID Reference 
PPIEL chr1 40024626 40025540 M UNK 4 4 Court PHP1B 
(Rochtus et 
al., 2016) 
DIRAS3_ex2 chr1 68512505 68513486 M S 8 8 Both PHP1B (Begemann et 
al., 2018; 
Fontana et al., 
2018; 
Sanchez-
Delgado et al., 
2016a) 
DIRAS3 chr1 68515433 68517545 M GL 21 23 Both PHP1B 
ZDBF2 chr2 207114583 207136544 P UNK 8 14 Both IUGR/MLID 
(Monteagudo-
Sánchez et al., 
2019) 
NAP1L5 chr4 89618184 89619237 M GL 15 13 Both MLID 
(Bak et al., 
2016; 
Sanchez-
Delgado et al., 
2016a) 
FAM50B chr6 3849082 3850359 M UNK 25 24 Court MLID (Bens et al., 
2016) 
PLAGL1 chr6 144328078 144329888 M GL 17 15 Court TNDM1 
(Mackay et al., 
2005) 
IGF2R chr6 160426265 160427561 M UNK 4 5 Both N/A N/A 
GRB10g chr7 50848726 50851312 M GL 9 10 Both SRS 
(McCann et 
al., 2001) 
PEG10 chr7 94284759 94287960 M GL 72 68 Both SRS 
(Hannula-
Jouppi et al., 
2013) 
MEST chr7 130130122 130134388 M GL 62 54 Both SRS 
(Hannula-
Jouppi et al., 
2013) 
HTR5A chr7 154862719 154863382 M UNK 6 8 Court SRS 
(Hannula-




chr8 37604992 37606088 M UNK 7 7 Court N/A N/A 
TRAPPC9 chr8 141108147 141111081 M UNK 8 9 Court N/A N/A 
INPP5F chr10 121577530 121578727 M GL 6 7 Both MLID 
(Maeda et al., 
2014) 





IGF2_DMR2 chr11 2153834 2155112 P S 10 10 Woodfine MLID (Maeda et al., 
2014) IGF2_DMR0 chr11 2168333 2170145 P S 1 2 Woodfine MLID 
KvDMR1 chr11 2719948 2722259 M GL 33 26 Both BWS 
(Smilinich et 
al., 1999) 
RB1 chr13 48892341 48895763 M GL 13 13 Both SRS 
(Prickett et al., 
2015) 
MEG3 chr14 101290524 101293978 P S 33 35 Both TS 
(Temple et al., 
1991) 
MEG8 chr14 101370741 101371419 M S 1 1 Court TS 
(Temple et al., 
1991) 





NDN chr15 23931451 23932759 M S 8 10 Court PWS/AM 
SNRPN_ 
intraCpG29 
chr15 24671872 24672679 M 
UNK 
4 3 Court N/A N/A 
SNRPN_ 
intraCpG40 
chr15 25017924 25018886 M 
UNK 
4 4 Court N/A N/A 





Table 3.1:  Imprinted DMRs used for investigation. The table shows the location within the genome, parent of origin, the 
establishment of the mark, probe coverage based on the 450k and 450k array, source of the DMR location and any associated 
disorders linked to loss of imprinting at the respective DMR and the reference is a source linking the DMR to the respective 
disorder. M, Maternal; P, Paternal; Unknown, Methylation and/or Marks establishment unknown; PHP1B, 
pseudohypoparathyroidism type 1B; MLID, Multilocus imprinting disturbance;  IUGR, intrauterine growth restriction; 
TNDM1, Diabetes Mellitus, Transient Neonatal 1; SRS, Silver Russell Syndrome; PWS, Prader-Willi syndrome; AM Angelman 
syndrome; BWS, Beckwith-Wiedemann syndrome; Upd16mat, maternal uniparental disomy of chromosome 16; TS, Temple 
Syndrome; GL. Germ-line; S, Somatic; UNK, Unknown; ID, Imprinting Disorders; MO, Methylation Origin; Chr, Chromosome; 




SNRPN_2 chr15 25093008 25093829 M UNK 4 4 Court N/A N/A 
SNRPN_3 chr15 25123027 25123905 M UNK 6 5 Court N/A N/A 






IGF1R chr15 99408496 99409650 M UNK 7 7 Court MLID 
(Begemann et 
al., 2018) 
ZNF597 chr16 3481801 3482388 M GL 2 3 Court Upd16mat 




chr16 3492828 3494463 P S 12 15 Court Upd16mat 
ZNF331 chr19 54057086 54058425 M S 16 30 Court IUGR 
(Petre et al., 
2018) 
PEG3 chr19 57348493 57353271 M GL 37 36 Both MLID 
(Baple et al., 
2011; Boonen 
et al., 2013) 
MCTS2P_ 
HM13 
chr20 30134663 30135933 M GL 10 8 Both N/A  
BLCAP_NNAT chr20 36148604 36150528 M S 37 37 Both MLID 
(Sanchez-
Delgado et al., 
2016a) 
L3MBTL chr20 42142365 42144040 M GL 26 26 Both MLID 
(Bak et al., 
2016; 
Sanchez-
Delgado et al., 
2016a) 
GNAS chr20 57414039 57418612 P UNK 23 26 Court MLID (Bak et al., 
2016; Baple et 
al., 2011; Bliek 
et al., 2009; 





chr20 57425649 57428033 M S 66 59 Court MLID 
GNAS_XL chr20 57428905 57431463 M GL 6 7 Both MLID 
GNAS_1A chr20 57463453 57467939 M S 62 58 Both MLID 
NHP2L1 chr22 42077774 42078873 M UNK 8 8 Court MLID 
(Bak et al., 
2016; Rochtus 





3.4.2 Categorising imprinted methylation with 450k 
To initially look to see whether the methylation bead chip arrays can differentiate between 
imprinted DMRs/ICRs and other methylated controlled regions, 3 well-described DMRs (H19, 
KvDMR and SNURF) were compared to hypermethylated and hypomethylated CGIs at the 
promoter regions of DAZL and MTHFR respectively in the blood (Figure 3.3). It was clear that 
the methylation at the imprinted DMRs investigated was indicative of imprinted DMRs (35-
65%) while the DAZL and MTHFR promoter CGI’s showed clear hypermethylation and 
hypomethylation, respectively, in both the 450k (A) and EPIC (B) array. The EPIC was analysed 
due investigate whether greater probe coverage at the regions resulted in any changes of 
variability at the DMR (Hernandez Mora et al., 2018). As well as greater probe coverage the 
EPIC array also covers the IG-DMR not covered by the 450k array as shown in the next chapter 
(Figure 4.5). Due to lack of Imprinted disorder datasets for the 850k array, the 450k array will 
be used for further analysis.  
Figure 3.3: Ability of the array to detect well-established imprinted DMRs in blood and saliva tissue. Average methylation 
of probes found within the genomic coordinates for the H19 (51 probes (450k) 43 probes (EPIC)), KvDMR (33 probes (450k) 
26 probes (EPIC)) and SNURF (7 probes (450k) 10 probes (EPIC)) DMRs with DAZL (Chr3:16646340-16647237) (8 probes (450k) 
12 probes (EPIC))  and MTHFR (Ch1:11865387-11866780) (15 probes (450k) 19 probes (EPIC))  promoter region CGI’s as 
positive and negative controls of common methylation control regions in (A) 5 healthy peripheral blood 450k samples and 
(B) 23 healthy Saliva 850k samples. X; Mean, Line; Median, Box; interquartile range (IQR), Whiskers; IQR*1.5, Circles; probe 
outliers. Using the Mann Whitney U test (MWU) all imprinted DMRs tested were significantly different (p<0.001) to both 





Figure 3.4: Variability at well-established DMRs across different somatic tissues Average methylation of probes found 
within the genomic coordinates for the (A) H19 (51 probes), (B) KvDMR (33 probes) and (C) SNURF (7 probes) DMRs in 450k 
blood (n=5), muscle (n=1), liver (n=1) and brain (n=1). The box represents the interquartile range (IQR), the whiskers are 
IQR*1.5; the X marks the mean and a line represents the median; circles are outlier probes. MWU significance in comparison 
to blood demonstrated by *p < 0.05; **p < 0.01; ***p < 0.001. 
To further understand the ability of the 450k array to categorise imprinted DMRs the 
variability across different somatic tissues was examined. As expected, the average 
methylation fell within the expected imprinted DMR range of 35-65% (Figure 3.4). As 
expected, normal methylation was observed across the imprinted DMRs tested, with only the 
liver sample appearing as statistically different when compared to blood for the imprinted 
DMRs H19 and KvDMR. Although sample numbers were low for other somatic tissues, these 
results nevertheless suggested that in blood and saliva at least (two readily accessible tissues) 







We now wished to test if the 450k could be used to differentiate abnormal from normal 
methylation patterns at these DMRs. To do so, 450k datasets from the blood of rare cases of 
genome-wide maternal and paternal UPD were utilised (Court et al., 2014). The GSE52578 
dataset was from the detailed beadchip analysis from Court et al (2014), the authors 
investigated a large collection of imprinted DMRs in different somatic tissues and genome-
wide UPD patients allowing for novel DMRs to be discovered. However, for categorising 
imprinted DMRs the authors lacked sample numbers so would not show the true value of 
methylation-based on sample variability. When compared to the control blood dataset, the 
genome-wide UPD patients’ samples showed the expected methylation bias i.e. the 
maternally methylated H19 DMR was hypermethylated and hypomethylated in the mUPD 
and paternal UPD (pUPD) respectively and vice versa in the paternally methylated DMRs 
KvDMR and SNURF (Figure 3.5A-C). As a control, the CGIs at the promoter region of DAZL and 
MTHFR remain hyper- and hypomethylated respectively, though small differences (<10%) can 
be detected (Figure 3.5 D-E). Therefore, proof of concept has been shown, that the 450k can 
detect methylation levels indicative of normal methylation levels in control blood with the 
ability to differentiate between normal and abnormal samples due to unique methylation 





Figure 3.5: The 450K array can differentiate between normal and abnormal methylation in tissues with known uniparental 
bias. Utilising 450k array data for genome-wide UPD, it is possible to see distinct changes of methylation at the Imprinted 
DMRs near the (A) H19, (B) KvDMR and (C) SNURF loci in comparison to a normal blood control. To ensure that the changes 
of methylation between the genome-wide UPD samples and blood were unique to the Imprinted DMRs methylation was 
examined at the heavily methylated CGI at the (D) DAZL promoter region and the lightly methylated CGI at the (E) MTHFR 
promoter region. pUPD, paternal uniparental disomy; mUPD, maternal uniparental disomy. Box and whiskers as before, 







3.4.3 Application of concept to a larger set of imprinted DMRs 
Since it was established that aberrant methylation could be detected at the H19, KvDMR and 
SNURF/SNRPN DMRs in the control UPD samples, the same method was applied to all of the 
imprinted DMRs described in Table 3.1. Many of these DMRs were not as well described as 
the previously tested DMRs. Therefore, to determine the normal ranges for each maternally 
methylated DMR the datasets GSE73103 (Blood) and GSE52578 (Muscle, Liver and Brain) 
were utilised to score methylation at imprinted DMRs across different somatic tissues, though 
only blood was used for further downstream analysis in order to match tissue from the 
imprinted disorder datasets (Figure 3.6A).  Similarly, this was carried out for the paternally 
methylated DMRs (Figure 3.6B).  
Figure 3.6: Characterising methylation at Imprinted DMRs across somatic tissues. (A)Variability of methylation at paternally 
methylated Imprinted DMRs in different somatic tissues. (B) Variability of methylation at maternally methylated Imprinted 
DMRs in somatic tissues. The average methylation was calculated using all probes within the DMR for each individual blood 
control sample. The average DMR methylation for each sample was then averaged and the median methylation at each DMR 
was used to plot the line graph with error bars representing IQR. Only 1 sample was used for Muscle, Liver and Brain so mean 





Imprinted DMRs were excluded if methylation levels were above 70% or less than 40% a 
similar exclusion criteria carried out by (Hernandez Mora et al., 2018). Further to this if the 
interquartile range (IQR) was over 10% these DMRs were also excluded from any further 
testing due to having methylation not indicative of a DMR or an IQR suggestive of a highly 
variable region as indicated by the red boxes in Figure 3.7 A and B.  The excluded regions are 
listed in Fig. 3.7C: a number of these are novel regions defined by a single study (Court et al., 
2014) or further studies from within the same group and so did not have extensive support 
for being imprinted. While the methylation bias is also detectable here, the authors only used 
a small sample size of somatic tissues, within a large collection of normal samples these 
regions appear to be highly variable which would make it difficult to detect abnormal 
methylation in patient samples.  
Figure 3.7: Characterising methylation at Imprinted DMRs in control blood. (A)Variability of methylation at (A) maternally- 
methylated and (B) paternally-methylated imprinted DMRs. The average methylation was calculated using all probes within 
the DMR for each individual blood control sample and the median methylation from 100 samples plotted, with error bars 





As a further criterion for using the array to score methylation, we compared methylation in 
the normal blood samples to that of the genome-wide UPD patient samples: if the median 
methylation values in either of the UPD samples were within the IQR of the control blood 
samples, as indicated by the red boxes in Figure 3.8A, that DMR was also excluded from 
further testing. Using these criteria excludes any DMRs which may complicate further results 
due to the inability to determine normal and abnormal methylation results.  The DMRs 
remaining show clear methylation bias in both pUPD and mUPD samples within a methylation 
range of 40-70% (Figure 3.8A and B).  
Figure 3.8: Investigating abnormal methylation at imprinted DMRs. (A) Methylation at paternally methylated Imprinted 
DMRs in control blood samples and paternal and maternal genomewide uniparental disomy patients. (B) Methylation at 
maternally methylated Imprinted DMRs in control blood samples and paternal and maternal genomewide uniparental 
disomy patients. The average methylation was calculated using all probes within the DMR for each individual blood control 
sample. The average DMR methylation for each sample was then averaged and the median methylation at each DMR was 
used to plot the line graph with error bars representing IQR. Red boxes indicate DMRs excluded from further testing and are 





Once this clear set of testable Imprinted DMRs had been established, they were used to 
investigate methylation abnormalities in imprinting disorder patients. To facilitate this, a 
methylation index (MI) was formulated based on median methylation of each individual DMR 
across 100 normal patient blood samples and using the Interquartile rule to find outliers was 
used as a criterion to define gains and losses of methylation outside the normal range so that 
each MI was uniquely based on the intervariable methylation of each distinctive imprinted 
DMR associated with single-locus disorders.  For multi-locus imprinting disorders (MLID) an 
adjusted MI was used with an additional +/-5% to increase stringency and therefore the 
likelihood that the change of methylation is involved in MLID as many of these regions are 
not functionally described or previously observed in the literature to be involved with MLID.  
3.4.4 Ability of the array to accurately identify Prader-Willi and Angelman syndrome 
patients 
As the molecular diagnosis of PWS is well described (see chapter Introduction), this was the 
first to be investigated using the array to determine if the MI criteria would be sufficient to 
accurately score patients with epigenetic changes. To do so, we availed of a published dataset 
from GSE78956 which was generated during a study carried out by Bens et al (2016) 
investigating the phenotypical spectrum and methylation defects within MLID. This was a 
good collection of imprinting disorder patients containing 37 patients’ samples of varying 
imprinting disorders and compared them against 39 control patient samples to test if the 450k 
array could detect methylation disturbances in patient samples outside the normal disease-
causing locations. The authors here described hypomethylation and hypermethylation values 
with changes over 10% from the normal blood samples. This was a highly valuable collection 
due to the variety and number of imprinting disorders examined using the infimum bead chip 
array especially for the work planned to be carried out in this chapter. RStudio along with the 
RNbeads package was utilised to download this dataset from the GEO expression omnibus as 
described in chapter 2. Table 2 shows the result of processing the dataset from Bens et al 
(2016), concentrating on Chromosome 15p etc around the defined imprinted genes 
SNURF/SNRPN. Three PWS and three AM patients were available and their methylation values 
was compared to a defined MI by using the median methylation seen across the same regions 





imprinting cluster on chromosome 15 while the AM patients appeared with paternal specific 
methylation. The abnormal methylation discovered here had a 100% match to the previously 
diagnosed epimutations. The MI described above, identified all tested DMRs within this 
imprinted cluster as abnormal across all patients with hypomethylation or hypermethylation 
in PWS and AM respectively.  As this dataset also contained sample data for TS and TNDM, 
these imprinting disorders were also tested using the MI. However, the dataset only 
contained one patient sample for both TS and TNDM so the data was not shown here but can 






Table 3.2: Median methylation across imprinted DMRs in Angelman and Prader-Willi syndrome patient samples. Methylation values with red underlined text showed gains of methylation 
relative to the methylation index (MI) for that DMR, while blue underlined text shows loss of methylation relative to the MI. PWS patients show clearly the expected hypermethylation at the 
chromosome 15 imprinted cluster while AM shows clear hypomethylation at the same region. The blood sample displays the mean methylation across 100 control blood samples, while disease 
samples represent individual cases. MWU in comparison to blood *p < 0.05; **p < 0.01; ***p < 0.001. MO, Methylation Origin; Chr, Chromosome; Est, Established; G, Germ-line; M, Maternal, 





Imprinted DMR Est MO Chr Start End Blood PWS 1 PWS 2 PWS 3 AM 1 AM 2 AM 3 
MI  
Upper 
MI    
Lower 
 
IGF1R U M chr15 99408496 99409650 63.94 51.15 56.16 56.13 51.67 57.79 50.35 81.88 45.73  
MAGEL2 G M chr15 23892425 23894029 58.39 81.33 * 82.99 * 82.86 * 23.92 * 20.38 * 15.48 * 64.86 51.14  
NDN G M chr15 23931451 23932759 50.99 73.73* 71.6 * 71.07 * 28.53 * 28.45 * 24.43 * 62.15 37.88  
SNRPN_1 G M chr15 25068564 25069481 62.48 80.53* 83.94 * 83.79 * 32.89 * 29.22 * 22.69 * 69.2 55.78  





3.4.5 Using the 450k array for diagnostic testing in Beckwith-Wiedemann syndrome 
BWS has a slightly more complex molecular diagnosis than that of PWS and AM but contains 
clear molecular aberrations involved with the disorder. To test this, two datasets from the 
GEO expression omnibus GSE95488 and GSE78956 from two studies carried out by Bens et al 
(2016) as was used for the PWS and AM patients and a case study of 3 BWS patients carried 
out by Brzezinski et al (2017). Brzezinski et al (2017) evaluated the tumour surveillance 
programme within children with KvDMR epimutations, this dataset extended the number of 
BWS samples we could investigate including a mosaic patUPD patient. Like the dataset used 
for AM and PWS patients, the GSE95488 dataset was downloaded and processed using R 
studio and the RNbeads package. The expected molecular defects at chromosome 11 were 
observed in all BWS patient according to the MI, 1 patient had methylation indicative of 
Pat11UPD due to hypermethylation at the H19 DMR and hypomethylation at the KvDMR 
(BWS1). Two patients (22%) were observed with hypermethylation at H19 (BWS 4 and 5) 
while the remaining 6 were identified with hypomethylation at KvDMR (66%) (Table 3). The 
methylation abnormalities identified by the MI were seen to be significant through testing by 
MWU.  Further to this, the MI had a 100% match to what was previously described for the 






Table 3.3: Table methylation across imprinted DMRs in Beckwith-Wiedeman syndrome patient samples. Methylation across imprinted DMRs associated with the respective diseases, 
methylation values with red underlining text showing gains of methylation outside the defined methylation index (MI) while blue underlined text shows loss of methylation outside the defined 
MI. All patients show the expected epimutations either displaying methylation values suggesting Pat11UPD, due to hyper and hypomethylation at the H19 and KvDMR respectively, or singular 
epimutations at either H19 or KvDMR. The blood sample displays the median methylation of the average methylation of the DMR across 100 control blood samples, while disease samples 
display mean methylation at the DMR as individual samples. Mann Whitney u significance in comparison to blood demonstrated by *p < 0.05; **p < 0.01; ***p < 0.001. MO, Methylation Origin; 











MI   
Lower 
MEG8 G M chr14 101370741 101371419 68.89 59.3 63 63.6 62.11 55.33 59.44 58.7 57.05 55.37 85.09 51.033 
H19 G P chr11 2018812 2024740 59.2 64.74* 59.03 57.3 86.81* 86.73* 55.82 60.15 54.97 59.73 63.95 54.29 





3.4.6 Potential for diagnostic testing in Silver-Russell syndrome with the 450K array 
SRS is one of the more complicated imprinting disorders, so it provides an opportunity to fully 
test the ability of the 450k array and the defined MI to detect aberrant methylation. The 
GSE55491 data set generated by Prickett et al (2015) carried out a genome-wide methylation 
analysis on a large collection of SRS patients with detailed patient data. They showed that 
some epimutations were detectable in the 450k datasets in patients that had no molecular 
disturbances identified in previous diagnostic tests. The focus of this paper was to test a novel 
methodology to analyse DMR changes genome-wide describing some novel DMR locations 
across their samples. As above the dataset was downloaded and processed through the use 
of Rstudio and the RNbeads package. The MI defined here was able to confirm all SRS patients 
that were diagnosed by Pricket et al (2015) including those that were not able to be previously 
diagnosed using current standard diagnostic tests. Despite this, 50% of the cases (n=18) 
showed no methylation disturbances at the expected DMRs such as mat7UPD or H19. Of 
these, abnormal methylation suggestive of mat7UPD was observed in 3  of the SRS patients 
(SRS Patient 3, 8 and 15) while another 6 were observed with hypomethylation at the H19 
DMR (SRS Patient 4, 10, 12, 13, 14 and 17) (Table 4). Again, each epimutation identified 
through the use of the MI were seen to be statistically significant through the use of MWU.  
Further to this, each patient-matched the epimutation that was described by Pricket el al 
(2015), however, the methodology used to ‘score’ the DMRs defined in this thesis is less 







Table 3.4: Table methylation across imprinted DMRs in Silver-Russell syndrome patient samples. Methylation across imprinted DMRs associated with the respective diseases, 
methylation values with red underlining text showing gains of methylation outside the defined methylation index while blue underlined text shows loss of methylation outside the defined 
methylation index. The 50% of patients present with the expected methylation abnormalities such as mat7UPD or H19 hypomethylation.  The blood sample displays the median methylation of 
the average methylation of the DMR across 100 control blood samples, while disease samples display mean methylation at the DMR as individual samples. Mann Whitney u significance in 
comparison to blood demonstrated by *p < 0.05; **p < 0.01; ***p < 0.001. MO, Methylation Origin; Chr, Chromosome; Est, Established; G, Germ-line; M, Maternal, P; Paternal; MI, Methylation 
Index; DMR, Differentially methylated region; SRS, Silver-Russell syndrome.  
 





NAP1L5 G M chr4 89618184 89619237 60.09 59.55 60.53 59.83 59.84 60.86 59.85 65.68 59.61 59.65 69.21 48.67 
GRB10g G M chr7 50848726 50851312 61.75 63.17 60.17 87.69* 59.26 59.21 63.2 63.36 87.53* 61.54 70.59 52.79 
HTR5A G M chr7 154862719 154863382 56.08 52.6 50.8 71.05* 54.67 58.27 55.03 57.92 71.43* 51.65 65.35 46.47 
MEST G M chr7 130130122 130134388 63.44 59.9 57.39 91.26* 59.4 60.47 59.85 60.75 92.81* 58.66 69.33 56.4 
PEG10 G M chr7 94284759 94287960 43.14 42.85 40.78 70.86* 41.73 43.09 43.34 43.3 70.28* 42.27 46.7 39.41 
H19 G P chr11 2018812 2024740 59.2 59.81 59.41 58.25 49.88* 60.87 59.47 56.66 59.77 59.74 63.95 54.29 
Imprinted DMR Est M-O Chromosome Start End Blood SRS 10 SRS 11 SRS 12 SRS 13 SRS 14 SRS 15 SRS 16 SRS 17 SRS 18 
MI 
Upper 
MI   
Lower 
NAP1L5 G M chr4 89618184 89619237 60.09 57.57 59.08 58.95 58.79 59.73 54.11 59.86 64.87 55.15 69.21 48.67 
GRB10g G M chr7 50848726 50851312 61.75 58.07 58.97 59.82 61.27 62.27 84.03* 62 61.5 57.46 70.59 52.79 
HTR5A G M chr7 154862719 154863382 56.08 54.48 54.07 52.8 58.32 54.42 72.45* 54.15 55.58 58.28 65.35 46.47 
MEST G M chr7 130130122 130134388 63.44 56.18* 58.51 55.97* 58.05 60.52 92.98* 60.25 60.28 53.32* 69.33 56.4 
PEG10 G M chr7 94284759 94287960 43.14 39.57 41.31 41.49 40.52 41.49 70.62* 41.94 41.8 38.15 46.7 39.41 





3.4.7 Multilocus imprinting disturbances 
A current restriction to the current diagnostic testing is the inability to diagnose MLID that 
may be involved with the patients. Few studies have described the need for diagnostic tests 
to diagnose MLID in imprinting disorder patients, with the beadchip array being described as 
a potential candidate to carry this out, however, one issue is what loci’s should be considered 
as MLID and to what extent do changes of methylation result in MLID  (Eggermann et al., 
2014; Eggermann et al., 2016; Sanchez-Delgado et al., 2016a). In this chapter, I aim to further 
investigate these issues by defining a more stringent MI than that was used for identifying 
disease-causing loci. This increased stringency should help removed potential false positives 
increasing the likelihood that the identified target is involved in MLID and could warrant 
further investigations. This was carried out as sDMRs have variable methylation levels on 
different alleles, the increased range will also help rule out this variability, helping confirm 
true loss or gain of methylation from the hypermethylated/hypomethylated alleles, 
respectively. As sDMRs normally only affect the expression of the nearby imprinted gene 
rather than the entire cluster aberrant methylation may result in phenotypical changes to the 
disease respective to the gene/sDMR affected. 
MLID in AM and PWS is not commonly seen as it is in other imprinting disorders (Sanchez-
Delgado et al., 2016a). It is clear from the results for this the AM and PWS patients from 
GSE78956, that the disturbance is primarily localised to the large imprinting region on 
chromosome 15 and is not suggestive of chromosomal 15 UPD, as these patients do not 
appear to have abnormal methylation at the IGF1R DMR. However, 66% of AM and PWS 
patients were observed with possible MLID targets outside the expected regions. 33% of AM 
and PWS patients appeared with hypomethylation at the PLAGL1 DMR just outside the 
defined MI (Table 5). PEG3 DMR hypomethylation was observed in 33% of PWS patients and 
all AM patients, like the disturbances at the PLAGL1 DMR the PEG3 DMR hypomethylation 
was just outside the defined MI. Finally, the RB1 DMR was observed to be hypomethylated 
across all patients with multiple methylation disturbances, though similar to the previous 





Out of the imprinting disorders examined here, BWS is most commonly found to present with 
MLID (Azzi et al., 2009). Using the datasets GSE95488 and GSE78956 possible MLID targets 
were indicated in 88% (8/9) of the BWS patients with BWS7 being the only exception. The 
somatic IGF2_DMR0 was seen to be also hypermethylated in 100% of BWS patients with H19 
hypermethylation as the primary epimutation. 33% of patients were observed with extreme 
MLID with 3+ DMRs affected outside the disease-causing primary epimutation of KvDMR.  
Most of the disturbances outside the disease-causing regions were observed to be 
hypomethylated and just below the defined MI. However, extreme LOM (~10-20%) was 
observed in BWS3 at both DIRAS3 DMRs and the IGF1R and L3MBTL1 DMRs (Table 6).  
GSE55491 a dataset generated by Prickett et al (2015) was used to investigate potential 
targets of MLID and explain the SRS phenotype in patients with no primary epimutation 
defined. This was done with the use of the expanded DMR list. MLID was only observed in SRS 
patients with H19 hypomethylation. 66% (3/6) of SRS patients with the primary H19 DMR 
epimutation were observed with a further methylation disturbance at the IGF2_DMR0 DMR. 
SRS 10 was observed with hypomethylation at the PLAGL1 DMR just below the defined lower 
MI. SRS12 was observed with multiple disturbed DMRs with a LOM below the defined MI for 
MEG8 (2.63%) and IGF1R (27.76%) DMRs. SRS9 a patient with no primary epimutation showed 
an unexpected LOM at the MEG3 somatic DMR and hypermethylation at the MEG8 gametic 
DMR suggesting maternal methylation bias at this region or possibly the maternal 
chromosome 14 UPD (mUPD14). mUPD14 is a disease-causing aberration observed in TS and 
interestingly the methylation pattern observed at chromosome 14 in SRS9 is the same pattern 
observed in the TS patient sample in Appendix Table A1 (Temple et al., 1991). A further SRS 
patient (SRS 18) with no primary epimutations was observed with a 2.77% LOM outside the 






Table 3.5: Table investigating the incidence of MLID in Angelman and Prader-Willi syndrome patient samples. Legend as before (Table2), Imprinted DMRs with abnormal methylation falling 
outside the primary disease-causing regions in AM and PWS patients as highlighted by outside borders. 2/3 of AM and PWS patients are observed with MLID outside the primary disturbed 






Imprinted DMR Est MO Chr Start End Blood PWS 1 PWS 2 PWS 3 AM 1 AM 2 AM 3 
MI     
Upper 
MI   
Lower 
PLAGL1 G M chr6 1.44E+08 1.44E+08 63.1 52.81 59.89 55.64 53.09 55.64 54.65 73.48 53.34 
RB1 G M chr13 48892341 48895763 62.17 49.04 53.36 49.65 44.95 50.71 48.1 75 49.65 
MAGEL2 G M chr15 23892425 23894029 57.9 81.33 82.99 82.86 23.92 20.38 15.48 64.86 51.14 
NDN G M chr15 23931451 23932759 50.16 73.73 71.6 71.07 28.53 28.45 24.43 62.15 37.88 
SNRPN_1 G M chr15 25068564 25069481 62.11 80.53 83.94 83.79 32.89 29.22 22.69 69.2 55.78 
SNURF G M chr15 25200004 25201976 63.05 93.94 92.87 92.84 15.07 11.42 4.09 75.84 56.4 





Table 6  



















MI     
Upper 
MI   
Lower 
DIRAS3 G M chr1 68515433 68517545 60.22 46.92 55.87 31.49 54.64 45.28 48.04 54.66 51.69 47.26 71.58 47.78 
DIRAS3_ex2 G M chr1 68512505 68513486 62.48 49.25 47.7 28.64 52.13 46.59 47.95 52.26 50.17 44.5 79.03 46.03 
FAM50B U M chr6 3849082 3850359 58.02 51.2 35.64 41.62 53.48 51.97 51.1 55.35 50.97 47.75 71.41 43.06 
PLAGL1 G M chr6 144328078 144329888 63.66 53.26 59.02 55.89 60.29 56.41 57.4 62.38 53.92 53.08 73.48 53.34 
MEST G M chr7 130130122 130134388 63.44 54.95 57.47 43.96 59.18 56.37 54.59 59.95 55.23 52.52 74.33 51.4 
H19 G P chr11 2018812 2024740 59.2 64.74 59.03 57.3 86.81 86.73 55.82 60.15 54.97 59.73 63.95 54.29 
IGF2_DMR0 S P chr11 2168333 2170145 57.18 62.2 63.5 56.6 71.93 81.24 51.08 55.56 51.06 57.89 71.15 43.39 
KvDMR1 G M chr11 2719948 2722259 57.98 45.12 26.11 28.22 55.64 55.7 24.56 21.72 16.73 43.4 66.04 49.04 
RB1 G M chr13 48892341 48895763 62.48 53.22 55.8 51.82 52.58 53.53 52.76 55.39 47.87 47.02 75 49.65 
IGF1R U M chr15 99408496 99409650 63.94 55.46 54.91 35.94 59.16 57.23 81.52 55.99 52.14 45.79 81.88 45.73 
SNURF G M chr15 25200004 25201976 63.73 56.01 58.29 55.23 55.34 55.02 52.66 56.84 50.99 47.18 75.84 51.4 
PEG3 G M chr19 57348493 57353271 67.4 56.67 60.46 58.7 59.18 52.39 54.81 60.29 54.29 53.14 78.95 55.01 
ZNF331 G M chr19 54057086 54058425 54.8 45.03 48.21 44.66 43.22 41.04 45.85 45.72 40.78 37.69 70.81 39 
L3MBTL G M chr20 42142365 42144040 63.37 54.86 58.45 32.78 55.88 59.47 54.44 54.66 54.61 50.61 75.1 49.74 
NESP-AS_GNAS-
AS1 
S M chr20 57425649 57428033 48.81 48.02 30.31 40.26 52.08 42.54 46.18 47.21 50.39 42.01 64.02 34.17 
Table 3.6: Table investigating the association of MLIDs in Beckwith-Wiedeman syndrome patient samples. Legend as before (Table3), Imprinted DMRs with abnormal methylation falling 
outside the primary disease-causing regions in BWS patients as highlighted by outside borders. All patients with the exception of BWS patient 7 were flagged with MLID outside the primary 
epimutation.  This was found throughout a number of different DMRs, but a clear pattern of hypermethylation was observed between the gametic and somatic DMRs H19 and IGF2_DMR0. 
DIRAS3 and PEG3 DMRs were observed to be disturbed outside the primary epimutation in ½ of the BWS patients. BWS patients with the primary epimutation at the KvDMR appears to be more 








Table 3.7: Table methylation across imprinted DMRs in Silver-Russell syndrome patient samples. Legend as before (Table4), Imprinted DMRs with abnormal methylation falling outside the 
primary disease-causing regions in SRS patients as highlighted by outside borders. Similar to the observation in BWS patients, almost all SRS patients that contain primary epimutations at the 
H19 DMR was also observed with hypomethylation at the somatic IGF2_DMR0. Disturbances outside the primary epimutation was limited to mostly 1 other DMR with the exception of SRS 12 
which was flagged with MLID at the MEG8 and IGF1R DMRs.  Patients with methylation patterns suggestive of mat7UPD appeared with no MLIDs. SRS patient 9 did not contain any epimutations 
associated with SRS but disturbances were detected at the MEG3, MEG8 and SNURF DMRs using the MI. 
Imprinted DMR Est MO Chr Start End Blood SRS 1 SRS 2 SRS 3 SRS 4 SRS 5 SRS 6 SRS 7 SRS 8 SRS 9 MI     Upper MI   Lower 
PLAGL1 G M chr6 1.44E+08 1.44E+08 63.66 59.88 58.78 58.24 54.22 59.01 57.52 57.8 57.92 57.16 73.48 53.34 
GRB10g G M chr7 50848726 50851312 61.75 63.17 60.17 87.69 59.26 59.21 63.2 63.36 87.53 61.54 75.59 47.79 
HTR5A G M chr7 1.55E+08 1.55E+08 56.08 52.6 50.8 71.05 54.67 58.27 55.03 57.92 71.43 51.65 70.35 41.47 
MEST G M chr7 1.3E+08 1.3E+08 63.44 59.9 57.39 91.26 59.4 60.47 59.85 60.75 92.81 58.66 74.33 51.4 
PEG10 G M chr7 94284759 94287960 43.14 42.85 40.78 70.86 41.73 43.09 43.34 43.3 70.28 42.27 51.7 34.41 
H19 G P chr11 2018812 2024740 59.2 59.81 59.41 58.25 49.88 60.87 59.47 56.66 59.77 59.74 68.95 49.29 
IGF2_DMR0 S P chr11 2168333 2170145 57.18 59.1 55.7 60.3 51.2 60.6 63.5 46.5 61.8 58.1 71.15 43.39 
MEG3 S P chr14 1.01E+08 1.01E+08 59.58 59.21 56.3 56.46 57.93 60.17 59.64 59.79 59.32 23.74 69.79 48.9 
MEG8 G M chr14 1.01E+08 1.01E+08 68.89 58.5 61.2 61.1 58 60.3 61.7 60.2 58.2 98.6 85.09 51.03 
IGF1R U M chr15 99408496 99409650 63.94 55.86 52.99 56.83 51.61 56.07 57.01 57.21 58.73 53.57 81.88 45.73 
SNURF G M chr15 25200004 25201976 63.73 55.11 54.26 54.37 55.51 56.46 55.96 53.76 56.09 51.96 75.84 51.4 
Imprinted DMR Est MO Chr Start End Blood SRS 10 SRS 11 SRS 12 SRS 13 SRS 14 SRS 15 SRS 16 SRS 17  SRS 18 MI     Upper MI   Lower 
PLAGL1 G M chr6 1.44E+08 1.44E+08 63.66 52.25 53.58 56.52 56.34 56.98 55.16 56.91 57.99 54.44 73.48 53.34 
GRB10g G M chr7 50848726 50851312 61.75 58.07 58.97 59.82 61.27 62.27 84.03 62 61.5 57.46 75.59 47.79 
HTR5A G M chr7 1.55E+08 1.55E+08 56.08 54.48 54.07 52.8 58.32 54.42 72.45 54.15 55.58 58.28 70.35 41.47 
MEST G M chr7 1.3E+08 1.3E+08 63.44 56.18 58.51 55.97 58.05 60.52 92.98 60.25 60.28 53.32 74.33 51.4 
PEG10 G M chr7 94284759 94287960 43.14 39.57 41.31 41.49 40.52 41.49 70.62 41.94 41.8 38.15 51.7 34.41 
H19 G P chr11 2018812 2024740 59.2 47.09 59.21 41.02 43.76 41 61.21 59.01 36.09 54.58 68.95 49.29 
IGF2_DMR0 S P chr11 2168333 2170145 57.18 43.8 58.2 38.9 40.8 44.1 59.1 61.5 42.2 53.6 71.15 43.39 
MEG3 S P chr14 1.01E+08 1.01E+08 59.58 55.61 57.41 58.45 58.06 58.53 57.28 58.34 59.03 53.17 69.79 48.9 
MEG8 G M chr14 1.01E+08 1.01E+08 68.89 61.3 63.6 48.4 59.2 56.9 54.2 60.4 55.8 56.2 85.09 51.03 
IGF1R U M chr15 99408496 99409650 63.94 49.86 55.86 17.97 52.47 56.79 52.13 58.59 60.09 57.86 81.88 45.73 






How genomic imprinting and its related disorders are investigated is currently lacking 
consistency and can often be confusing. To shed light on these issues papers have suggested 
1) a nomenclature system when discussing Imprinted DMRs, 2) the need for multilocus testing 
in imprinting disorders, 3) a clear definition for gains and losses of methylation at imprinted 
DMRs and  4) development of a consistent and reproducible molecular method for testing  
(Monk et al., 2018; Poole et al., 2013). The extant techniques used in molecular diagnosis are 
presently not sufficient for imprinting disorders, given the complexity behind imprinting 
disorders, especially SRS which contains multiple regions with molecular abnormalities being 
linked to the disease phenotype and the increasing number of investigations showing MLID 
and its association with severity of phenotype (Poole et al., 2013). At present, molecular 
diagnosis is carried out by investigating the primary epimutations involved with the imprinting 
disorder and/or chromosomal abnormalities such as UPD or deletions. However, many 
molecular abnormalities are undiagnosed in imprinting disorders and locus-specific assays are 
not able to detect MLID. In some cases current methods have led to misdiagnosis due to the 
overlap in clinical features, which may cause further complications due to incorrect treatment 
not targeting the actual disorder (Fontana et al., 2018; Luk, 2016; Petit et al., 2012; Wakeling 
et al., 2016). Due to these reasons, it is important to identify the molecular defects as well as 
any other disturbances that may be altering the phenotype efficiently and effectively in the 
syndrome in order to fully understand the underlying disorder and treat accordingly. In this 
chapter, the 450k array was examined to address some of the issues with the current 
diagnostic methods.  
The 450k bead chip array is one of the most cost-effective and least bioinformatically complex 
tools for whole-genome DNA methylation profiling (Dedeurwaerder et al., 2011). The 450k 
array has proven to be an invaluable approach for investigating genomic imprinting and its 
related disorders by being used as a tool for identifying novel DMRs at/near imprinted genes, 
as well as identifying further molecular disturbances associated with imprinting disorders and 
profiling patients with MLID (Court et al., 2014; Prickett et al., 2015; Rezwan et al., 2015). In 
this chapter, I utilised publicly available datasets and processed them with R and then 





by the Walsh lab which does not require high-grade bioinformatic skills. The DMRs were 
thoroughly tested to get a collection which shows normal methylation with little variability 
between the 100 control blood samples yet showed clear differences between control and 
disease state in blood samples. This was an important step to simplify the test, as many of the 
regions excluded are defined as DMRs in the literature (Court et al., 2014; Sharp et al., 2010; 
Woodfine et al., 2011). In this investigation, even though methylation bias is observed in the 
genome-wide UPD samples for these DMR, the regions were excluded as diagnostic sites as 
they were observed to differ from canonical imprinted DMR by having excess levels of 
methylation and/or large variability between control blood samples.  
The array with the defined MI was able to identify the expected methylation abnormalities 
which had been previously diagnosed/described in the source articles. Not only was it 
possible to identify DMRs with epimutations but it was able to indicate UPD in the respective 
patients due to parental-specific methylation at multiple DMRs. The results from the AM and 
PWS patients agrees with the literature in that the chromosome 15 imprinting region was 
associated with the disorders, though a larger dataset would be required to fully investigate 
the use of the defined MI in these imprinting disorders (Buiting et al., 2016; Butler et al., 
2016). The epimutations identified in BWS patients were also in line with the literature in 
which hypomethylation at the KvDMR was the leading cause of BWS, followed by 
hypermethylation at the H19 DMR, then chromosome 11 UPD (Ibrahim et al., 2014; Luk, 2017; 
Weksberg et al., 2010). Finally, the results for the SRS patients was in accord with the 
literature with hypomethylation at the H19 DMR being the most common epimutation of SRS, 
followed by mat7UPD and a large portion of SRS patients with no identifiable underlying 
molecular cause (Azzi et al., 2015; Fokstuen and Kotzot, 2014; Õunap, 2016).  
As no common DMRs have been associated with MLID for any imprinting disorder and the 
expanded list of DMRs are not characterised as well as the disease-causing DMRs, an extra 
+/-5% was applied to the MI, to increase confidence that this was a disturbance and not just 
variability. Further to this, many DMRs on the expanded list have little information on their 
functionality such as the extent to which changes of methylation are required to change the 
expression of genes controlled by the DMR, this is an important factor to consider when 





may be detected though not necessarily lead to a physiological effect. MLID in AS and PWS 
does not appear too common with only two AM  cases being described with MLID and no 
PWS patients described with MLID (Sanchez-Delgado et al., 2016a). The method applied in 
this study observed LOM outside the expected imprinting region of chromosome 15, at 3 
other DMRs on/near the imprinted genes PLAGL1, RB1 and PEG3 in both AM and PWS. Both 
RB1 and PEG3 were previously described with LOM in AM patients, further suggesting that 
these two DMRs may play a role in MLID in these disorders (Baple et al., 2011). BWS has been 
observed to present with multiple imprinting disturbances outside the expected regions, 
more than any other imprinting disorder examined in this study (Azzi et al., 2009). Here we 
show a large proportion of BWS patients (88%) presented with many hypomethylated regions 
outside the expected DMRs, this was extremely high in comparison to the literature (Maeda 
et al., 2014). Despite this, all of the regions identified as possible targets for MLIDs have been 
previously described in the literature (Bliek et al., 2009; Docherty et al., 2014; Sanchez-
Delgado et al., 2016a). The BWS patients which were observed with hypermethylation at the 
H19 DMR were also observed with concurrent hypermethylation at the nearby somatic DMR 
IGF2_DMR0, though this was not observed in the UPD patient. On the other hand, SRS 
patients with H19 DMR hypomethylation was observed with nearby hypomethylation at the 
somatic IGF2_DMR0. Hypomethylation at the PLAGL1 and IGF1R DMRs have been previously 
shown for MLID in SRS, while the MEG8 DMR  to our knowledge has not been previously 
described as associated with SRS (Sanchez-Delgado et al., 2016a).  
Apart from identifying the epimutation causing the disorder and possible MLID targets, 
through the use of the array and defined MI, we may have detected a misdiagnosed patient. 
SRS9 was diagnosed without molecular abnormalities and presents with clinodactyly  
(curvature of a digit) and growth restriction with a negative SDS birth weight and height and 
weight at assessment (Prickett et al., 2015). Considering the patient information and the 
maternal specific methylation pattern observed at the MEG3 and MEG8 DMRs this would 
suggest Temple syndrome. Temple syndrome presents with many clinical features 
overlapping with SRS, including but not limited to pre-and postnatal growth alterations and 
clinodactyly. A recent study by Luk (2016) has described a case in which a one-year-old boy 





MEG3 DMR hypomethylation was detected (Habib et al., 2019; Kagami et al., 2017). SRS 18 
only showed hypomethylation at the SNURF DMR, though not to the extent seen in AS.  
While the 450K and the defined MIs showed clear benefits for use as a diagnostic tool for 
imprinting there are some minor restrictions to this method. A number of the imprinted DMRs 
have little probe coverage in the 450k array, while some have none at all such as the IG-DMR 
on chromosome 14. The 100 blood samples allowed for assessment of variability in mean 
methylation at the DMRs, but the low probe coverage at some DMRs may mean this is not 
truly representative of methylation across the region. This could be improved by using the 
850k (EPIC) array which increases the probe coverage from 716 to 789 across the imprinted 
DMRs as well containing two probes at the IG-DMR not originally covered by the 450k array 
(Hernandez Mora et al., 2018). While the MI for the MLID was larger than that of the known 
aetiological DMRs, targets identified may not have functional effects and would require 
further investigations to implicate these regions in MLID.  A number of improvements could 
help reduce the current limitations of this approach, such as the use of the 850k array to 
investigate genome-wide methylation and using a larger sample size of imprinting disorder 
patients some without a previous molecular diagnosis. The ability to confirm transcriptional 
changes for the imprinting disorder patients through PCR or RNA-seq techniques would also 
allow for the DMRs outside the disease-causing DMRs to be better characterised and further 
our understanding of MLIDs. It would also be beneficial to apply this method to more novel 
imprinting disorders such as TS and TNDM etc in order to prove that the concept applies to 
all imprinting disorder (Sanchez-Delgado et al., 2016a). Further use of the beadchip array that 
was not explored here is copy number variation (CNV) analysis, which can be done by using 
probe signal ratios and is built into a number of the newer or updated methylation beadchip 
array analysis pipelines such as WateRmelon and RnBeads 2.0 (Assenov et al., 2014; Pidsley 
et al., 2013). Use of the array to estimate CNV at the imprinted regions could help to explain 







The 450k has proven itself to be an invaluable tool for methylation studies of the epigenetic 
phenomena imprinting. In this chapter, the array was investigated as a tool for molecular 
diagnosis in selected imprinting disorders. The 450k array along with the methylation index 
(MI) described here was seen to be an accurate tool providing a more detailed genome-wide 
assessment than current molecular diagnostic methods. The 450k could diagnose aberrant 
methylation in previously tested patients and differentiate between UPD and epimutations 
associated with imprinting disorders. Further to this it also presented with an added benefit 
of being able to identify possible targets for MLID outside the expected region for all of 
imprinting disorder patients as well as describing a patient which was likely misdiagnosed. 
The results here show that the beadchip array (450k or 850k) could be utilised as a diagnostic 
tool alongside scoring of clinical features to diagnose patients with imprinting disorders, this 
would prove to be especially beneficial in cases in which SRS is suspected due to the 
complexity of this disorder. A better categorisation and understanding of the disease 
provided by the beadchip array would be beneficial for accurate treatment and reduction of 
misdiagnosis for imprinting disorder patients.  Not only would the increased usage of the 
beadchip array have a benefit to the patient if the datasets were also available for research 
purposes it could be used to further investigate the mechanism behind imprinting and 
imprinting-like disorders as well as the methylation disturbances behind MLIDs. As the 
understanding of the methylation mechanism behind the less described DMRs is expanded 










Chapter 4- DMR cross-talk in DNMT1 depleted hTERT-1604 human fibroblastic cell line  
4.1 Introduction  
4.1.1 Establishment of imprinting DMRs and mechanism of action 
Imprinting DMRs can be established in both the germline and after fertilisation in somatic 
tissues which are known as germline DMRs (gDMR) or somatic DMRs (sDMR) respectively as 
described previously (Nechin et al., 2019). gDMRs are defined by their establishment during 
gametogenesis and maintenance as a lifelong mark, this establishment and maintenance is 
reliant on the action of DNMTs. gDMRs are mostly methylated on the maternal allele are 
usually found within a cluster of imprinted regions controlling their expression (Cheong et al., 
2015). A further characteristic of gDMRs are the open chromatin and close chromatin histone 
marks found on the active and inactivate alleles respectively. Further to this maternally 
methylated DMR’s are usually found intragenic generally corresponding to promoters often 
of lncRNAs, while paternally methylated gDMRs are intergenic and function as insulators or 
enhancers (Edwards and Ferguson-Smith, 2007). sDMRs are defined by their establishment 
outside the germ line and may be tissue-specific and depend on the presence of a gDMR 
(Ferguson-Smith, 2011). sDMRs are relatively rare and correlate with gene promoters and 
transcription factor binding sites, higher-order chromatin structure, chromatin modifications 
and lncRNAs involved with silencing nearby imprinted genes in cis (Barlow and Bartolomei, 
2014; Monk et al., 2019).  
As discussed in the introduction to this thesis the H19 and IGF2 DMRs are a well-described 
model of the hierarchical function of the gDMR. A further imprinting cluster on chromosome 
14 appears to display a hierarchy interaction in which loss of the gDMR IG-DMR by deletions 
is associated with hypermethylation of the sDMR MEG3 (Beygo et al., 2015; Kagami et al., 
2010). Furthering this a study observed that transcription from the MEG3 promoter was 
essential for establishing methylation at another sDMR at MEG8 (Beygo et al., 2017). A similar 
interaction was also observed at the imprinting cluster on chromosome 20 in which the gDMR  
found at the GNAS loci would result in hypermethylation at the NESP sDMR suggesting that 





imprinting status of somatic DMR at the Igf2r locus in mouse appears to be independent of 
the gDMR (Stöger et al., 1993).  
Considering the conflict we wished to investigate if in a system where methylation levels had 
been lowered, this affected both gDMRs and sDMRs equally, or whether effects were more 
marked on one and if so, was there a concomitant effect on the other. Preliminary 
examination of methylation in a human cell line model derived by the lab suggested that the 
latter was the case, so I set out to investigate this in more detail. For this, I chose three 
gDMR/sDMR pairs based on those which had the most normal levels of methylation in the 
model cell line. I will first describe these three loci, then outline the approaches to be taken.  
The three imprinted genes that I will investigate in this study are Growth Factor Receptor 
Bound Protein 10 (GRB10), Small nuclear ribonucleoprotein polypeptide N (SNRPN) and 
nucleotide-binding, leucine-rich repeat-containing proteins Family Pyrin Domain Containing 
2 (NLRP2). The gDMRs at GRB10 and SNRPN have been well characterised in both mouse and 
human showing functional importance (Blagitko et al., 2000; Nicholls and Knepper, 2001). We 
hypothesise that changing methylation at the gDMR will affect methylation at the sDMR. The 
alternative is that methylation at one will not affect methylation at the other.  
4.1.2 Methylation controlled expression of SNRPN 
SNRPN is a paternally expressed imprinted gene that is a part of the small nuclear 
ribonucleoprotein (SmN) family, SNRPN is located at the PWS locus on chromosome 15 
(Figure 4.1). SNRPN is expressed from a bicistronic transcript which also encodes for SNRPN 
Upstream Reading Frame (SNURF) (Gray et al., 1999). The function of the genes at this 
imprinted cluster is poorly understood, however, the SmN family has been found in the 
mouse brain and heart where it is involved with pre-mRNA processing (Bervini and Herzog, 
2013). Leff et al (1992) reported the maternal imprinting of the mouse Snrpn gene as well as 
its homology to the human gene and concluded that SNRPN could be a candidate gene for 
Prader-Willi syndrome (Leff et al., 1992). It was later reported that the expression of the 
human SNRPN gene was imprinted using Angelman and Prader-Willi patients (Glenn et al., 
1993). A further study by Glenn et al (1996) reported preferential methylation at the 





in mouse as DMR1, this showed high resemblance between human and mouse (Glenn et al., 
1996; Shemer et al., 1997). The whole cluster at this region is largely imprinted with a number 
of genes being paternally expressed due to imprinting and several maternally methylated 
DMRs close by and within the SNRPN locus itself, however, the DMR located at SNURF-SNRPN 
promoter is the gDMR and functionally defined as the ICR (Figure 4.1) with Bielinska et al., 
(2000) showing that loss of this region in both human and mouse leads to maternal imprinting 
on both alleles  (Court et al., 2014; Horsthemke and Buiting, 2006; Sharp et al., 2010). This ICR 
also known as the PWS-IC is established during oogenesis and drives the epigenetic imprinted 
control of the remaining DMRs (Chamberlain and Lalande, 2010b).ATP10a and UBE3A are the 
only maternally expressed genes in this region (Herzing et al., 2001; Rougeulle et al., 1997). 
The ATP10a gene contains a somatically acquired DMR which has been observed to be 
present in the placental tissue (Woodfine et al., 2011). Loss of function of the UBE3A gene 
results in AS which is the paternal imprinted disorder related to this region. However, it is 
unclear which gene is associated with PWS which is the maternal imprinted disorder for this 
region, it has been shown that the paternally expressed SNORD116 can result in a PWS-like 
phenotype (Buiting, 2010).  
Figure 4.1: Methylation and expression in the human imprinted genes SNRPN. Most imprinted genes are found in clusters 
and are regulated by an Imprinted control region (ICR) or differentially methylated region (DMR). (A) The SNURF/SNRPN 
DMR Controls the paternal expression of SNURF, SNRPN and SNORD miRNAs and the maternal expression of ATP10A and 
UBE3A. The ATP10a DMR is hypomethylated in most tissues, though in placenta methylation levels consistent with that of a 
DMR can be seen. Key unchanged from figure 1.5. 
4.1.3 Methylation-controlled expression of GRB10 
GRB10 codes for an adapter protein on chromosome 7 that belongs to the Grb7  family of 
adaptor molecules, GRB10 interacts with receptor proteins and has been associated with 
metabolism, cell proliferation and apoptosis (Holt and Siddle, 2005). Mouse GRB10 knockout 
models have exhibited overgrowth in many organs and tissues as well as an increase of social 





behaviour (Charalambous et al., 2003; Garfield et al., 2011). GRB10 does not have an 
imprinted disorder linked with aberrant methylation at the DMR, however, patients suffering 
from Silver-Russell Syndrome (SRS) have been associated with maternal UPD 7 (mUPD7), but 
the data is merely suggestive that the maternal diploidy of chromosome 7 causing 
overexpression of maternal GRB10 may be the cause of the SRS symptoms, due to protein 
playing a role in growth regulation (Prickett et al., 2015). Blagitko et al (2000) showed that 
GRB10 expression was highly tissue- and isoform-specific as seen in Figure 4.2. In human 
GRB10 is biallelically expressed in most adult tissue from the major promoter. However, the 
imprinted expression is highly isoformic and tissue-specific with paternal expression being 
observed in the fetal brain from the brain-specific promoter which contains the maternally 
methylated gDMR, while maternal expression is only observed in skeletal muscle and 
placental trophoblast from the major promoter which contains the sDMR which is 
unmethylated on both alleles in these tissues. The imprinted maternal expression in skeletal 
muscle and placental trophoblast is yet to be determined with chromatin and methylation 
marks being ruled out by previous investigations (Blagitko et al., 2000; Monk et al., 2009). The 
mouse Grb10 is expressed in a maternal-specific manner in most tissues except the brain 
where paternal expression is observed. Interestingly the methylation pattern is consistent 
with that seen at the human locus, the only difference being that the mouse gDMR contains 
CTCF binding sites in which the insulator function causes maternal expression. The lack of a 
CTCF binding site at the human GRB10 gDMR is believed to be the explanation for the biallelic 
expression in most tissues (Hikichi et al., 2003; Plasschaert and Bartolomei, 2015).  
Figure 4.2: GRB10 is an imprinted gene that is expressed in an isoformic and tissue-specific manner. The major transcript is 
biallelically expressed from the first transcription start site (TSS)in almost all tissues except in placenta trophoblast where a 
maternally expressed transcript is found. Further downstream there is a secondary TSS. Transcripts expressed from this TSS 
are only expressed in a monoallelic fashion with maternal expression found in the skeletal muscle and paternal expression 
found in the fetal brain. Methylation is consistent throughout all tissues suggesting that transcription factors rather than 
methylation may control the expression of GRB10. However, methylation in the adult brain is different with the somatic DMR 





4.1.4 Methylation controlled expression of NLRP2 
NLRP2 belongs to the nucleotide-binding, leucine-rich repeat-containing proteins (NLR) 
protein family, which is a member of the inflammasome and was the first recorded imprinted 
gene involved with inflammation (Agostini et al., 2004; Bruey et al., 2004). It was first 
discovered to have preferential maternal expression in the placenta and allelic skewing in 
kidney and fetal heart (Bjornsson et al., 2008). Unlike in human, Nlrp2 in mouse does not 
appear to be imprinted, however, it plays an important role in early embryogenesis after 
oocyte activation, as female Nlrp2 null mice were likely to show early embryonic death of 
their offspring, while surviving offspring had aberrant methylation at imprints, most likely due 
to the abnormal localisation of DNMT1 in the oocyte due to loss of the SCMC complex 
(Kuchmiy et al., 2016; Mahadevan et al., 2017). Due to this, human NLRP2 is suspected to be 
associated with the SCMC complex as well, supported by its high expression in oocytes and 
preimplantation embryos. Furthermore,  a mother with a germline homozygous frameshift 
NLRP2 mutation resulted in familial BWS affecting 2/3 of her offspring (Meyer et al., 2009; 
Monk et al., 2017). In somatic tissue such as fibroblasts and ES cells, NLRP2 has a low level of 
expression though in induced pluripotent stem cells (iPSC) NLRP2 is highly expressed 
suggesting it may have an important role in reprogramming (Cai et al., 2015). A study from 
Jefferies et al showed iPSCs to have a random imbalanced allelic expression between two 
clones with one clone showing biallelic expression and monoallelic expression in the other 
clone. However, interestingly unlike the other randomly imbalanced allelic genes seen in this 
study, NLRP2 expression became monoallelic in the clone that was originally biallelic after 
neuralization (Jeffries et al., 2016).  Evidence supporting the imprinted status of NLRP2 is the 
monoallelic expression noted by Bjornsson et al (2008), matched with the tissue-specific DMR 
described by Woodfine et al (2011) (Figure 4.3). While the sDMR was not clearly investigated 
by Woodfine et al (2011), the tissue-specific nature of DMR would suggest somatic 
establishment. Therefore, there may be a gDMR present within or near the gene body of 
NLRP2, with this in mind methylation at the promoter has been found to be inversely 
correlated with the expression of NLRP2 and for this reason, it would be a strong candidate 
region for further investigations to explain the monoallelic/imprinted expression of NLRP2 





Figure 4.3: The imprinting of NLRP2 has not been well characterised, the expression of NLRP2 however, is negatively 
correlated with the level of methylation at the TSS, for this reason, it has been labelled and will be investigated as a possible 
gDMR in this study, a DMR has been described downstream, however, its establishment and parent of origin is unknown, 
though as it is tissue-specific it will be investigated as an sDMR candidate.  
4.1.5 Uniparental ESCs 
The generation of androgenetic and parthenogenetic embryonic stem cells furthered the 
ability to understand the mechanism behind genomic imprinting. Mouse parthenogenetic 
ESCs (phESC) were the first uniparental cell line generated firstly by activation of an oocyte 
without fertilisation (parthenogenesis), later that same year another lab generated mouse 
phESCs by removal of the male genome after fertilisation (gynogenesis) (Kaufman et al., 1983; 
Surani and Barton, 1983). It wasn’t until a few years later that the mouse androgenetic ESC 
(aESC) cell line was generated, by androgenesis in which an oocyte void of its maternal 
genome has a paternal genome introduced (Mann et al., 1990). In 2007 two labs used the 
parthenogenesis technique to create human phESCs from parthenogenetic blastocysts which 
genetically matched their donor oocyte and showed methylation patterns at the imprints that 
were of parthenogenetic origin (Kim et al., 2007; Revazova et al., 2007). It wasn’t until more 
recently that a human aESC cell was generated, they were observed to have maintained a 
certain level of sperm methylation at the imprints (Ding et al., 2015). A recent study by Sagi 
et al (2019) showed the power behind human uniparental ESCs, by utilising methylation and 
expression array technologies they were able to identify parental specific methylation and 
expression of known imprints and even identified several possible novel imprints and even 
suggests the possibility of additional imprinted genes still to be found that have a more 






4.1.6 In vitro Models investigating DNMTs in imprinting 
The use of mouse ESC (mESC) is a well-recognised approach for investigating the effect of the 
loss of important DNMTs (Li et al., 1992). DNMT KOs are tolerable with numerous knockouts 
being carried out from 1 ESC to triple KO ESCs (TKO) (Tsumura et al., 2006). The Walsh lab has 
previously shown that imprinting could be recovered in mouse Dnmt3a2 KO ESCs upon rescue 
with Dnmt3a2 but was unable to recover imprinting in Dnmt1 KO mESCs with the subsequent 
rescue of Dnmt1. This has been beneficial to increase the understanding of Dnmts in mouse, 
however, the KO of DNMT1 could not be replicated in human ESCs with the KO appearing to 
be lethal (Liao et al., 2015).   A DNMT1 hypomorphic mutation could, however, be tolerated 
in a colorectal carcinoma line known as HCT116 (Rhee et al., 2000), but this is not suitable for 
imprinting studies due to the fact that it is aneuploid. Instead, the Walsh lab used TERT-
immortalised fibroblasts known as hTERT-1604s to generate isogenic human cell lines with 
intermediate knockdown of DNMT1 (labelled as d8 and d10) and a more severe knockdown 
(labelled d16 -Figure 4.4 A and B) (O’Neill et al., 2018).  The hTERT-1604 cell line was 
immortalised by overexpression of the human telomerase gene ensuring chromosomal 
integrity making it a highly suitable model for the study of methylation especially for 
imprinting (Ouellette, 2000). A study carried out by the Walsh lab showed robust 
demethylation effects in hTERT-1604 cells after a DNMT1 knockdown (KD) (Loughery et al., 
2011). The methylation microarrays showed that d8 and d10 had a similar loss of methylation 
while d16 had a more extreme loss of methylation when compared to the WT (Figure 4.4C). 
However, a more in-depth analysis revealed that 1/3 of the probes lost methylation as 
expected but surprisingly the remaining 1/3 of probes were observed with hypermethylation 
with targets shared among the 3 clonal DNMT1 knockdowns (Figure 4.4D). Using this DNTM1 
depleted cell line our lab has recently highlighted sensitive genes that have an interesting 
interplay with polycomb repressive marks appearing to block remethylation.  As methylation 
plays an important role in the regulation of imprints, this model is an excellent opportunity 









Figure 4.4: Establishment of DNMT1 depleted hTERT-1604s and changes of methylation. (A) Shows the experimental 
approach taken to generate and analyse the DNMT1-depleted hTERT-1604s. Transfection was carried out using an shRNA 
targeting DNMT1 and then cells grown in selective media until colonies appeared. Three separate clonally-derived cell lines 
were expanded (d8, d10 and d16) and further analysed with methylation and transcription arrays and confirmed with wet-





bars represent 95% confidence intervals around the median and standard error of the mean (SEM), respectively. (C)  Overall 
changes of methylation observed across all probes on the Infinium human 450k array: a βvalue of 1 equates to 100% 
methylation. Median values are indicated by the line and whiskers represent interquartile range. The positions of the 
medians are also indicated at right (arrowheads). (D) The difference in median of DNMT1 depleted cells lines vs WT at 
different CG regions (E) The number of sites showing loss and gain of methylation in d8, d10 and d16 per no. of probes x104. 
Figure derived from O’Neill et al (2018)  
4.2 Hypothesis and aim  
We hypothesise that the promoter region of NLRP2 controls the monoallelic expression of the 
protein. Secondly, as DNMT1 provides an important role in the maintenance of genomic 
imprinted regions a long-term depletion will result in abrogation of the imprinted marks.  
The main aims of this study were to: 
• Investigate the suspected imprinted status of NLRP2 by using publicly available 
parental specific ESC datasets. The imprinting of NLRP2 will be further investigated 
using the DNMT1 depleted chromosomally stable hTERT-1604 cell lines.  
• Secondly, we aim to use the 450k array data generated by the Walsh lab, to investigate 
the impact of the long-term depletion of DNMT1 on the imprinted gametic and 
somatic DMRs in the chromosomally stable human fibroblastic cell model hTERT-1604. 
• Known and well described imprinted regions that show large changes of methylation 
will also be investigated with wet lab techniques to fully understand any mechanistic 
changes occurring due to the long-term depletion of DNMT1 in a human 
chromosomally stable model.  
4.3 Materials and Methods 
Methylation analysis of the 450k and pyrosequencing and expression analysis by qPCR was 
carried out as described in chapter 2. Uniparental human ESCs publicly available methylation 
and expression array datasets were analysed (GSE114679). Publicly available ChIP-SEQ ZFP57 
and ZFP445 in hESC datasets (GSE57989) were utilised to generate tracks on UCSC. 850K 
methylation datasets were downloaded and processed as described in chapter 2. GSE114679 





(850k beadchip array) and RNA-seq on androgenetic and parthenogenetic stem cells. This 
allowed Sagi et al (2019) to investigate methylation bias and distinct imprinting signatures. 
The second dataset GSE57989 was from a study carried out by Takahashi et al (2019), this 
investigation contributed to the literature by furthering our understanding of ZFP binding and 
imprinting in both human and mouse models.  
4.3.1 UseGalaxy RNA-seq analysis  
RNA-seq data was analysed using USEgalaxy, the data was uploaded to usegalaxy from the 
European nucleotide archive (ENA) in the compressed fastqsanger.gz format. First, the data 
was subjected to quality control which was tested by the FastQC (v 0.72+galaxy1) and carried 
out by the Cutadapt (v1.16.6) tool to trim low-quality sequences. The data was then mapped 
to the reference genome hg19 using the HISAT2 (v2.1.0+galaxy5) tool providing a BAM output 
file which was then processed with the featureCounts (v1.6.3) tool providing a table 
containing Entrez gene ID with its respective count. The Entrez Gene ID was then used to 
annotate the genes with Ensemble ID, Entrez ID, gene symbol and gene name using the tool 
annotatemyids (v3.7.0). Differential expression was carried out with limma-voom using the 
limma (v3.38.3+galaxy3) tool. 
4.3.2 UseGalaxy ChIP-seq analysis 
ChIP-seq data was analysed using USEgalaxy, the data was uploaded to usegalaxy from the 
European nucleotide archive (ENA) in the compressed fastqsanger.gz format. First, the data 
was subjected to quality control which was tested by the FastQC (v 0.72+galaxy1) and then 
manipulated to remove low quality reads with the Filter by quality (v1.0.2) and FASTQ Quality 
Trimmer (v1.1.1) tools. The data was then mapped to the reference genome hg19 using the 
Map with BWA (v0.7.17.4) tool providing a BAM output file. Data was then subjected to post-
map processing which involved the removal of duplicates RmDup tool (v2.0.1). The 
bamCoverage (v3.3.0.0.0) tool was then used to generates a coverage bigWig file from the 






Table 4.1- RT-qPCR primers used in this chapter  
Gene Primer Oligo sequence (5’-3’) 
GRB10 FWD GCACGAAGACAACCAGGTG 
 REV GAACGATCACTGCCTTACCC 
SNRPN FWD CACCAAGAGGTGGTTAAAGC 
 REV GATTGCTGTTCCACCAAATCC 
NLRP2 FWD CGGCCGAGAGAGAAGCCTTATTAG 
 REV CAACACCTGGCCCTACTCGC 
 
Table 4.2- Pyrosequencing primers used in this chapter  
Gene Primer Oligo sequence (5’-3’) 
GRB10 gDMR FWD GGGAGAAAGAGGTTTTTA 
 REV (Biotin) AAATCTAAACATCC 
 SEQ ATTTAAAAAATAAATAAATCTAAACATCC 
GRB10 sDMR FWD AGTGAAAGGATAAATTGGATT 





 SEQ GAAAGGATAAATTGGATTTG 
SNRPN gDMR Qiagen Assay Hs_SNURF/SNRPN_01_PM PyroMark CpG assay 
ATP10a sDMR FWD GGAGGTATAGAGAGGTTTTG 
 REV (Biotin) AAATACTTAAAAAACAACTCCACTCA 
 SEQ AAATACTTAAAAAACAACTCCACTCA 
NLRP2 gDMR FWD GGGATTGGTTTGAATTGTAG 
 REV (Biotin) CCTTAAATAACATCACCCTATTCAACA 
 SEQ ATTGGTTTGAATTGTAGGA 
NLRP2 sDMR FWD GATGGAGGATTATAGGTGGAGAT 
 REV (Biotin) TCCCAACACCTAACCCTACT 









4.4.1 Imprinting of NLRP2 
Imprinting of NLRP2 is not clear and not well investigated in the literature, initial analysis of 
the NLRP2 promoter region reveals a methylation pattern indicative of maternal methylation 
bias in genome-wide UPD patients (Figure 4.5). Further to this figure, 4.5B showed that the 
methylation variability at the NLRP2 promoter region is higher than that of what is seen at 
other imprinted DMRs and confirms that the IG-DMR is covered in the 850K array. To further 
understand the imprinting behind this region and confirm if it is imprinted, a 450k and an 
RNA-seq dataset for uniparental ESCs were utilised. To ensure that the methylation array 
shows normal methylation patterns the methylation was examined in the aESCs and phESCs 
and compared to WT ESCs at the H19 (paternally methylated) and SNURF (maternally 
methylated) DMRs. This showed hypermethylation in the aESCs and hypomethylation in 
phESCs at the paternally methylated H19 DMR as expected (Figure 4.6A). The methylation at 
the maternally methylated DMR showed the opposite response with hypomethylation in 
aESCs and hypermethylation in the phESC at the SNURF DMR as also expected (Figure 4.6B). 
To ensure that these changes were unique to the imprinting DMRs the methylation was 
examined at the normally hypermethylated and hypomethylated CGIs at the non-imprinted 
genes DAZL and MTHFR promoter regions respectively, in which no change of methylation 






Figure 4.5: Methylation bias at NLRP2 using the beadchip array and variability of methylation at a subset of imprinted 
DMRs. NLRP2 promoter methylation bias in pUPD (n=1) and mUPD (n=1) in comparison to control blood (n=5). (B) 
Investigating the DMR variability between shows that the while the IG-DMR contains low probe coverage in the 850k epic 
array it still presents with tight variability across 23 healthy Saliva samples, similar to what is seen for the H19 and SNURF 
DMRs. Across 23 saliva samples, the suspected NLRP2 DMR presents with large variability which may suggest that this region 
is not imprinted in saliva. The box represents the interquartile range (IQR), the whiskers are IQR*1.5; the X marks the mean 
and a line represents the median; circles are outlier probes. MWU significance in comparison to blood demonstrated by 





Figure 4.6: Establishing methylation level at imprinting DMRs in aESCs and phESCs. Utilising 450k array data for uniparental 
ESCs, it is possible to see distinct changes of methylation at the imprinting DMRs near the (A) H19, (B) KvDMR and (C) SNURF 
loci in comparison to the control WT ESCs. To ensure that the changes of methylation between the uniparental ESC samples 
and WT ESCs were unique to the imprinting DMRs methylation was examined at the heavily methylated CGI at the (D) DAZL 
promoter region and the lowly methylated CGI at the (E) MTHFR promoter region. X; Mean, Line; Median, Box; interquartile 








Next, it was important to confirm the DMR at the promoter region, to achieve this, each CpG 
site was examined from 5’ end to the 3’ end of NLRP2 to fully investigate the imprinting at 
this region. This showed clear hypomethylation at the first 8 CG sites which represent the 
promoter region which was covered by the array in the phESCs and hypermethylation at the 
same CG sites at the aESCs (Figure 4.7). The remaining of the CG sites covered by probes 
covering the gene body show hypermethylation (Figure 4.7). Suggesting that NLRP2 has a 
paternal methylation bias similar to the H19 DMR. While both parental UPD patients and 
parental ESCs models showed a methylation bias, confusingly they are opposite in which the 
UPD patients show maternal methylation and the ESC’s show paternal methylation.  
Figure 4.7: Methylation at each probe covering NLRP2 in phESC and aESCs. Methylation at the probes in the 450k array, 
showing methylation paternal methylation bias in the aESC compared to the phESC at the promoter region (First 8 CG sites), 
then hypermethylation in both the aESC and phESCs at the probes covering the gene body region of NLRP2. aESC, 








After confirming the methylation bias in a second model for imprinting, RNA-seq analysis was 
utilised to investigate parental specific bias. Firstly, parental specific expression was examined 
in known maternally and paternally expressed genes. The maternally expressed genes MEG3, 
H19 and CDKN1C, were observed with upregulation in the phESCs in comparison to the WT 
ESC controls, while downregulation was observed in the aESCs in comparison to the WT ESCs 
controls (Figure 4.8 A & B). Contrary the paternally expressed genes PEG3, IGF2 and SNRPN 
were observed to have downregulated expression in the phESCs in comparison to the WT 
ESCs, while in the phESCs they are observed to have upregulation in aESCs (Figure 4.8 A & B). 
To ensure that the methylation bias observed at the imprinted DMRs were controlling the 
parental specific expression in these genes, DAZL and MTHFR genes were examined which 
were observed to have hypermethylation and hypomethylation at the CGIs at their promoter 
region respectively, both these genes showed similar expression trends in both the phESC and 
aESC in comparison to the WT ESCs confirming that the parental specific expression seen in 
these ESCs is unique to the Imprinted genes (Figure 4.8 A & B). As the methylation bias at the 
imprinted DMR methylation and gene expression is confirmed to followed expected patterns, 
the NLRP2 gene expression was then examined which showed upregulation in the phESCs in 
comparison to the aESCs, while in the aESCs it was observed to be downregulated in 
comparison to the WT ESCs (Figure 4.8 A & B). Taking this expression in account with the 
methylation data, NLRP2 appears to be expressed from the unmethylated maternal allele in 
these cell models.  As previously mentioned the androgenetic and parthenogenetic ESC’s 
resemble the genome of their respective gametes and therefore would suggest that this 






Figure 4.8: Single-cell RNA-seq expression analysis of a subset of imprinted genes androgenetic and parthenogenetic 
embryonic stem cells. RNA-seq analysis showed the expected parental specific expression for the maternally expressed 
genes (MEG3, H19 and CDKN1C) and paternally expressed genes (PEG3, IGF2 and SNRPN) in both (A) parthenogenetic ESCs 
(PhESCs)and (B) androgenetic ESCs (aESCs) vs WT control ESCs. NLRP2 appeared to have a biased expression increased 









To finish the investigation at the possible imprinting mechanism at the NLRP2 imprinted gene, 
histone modifications, ZFP57 and ZFP445 binding, CTCF binding and repetitive elements were 
examined using tracks on UCSC. Unexpectedly using all the histone modifications from the 
ENCODE project there were no histone modifications found at the NLRP2 DMR (Figure 4.9). 
At the novel NLRP2 DMR, there was no ZFP binding observed, but slightly upstream a small 
peak was observed for ZFP57 binding (Figure 4.9). Interestingly the whole region is full of SINE 
repetitive elements, except at the two different transcriptions start sites which both proceed 
LTR elements and correlate with the probes from the 450k array (Figure 4.9). While a clear 
methylation bias is observed at the promoter region, the imprinted status is still not clear due 
to the lack of other common epigenetic markers found at imprinted DMRs. However, as there 
is a clear allelic methylation bias, the region will be included in downstream studies in hopes 






Figure 4.9: UCSC tracks describing epigenetic regulators near the NLRP2 promoter region. DMR locations are marked in 
purple, orange indicates beta methylation. NCBI RefSeq was used to show the location of the gene. Mean_Beta_agESC 
represents the paternal methylation out of 1000 while the Mean_Beta_phESC represents the maternal methylation out of 
1000. Slight enrichment of ZFP57 is noticeable upstream from the novel gDMR and no enrichment of ZFP445 using hESC 
ChiP-SEQ data from (Takahashi et al., 2019). Using ENCODE tracks on UCSC no enrichment of histone marks could be 
observed. This region also contains many SINE repetitive elements nearby the transcription start sites (TSS) of NLRP2, though 






4.4.2 Aberrant methylation observed at imprinted genes in long term knockdown of DNMT1 
in hTERT-1604s 
The DNMT1 knockdown and WT cells had been analysed using the human Infinium 450k array 
(450k array), including subsequent visualisation of the data in the University of California, 
Santa Cruz (UCSC) genome browser, as tracks allowing. Through a bespoke GALAXY workflow 
developed in-house in the Walsh lab, the methylation values were analysed for the probes 
located at imprinted DMR coordinates as defined in Woodfine et al (2011) and Court et al 
(2014). The long-term depletion of DNMT1 resulted in widespread demethylation at most 
imprinted DMRs. However, a general trend is observed in which LOM is observed at the 
gDMRs (Figure 10A), while a number of DMRs characterised as somatic (sDMR) or unknown 
(uDMR) by Woodfine et al (2011) were seen to be gaining methylation as seen in Figure 4.10B 
and Figure 4.10C respectively. These unexpected gains of methylation provided interesting 
target regions for further analysis.  I chose three loci which showed this clear trend for further 
analysis:1) the GRB10 loci as it shows a large change at both the gDMR and sDMR;  2) the 
SNURF/SNRPN DMR and the ATP10a promoter region as they show loss and gain of 
methylation respectively and represent a well-understood imprinting locus in human and 
finally 3) NLRP2, as it showed a loss of methylation at our candidate gDMR matched with a 
considerable gain of methylation in d10 and d16 at the sDMR. All gametic, somatic and 
undescribed DMRs from the Woodfine et al (2011) and Court et al (2014) studies were 
included in this study. However, this did not include any placental DMRs found from the Court 





Figure 4.10: Changes of methylation (%) observed across DMRs found at/near imprinted loci in DNMT1 depleted hTER-
1604s. The figure shows % changes of methylation in the clones D8, D10 AND D16 in comparison to WT at (A) Gametic DMRs, 
(B) Somatic DMRs and (C) unknown DMRs which have not been fully investigated for the establishment of the mark. Red 
boxes indicated gDMRs which lose methylation while green boxes indicate the nearby sDMRs of interest that show gains of 






4.4.3 Changes of methylation at DMRs at the imprinted loci GRB10, SNRPN and NLRP2 
The data from the DNMT1 knockdown cell line demonstrated an accumulation of 
hypomethylated probes at gDMRs and accumulation of hypermethylated probes at the 
sDMRs at the imprinted genes GRB10, SNRPN and NLRP2 (Figure 4.11 A-D). Further analysis 
of the 450k array using the bespoke GALAXY workflow developed in-house was used to get 
mean methylation values at DMRs of interest, from this a switch-like mechanism of 
methylation between the gDMR and sDMR at the imprinted loci could be observed (Figure 
4.12). Though all gDMRs investigated showed loss of methylation only the gDMR at the GRB10 
in the d8 cell line showed significant loss of methylation when compared to the WT. At the 
sDMR, GRB10 and NLRP2 show the biggest gains of methylation for all KD cells except 
interestingly d8. ATP10a gains of methylation are very low, though probe coverage for this 
region is very poor so it may not be an accurate representation. As probe coverage was limited 
at the DMRs this lowered the statistical power, therefore, methylation needed to be further 





Figure 4.11: Long term knockdown by shRNA on hTERT-1604s led to an opposite methylation change at gDMR and sDMR 
at imprinted loci. DMR locations are marked in purple, Red indicates loss of methylation while blue indicates an increase of 
methylation. NCBI RefSeq was used to show the genomic location. FDR tracks compare the difference of the clonal cell lines 
d8, d10 and d16 to WT respectively. (A) The GRB10 gDMR indicate a loss of methylation while the probes at the sDMR 
indicate an increase of methylation for all of the knockdown cell lines. (B) The probes located at the SNRPN gDMR indicate a 
loss of methylation for all of the knockdown cell lines. (C) The probes located at the ATP10A sDMR indicated a gain of 
methylation for all of the knockdown cell lines.  (D) The NLRP2 gDMR indicates a loss of methylation while the probes at the 
sDMR indicate an increase of methylation for all of the knockdown cell lines with the exception of d8 at the sDMR which 
appears to lack probe coverage in comparison to D8 and D10. Red boxes highlight the gametic DMRs losing methylation 





Figure 4.12: Average methylation on the 450k array was decreased at the gDMRs and increased at the sDMRs of imprinted 
genes in DNMT1 KD lines. CpG probe sites at DMR locations for select imprinted genes were averaged for WT hTERT-1604 
and the clonal DNMT1 depleted cell lines (Blue), d8 (Orange), d10 (Grey) and d16 (yellow). (A) Average methylation at the 
gDMRs of the imprinted loci GRB10, SNRPN and NLRP2 in WT, d8, d10 and d16. (B) Average methylation at the sDMRs of the 
imprinted loci GRB10, ATP10A and NLRP2 in WT, d8, d10 and d16. 450K array was carried out for WT and each clonal cell line 
at passage number #22-#24 Error bars indicate standard deviation. Significance carried out with a Mann–Whitney U test vs 
WT with the following key, *p < 0.05; **p < 0.01; ***p < 0.001. 
4.4.4 Confirming changes of methylation observed in the 450k array  
To confirm the changes of methylation observed from the 450k array DNA was extracted from 
the WT and DNMT1 KD cell lines and underwent bisulphite conversion. Pyrosequencing was 
then utilised to confirm the changes of methylation observed in the 450k array. 
Pyrosequencing utilises sequencing by synthesis on bisulphite converted DNA, the 
methylation is quantified by the light given off as the region of interest is synthesized. Pyro 
assays were designed for the gDMR and sDMR at the GRB10, NLRP2 and the sDMR at ATP10a 
while the SNURF/SNRPN assay was purchased from Qiagen. These pyro assays involved 
carrying out a PCR with bisulphite primers targeting the region of interest for GRB10, SNRPN 
and NLRP2 as annotated on Figure 4.1, 4.2 and 4.3. A sequencing primer was then used to 
create a start point for the synthesis this was then sequenced and analysed using the Q24 
pyrosequencer.  At the gDMR of the loss of the imprinted gene, methylation was confirmed 
in each cell line compared to the WT. SNRPN showed significant loss of methylation in all cell 
lines as well as d8 at GRB10 (Figure 4.13A). Further to this, the gains of methylation were also 
confirmed at each of the loci for each cell line.  However, none appeared to be significant 





investigate the expression of these genes to fully understand the effect of this aberrant 
pattern observed 
Figure 4.13: Confirmation of methylation changes by pyrosequencing at the gDMRs and sDMRs of imprinted genes in 
hTERT-1604 with long term shRNA DNMT1. CpG sites at DMR locations for select imprinted genes were averaged for the 
cell lines WT (Blue), d8 (Orange), d10 (Grey) and d16 (yellow). (A) Average methylation at the gDMRs GRB10, SNRPN and 
NLRP2 WT, d8, d10 and d16. (B) Average methylation at the sDMRs GRB10, SNRPN and NLRP2 WT, d8, d10 and d16. 
Pyrosequencing was ran in duplicate with two biological replicates. Pyrosequencing was carried out for WT and each clonal 
cell line at passage number #22-#24 Error bars indicate standard deviation. Significance carried out with a Mann–Whitney U 
test vs WT with the following key, *p < 0.05; **p < 0.01; ***p < 0.001. 
4.4.5 Methylation pattern appears to have a functional effect on the expression of the 
imprinted genes  
Using complementary DNA (cDNA) the expression was investigated using qPCR with SYBR 
green, SYBR green is a DNA dye which emits green light which is picked up by the light cycler 
as the cDNA is amplified. This is then normalised using the housekeeping gene HPRT the 
results are seen in Figure 4.14A-C. GRB10 had significantly (p < 0.001) lost expression in all three 
knockdowns when compared to WT with a fold change of 0.22, 0.003 and 0.015 in d8, d10 
and d16 respectively. SNRPN followed the same direction of GRB10 with a significant (p < 0.001) 
fold change of 0.16, 0.15 and 0.28 in d8, d10 and d16 respectively. Finally, NLRP2 appeared 
to have significantly increased expression, with a fold change of 7.77, 2.43 (p < 0.01) and 4.86 
(p < 0.05) in d8, d10 and d16 respectively when compared to WT. The expression of GRB10 and 
NLRP2 was further investigated with RT PCR as seen in Figure 4.14C, this is a nonquantitative 





while NLRP2 is gaining expression in the KD when compared to the WT and normalized by 
HPRT.  
Figure 4.14: Aberrant methylation in long term shRNA knockdown of DNMT1 in hTERT-1604s correlates with aberrant 
expression of imprinted genes. (A-C) qPCR showing expression of the imprinted genes GRB10, NLRP2 and SNRPN in d8, d10 
and d16 when compared to WT, samples were normalised to HPRT. (D) RT PCR confirming the loss of expression in GRB10 
and gain of expression in NLRP2 with HPRT included for loading control. qPCR was ran in triplicate with two technical 
replicates and one biological replicate. WT and each clonal cell line were at passage number #22-#24 at point of transcription 
analysis. Error bars indicate standard deviation. Error bars indicate standard error of the mean. Significance carried out with 







4.4.6 The gain of methylation at sDMR is unique to the long term knockdown of DNMT1 in 
the hTERT-1604s  
As the interplay observed at the gDMR and sDMR of the imprinted genes investigated was 
unexpected, to determine whether or not the pattern observed was caused by the DNMT1 
depletion itself, or was a result of subsequent changes in response to the knockdown which 
were selected for following the long-term culture of DNMT1-depleted clonal cell lines, a 
transient KD of DNMT1 in hTERT-1604s using siRNA was utilised. The siRNA is a double-
stranded RNA that causes a knockdown of the targeted gene as long as the siRNA is being 
transfected into the cells. The siRNA has an overhang on the 3’ end which activates the RNA 
interference which leads to the degradation of the targeted mRNA. The 450k array was 
utilised once more to measure the methylation then compared to the WT. Investigation of 
the data on UCSC demonstrated an accumulation of hypomethylated probes at gDMRs of 
GRB10, SNRPN and NLRP2. However, unlike the shRNA, the sDMR at these imprinted genes 
also demonstrated an accumulation of hypomethylated probes (Figure 4.15 A-D). This is 
further confirmed by averaging the probes in these regions as seen in Figure 4.16 A and B, 
which shows a slight loss of methylation however, the decrease was not significant. This data 
present here suggests that the interplay between the gDMR and sDMR of these imprinted 
genes observed in the shRNA KD is unique to the long term culture of the DNMT1-depleted 
cells. This can be seen globally for all imprinted DMRs in which the transient siRNA knockdown 







Figure 4.15: Transient knockdown by siRNA on hTERT-1604s led to a loss of methylation at both the gDMR and sDMR at 
imprinted loci. DMR locations are marked in purple, Red indicates loss of methylation at the gDMR while green indicates 
loss of methylation at the sDMR. NCBI RefSeq was used to show the location of the gene. FDR tracks compare the difference 
of siRNA DNMT1 depletion to WT respectively. Both the gDMR and sDMR show loss of methylation at the imprinted loci (A) 





Figure 4.16: Loss of methylation at the gDMRs and sDMRs of imprinted genes in hTERT-1604 with transient knockdown of 
DNMT1. 450k array methylation levels at probes found with DMR locations for select imprinted genes were averaged for the 
WT and DNMT1 siRNA-depleted cell lines (A) Average methylation at the gDMRs of the imprinted loci GRB10, SNRPN and 
NLRP2 in WT and siRNA cell lines. (B) Average changes of methylation at the sDMRs of the imprinted loci GRB10, SNRPN and 
NLRP2 in WT and siRNA cell lines. Error bars indicate standard error of the mean. Significance carried out with a Mann–






Figure 4.17: Changes of methylation (%) observed across DMRs found at/near imprinted loci in siRNA transient DNMT1 
depletion vs WT. The figure shows % changes of methylation in siRNA transient knockdown of DNMT1 in comparison to WT 








Methylation patterns at imprinted DMRs are important for normal regulation of imprinted 
genes and disruption at these DMRs can lead to imprinting disorders. One method to 
investigate the effect of aberrant methylation at imprinted DMRs is to deplete or knockout 
essential enzymes involved in de novo DNA methylation or maintenance. Aberrant expression 
of DNMT1 has been shown to affect global methylation in somatic tissue (Etoh et al., 2004). 
Human transient or long-term depletion of DNMT1 has been shown to cause loss of 
imprinting in human cancer cells transfected with siRNA and shRNA (Anwar et al., 2012; Min 
et al., 2017). However, these studies are limited due to cancer cell lines being chromosomally 
unstable as mentioned previously. To circumnavigate this the Walsh lab carried out a long-
term knockdown of DNMT1 in a differentiated, chromosomally stable human fibroblast cell 
line and as expected global loss of methylation was observed. Imprinting marks established 
in the germline require DNMT1 to be maintained in somatic tissue, this explains the loss of 
methylation confirmed at the gDMRs in the DNMT1 depleted cell lines (Kurihara et al., 2008). 
However, a “meta-stable” switch was observed at some imprinted genes with the gDMR 
losing methylation and nearby sDMRs/uDMRs gaining methylation despite the loss of DNMT1. 
To ensure that the changes seen in the 450k array were accurately representing the 
methylation at the imprinting DMRs GRB10, SNRPN and NLRP2 were analysed with 
pyrosequencing. Though most changes of methylation observed were statistically 
insignificant, the fact it was seen with two different methods would suggest that a meta-
stable switch occurs in the DNMT1-depleted hTERT-1604s. One possible explanation for the 
hypermethylation could be an over-expression of de novo methyltransferases which have 
been known to have maintenance activity in somatic tissues (Lei et al., 1996). The majority of 
maintenance methylation in cultured adult human cancer cells is carried out by DNMT1 and 
DNMT3B (Rhee et al., 2002). While not shown in this thesis Investigation of the expression of 
DNMT3B in the DNMT1-depleted cell lines using the HT12 array showed no significant change 






Imprinted gene expression is tightly regulated by methylation, for this reason, the next step 
was to investigate the expression of the 3 target imprinted genes to see how the aberrant 
methylation pattern affected the expression. Though the changes of methylation were not 
seen to be significant, the expression was reproducibly affected by the DNMT1 depletion. 
GRB10 is highly tissue-specific with the sDMR controlling the expression of the major 
transcript, while the gDMR is present on the TSS of the imprinted GRB10 transcripts that are 
expressed in a tissue-specific manner (Blagitko et al., 2000; Monk et al., 2009). GRB10 
transcription analysis was carried out on different transcripts with primers binding to exons 
unique to each transcript, to investigate if the changes of methylation affected the transcripts 
differently, with loss of expression observed at each transcript investigated (data not shown). 
This could be due to lack of tissue-specific transcription factors that could be required to 
express the tissue-specific transcripts. However, according to the HT12 array, the maternally 
expressed genes are seen to have little to no change in expression.  According to Thürmann 
et al (2018) methylation at the NLRP2 promoter site negatively correlated with expression of 
the gene as described in our long-term depletion of DNMT1 loss of methylation at the novel 
NLRP2 DMR was observed which resulted in the subsequent overexpression. The depletion 
of DNMT1 causes loss of methylation at the SNURF/SNPRN gDMR and the unexpected 
repression of the SNRPN. Further to this, the loss of methylation at the SNRPN/SNURF gDMR 
has been shown to repress the many nearby paternally expressed genes and overexpress the 
two maternally expressed genes UBE3A and ATP10A (Court et al., 2014; Horsthemke and 
Buiting, 2006; Sharp et al., 2010). To further investigate this meta-stable switch observed at 
the tested imprinted genes it would be interesting to confirm the expression of nearby genes 
known to be controlled by the respective gDMRs.  
Initially, the only DMR at the NLRP2 loci was described by Woodfine et al (2011) with no 
definition of when the DMR was established, due to the initial investigations in our studies 
we investigated as it was a possible sDMR. Further to this the trend we seen at the gDMRs 
and sDMRs led to investigations into the promoter region as a gDMR. To our knowledge, this 
region has not been previously described as a DMR. Using uniparental ESCs 450k array and 
RNA-seq datasets this novel DMR appears to inherit methylation paternally resulting in 
maternal expression of NLRP2. The evidence of NLRP2 imprinting is conflicting with one study 





2015). However, studies which agree with the imprinting of NLRP2 describe maternal 
expression, as the promoter region was also observed to be negatively correlated with 
expression it would make sense for the promoter region to contain a monoallelic methylation 
pattern correlating to this maternal expression (Bjornsson et al., 2008; Mahadevan et al., 
2017; Thürmann et al., 2018; Pilvar et al., 2019). The novel DMR was also investigated using 
tracks on UCSC for preferential histone marks, for example, active histone modifications such 
as H3 and H4 acetylation and H3K4me2/3, an on the inactive allele active histone 
modifications such as  H3K27me2/3 and H3K9me2/3, this novel DMR observed none of these 
histone modifications which is uncharacteristic for imprinting DMRs (McEwen and Ferguson-
Smith, 2010). While not definitive of DMRs CTCF binding and ZFP binding was also investigated 
as they are found regularly at some imprinted DMRs, CTCF showed no binding at the DMR 
while some ZFP57 binding was found upstream of the DMR (Singh et al., 2012; Takahashi et 
al., 2019). This DMR while showing methylation patterns indicative of an imprinting DMR 
shows no other characteristics of being a DMR. 
The KvDMR imprinted cluster could be a future region of interest, as according to the 450K 
array the gDMR known as KvDMR, appears to be hypomethylated while the CDKN1C DMR 
appears to be hypermethylated. This is a well-characterised imprinting cluster that is 
associated with the imprinting disorder Beckwith-Wiedeman syndrome (Smilinich et al., 
1999). As mentioned earlier the Cdkn1c promoter site in mouse has been classed as an sDMR 
and has been found to be dependent on the KvDMR, though the methylation establishment 
has not been characterised in human (Bhogal et al., 2004; Woodfine et al., 2011). Another 
well-characterised imprinting cluster is the MEG3/DLK1 cluster which is associated with the 
imprinting disorder Temple syndrome (Ioannides et al., 2014). It can be seen that the DLK1 
and MEG8 sDMR are both hypermethylated, the nearby gDMR would be the IG-DMR but 
unfortunately, the 450k array does not have probe coverage for this region and would, 
therefore, need to be tested using a wet lab technique like pyrosequencing. Investigation of 
these imprinting clusters may give further insight into the mechanism of the “meta-stable” 
switch between the gDMRs and sDMRs observed in the long-term depletion of DNMT1 in a 





The Walsh lab recently showed that siRNA and shRNA depletion of DNMT1 results in an 
overall loss of methylation, with the shRNA showing gains of methylation (O’Neill et al., 2018). 
This showed that the long-term culture of hTERT-1604s with shRNA targeting DNMT1 causes 
unexpected gains of methylation, however, these gains were associated with particular 
chromatin marks. In the current study, there were no consistent chromatin marks that could 
be associated with the gains seen at the imprinting DMRs when investigated. Globally most 
imprinting DMRs lose methylation in the long-term depletion of DNMT1 with some regions 
maintaining or gaining methylation compared to the WT. In comparison, however, in a 
transient depletion of DNMT1, the imprinting DMRs showed widespread loss of methylation 
and no gains were observed. This suggests that the initial depletion of DNMT1 caused 
widespread loss of methylation, however, as the cells continued to be cultured it resulted in 
gains of methylation at sDMRs. It has been well established that the loss of methylation at 
gDMRs caused by loss of DNMT1 cannot be recovered in differentiated cells, therefore, the 
gains of methylation seen at the sDMR regions may be a “coping” mechanism in an attempt 
to normalise the expression of the imprinted genes as most sDMRs are present at promoter 
regions such as what was observed with GRB10 (Chen et al., 2003). A further explanation to 
the compensation is a similar model suggested by Wang et al., (2019) in which the 
hypomethylation caused by the depletion of DNMT1 may result in the epigenetic 
redistribution of nearby histone marks from the sDMR to the gDMR which cannot be restored 
without germline passage(Thakur et al., 2016). This epigenetic compensation could explain 
the silencing of SNRPN while the DMR is hypomethylated and the exchange of histone marks 
from the sDMR may explain why the sDMR retains methylation in the longterm depletion of 
DNMT1. Redistribution of histone marks is a consistent observation in cultured cells with 
widespread loss of DNA methylation (Cooper et al., 2014; Ohtani et al., 2018; Walter et al., 
2016; Wang et al., 2019). Though this is purely speculation and would require further testing 
to investigate if this can explain the meta-stable switch.  
Not much is currently known about the functionality of many of the sDMRs, The human 
GRB10 sDMR, is usually hypomethylated in somatic tissues, except for adult brain in which 
methylation levels of 35-65% are observed which are levels seen which are typical of a DMR 
according to Woodfine et al (2011) representing that one allele is hypermethylated whilst the 





levels to that observed in the adult brain. Additionally, the potential sDMR described at 
ATP10a the sDMR has only been observed with imprinted like methylation in the placenta. 
Finally, the DMR at NLRP2 described by Woodfine et al (2011) appears to be hypomethylated 
in the WT hTERT-1604, it has been previously observed to have methylation levels around 35-
65% in several different somatic tissues (Woodfine et al., 2011). Many sDMRs appear to be 
tissue-specific which may explain the lack of methylation seen at this NLRP2 DMRs in the WT 
hTERT-1604. According to the results here, it appears that the long term depletion of 
methylation at the gDMRs appear to result in the gains of methylation at the sDMRs in a 
differentiated human cell line, suggesting that the gDMR may play a role in maintaining 
normal levels of methylation at the sDMRs in human fibroblasts.  
4.6 Summary 
These results show that the long-term depletion and transient depletion results in different 
effects on methylation at imprinting DMRs.  The long-term depletion of DNMT1 results in a 
meta-stable switch of methylation between select DMRs defined as gDMR and the sDMR 
while the siRNA results on the widespread loss of methylation. The meta-stable switch of 
methylation observed in the long-term depletion of DNMT1 has a functional effect causing 
aberrant expression of imprinted genes, while previously we have shown that reprogramming 
can occur with KO and rescue of Dnmt3a2 in mESCs, here we observe to a certain extent 
reprogramming of imprinted DMRs in a DNMT1 depleted human differentiated cell line. 
Understanding the mechanism of this meta-stable switch may provide insight into the 
functionality of sDMRs and further the understanding of the regulation of imprinted genes. 
Further to this, we investigate a potentially novel DMR that appears to control the monoallelic 





Chapter 5: UHRF1 and its role in maintaining methylation at imprinted genes and transposable 
elements 
5.1 Introduction   
5.1.1 The role3 of UHRF1  
The domains and functions of UHRF1 were described during the introduction however the 
domains will be expanded further in this chapter. Recent research into UHRF1 has been 
investigating its potential as a biomarker and a target for cancer therapy even being referred 
to as a “universal oncogene” (Polepalli et al., 2019). This is not surprising as UHRF1 is essential 
for the G1/S transition in the cell cycle and is seen to be highly expressed in cells undergoing 
proliferation (Mousli et al., 2003). Furthering this UHRF1 has also been observed to have 
important roles in epigenetic inheritance by recruiting DNMT1 and is involved in silencing 
tumour suppressor genes during cancer progression (Babbio et al., 2012; Sharif et al., 2007). 
One of the most distinguishing abilities of UHRF1 is that it can link DNA and histone 
modifications through its SRA and TTD domains respectively (Bronner et al., 2013). Due to the 
important functions carried out by UHRF1, it is not unexpected that the deletion of Uhrf1 in 
mice causes a similar loss of methylation as the deletion of Dnmt1 (Muto et al., 2002; Sharif 
et al., 2007).   
As mentioned previously in this thesis, UHRF1 is made up of 5 domains the UBL, TTD, PHD, 
SRA and RING domains. The UBL domain is suggested to be involved with the proteasome 
pathway, the TTD and PHD domains act in conjunction to read the histone H3 code, while the 
SRA has been shown to elicit a flipping mechanism of the methylated cytosines and finally, 
the RING domain exhibits E3 ubiquitin ligase activity (Bronner et al., 2013). Until recently 
there were not many mechanistic studies carried out with disruptive mutations at the 
domains of UHRF1 in human. However, a recent study by Kong et al (2019) carried multiple 
exogenous disruptive point mutations in colorectal cancer (CRC) cell lines depleted of UHRF1. 
This study revealed that mutations in the TTD domain are unable to undo the 
hypermethylation observed in CRC, whereas the mutations at the PHD and SRA domains 





The authors suggest that the loss of cancer-specific methylation is due to the disruption of 
binding between UHRF1 and the histone H3 tail and ultimately interrupts UHRF1’s ability to 
bind to hemimethylated DNA (Cheng et al., 2013; Harrison et al., 2016). Finally, Kong et al 
(2019) also showed that a mutation in the RING domain resulted in a ∼17%–24% loss of 
methylation in CRC cell lines.  
5.1.2 UHRF1 and imprinting   
As UHRF1 plays such an important role in the regulation of DNA methylation it comes as no 
surprise that disruption of UHRF1 leads to the subsequent loss of imprinting. Sharif et al 
(2007) showed that the deletion of Uhrf1 in mESC lead to the loss of methylation at a number 
known imprinting DMRs. Expanding from this Qi et al (2015) rescued Uhrf1 null mESC and 
observed a non-germline restoration of imprints in a small subset of imprints unlike the 
widespread recovery of imprinted marks observed in Dnmt3ab null mESC rescued with 
Dnmt3a2. This suggested the possibility of the de novo enzymes playing a more prominent 
role in the reprogramming of the imprints than DNA maintenance enzymes, as our similar 
experiment with Dnmt1 showed no recovery of the imprints (Thakur et al., 2016).  
It was later shown that Uhrf1 null oocytes, when fertilised, would result in loss of methylation 
at ICRs during preimplantation development, further suggesting that maternal Uhrf1 is 
essential for ICR maintenance, though showed little to no effect at the ICRs during oocyte 
development (Maenohara et al., 2017). A more recent study, in contrast, observed that the 
Uhrf1 null oocytes do sustain reduced methylation at maternal ICRs as well as in pre-
implantation embryos, by showing a loss of methylation at Peg1 and Peg3, with the authors 
suggesting that the loss of imprinting observed in pre-implantation embryos could be an 
inheritance from the Uhrf1 null oocytes (Cao et al., 2019b).  However, it should be noted that 
Maenohara et al (2017) examined a larger set of imprints than Cao et al (2019) and showed 
no or insignificant loss of methylation in Uhrf1 null oocytes, possibly suggesting that Uhrf1 
has no vital role in de novo methylation at the imprints and that the loss of maternal Uhrf1 in 
pre-implantation embryos is what impacts the global reprogramming and subsequent loss of 





Gene knockout experiments in mice have recently implicated the Krüppel-associated box-
containing zinc-finger protein (KRAB-ZFP) ZFP57 in the establishment and maintenance of 
several imprinted loci (Li et al., 2008) and loss-of-function mutations in the human Zfp57 gene 
are associated with hypomethylation at multiple imprinted regions in individuals affected by 
transient neonatal diabetes (Mackay et al., 2008). KRAB recruits KRAB-associated protein 
1(KAP1), which acts as a scaffold for various heterochromatin-inducing factors, such as the 
histone methyltransferase SETDB1 (Schultz et al., 20001, 2002). Therefore, the binding of 
KRAB-ZFPs to specific chromosomal loci results in nearby transcriptional repression and 
establishes heterochromatin marks, such as H3K9me3. Correspondingly, KRAB-ZFPs can no 
longer mediate transcriptional repression when KAP1 is inactivated (Groner et al., 2010). 
Quenneville et al (2011) associated Uhrf1 with this complex by observing that it 
coimmunoprecipitates with KAP1 in mESCs. Further to this differential chromatin marks has 
been observed at the active and inactive alleles at imprinted genes, in particular, H3K9 is 
widely associated with the silent allele of imprinted genes (Chang and Bartolomei, 2020). The 
UHRF1’s binding to H3K9 and it's association with the ZFP57/KAP1 complex it is not a surprise 
that loss of UHRF1 results in the loss of imprinting.  
5.1.3 UHRF1 and retrotransposons 
Similar to ICRs, some transposable elements are also protected from demethylation through 
reprogramming during implantation (Reik et al., 2001). Interestingly a small number of 
imprinted genes resemble retrotransposons or have even been passively retrotransposed 
themselves (Cowley and Oakey, 2010). Further to this ERV’s and inactive imprinted alleles 
contain both the repressive mark H3K9me3 (Matsui et al., 2010). While seemingly widely 
different in their function and regulation it has been predicted by Barlow (1993) that 
imprinted genes may have arisen from a host defence mechanism to silence 
retrotransposons. While this was predicted 27 years ago, many of the predictions are still valid 
to this day, such as various maternal and paternal imprinting factors, imprinting boxes with 
the presence of a key sequence element containing ‘foreign invading DNA’ and a host system 
to neutralise the key sequence elements resulting in identical machinery used for repression 
at these elements (Ondičová et al., 2020). The KRAB-ZFP complex discussed earlier is one such 





this machinery works in a sequence-specific manner which is attributed to the unique 
combinations of zinc-fingers (Monteagudo-Sánchez et al., 2020). In particular ZFP57 one of the 
most studied members of this complex has been shown to target IAP, LTR and imprinted 
gDMRs (Li et al., 2008; Shi et al., 2019). The mapping of 200 KRAB-ZFP DNA binding proteins 
target shows was predominantly found at transposal elements including ERV’s (Imbeault et 
al., 2017). Similarly to the mechanism observed at the inactivated alleles at  imprinted regions, 
the retrotransposable elements once bound by KRAB-ZFP binding resulting in the recruitment 
of KAP1 and other proteins involved in the complex such as SET domain bifurcated 1 (SETDB1) 
and UHRF1 ultimately inducing local acquisition of H3K9me3 and DNA methylation 
(Quenneville et al., 2011; Shi et al., 2019). While studies investigating UHRF1 in regards to the 
maintenance of imprints appear to agree, the role of UHRF1 in maintaining transposable 
elements is clouded with conflicting literature.  
Mutations in UHRF1 were initially characterised as phenocopying loss of DNMT1 in mouse 
and resulted in widespread hypomethylation of the genome and dysregulation of imprinted 
genes, as well as ERV such as IAP (Bostick et al., 2007; Sharif et al., 2007). Mutations in the 
TTD-PHD region that affect H3K9me3 binding by UHRF1 have been shown in human to 
decrease DNA methylation at ribosomal DNA repeats in HeLa cells (Rothbart et al., 2012). A 
further study also observed an upregulation of endogenous retroviruses as well as up-
regulated expression of viral defence genes in a colorectal cancer cell line with a long-term 
depletion of UHRF1, a response which was greater than DNMTi treatment in the same cell 
line (Cai et al., 2017). The same group went on to show that point mutations in the PHD and 
SRA domain lead to similar demethylation and derepression of the endogenous retroviruses 
(Kong et al., 2019). In mouse, mutations in the same region gave only a 10% decrease in DNA 
methylation, which was genome-wide and not just restricted to repeats (Zhao et al., 2016). 
Controversially, Sharif et al (2016), contradicting a paper published previously from their lab, 
stated in their study from 2016 that repression of transposable elements requires both 
methylation-dependent and methylation-independent pathways, suggesting the activation 
seen in Dnmt null mice was due to prolonged binding of UHRF1 preventing the establishment 
of H3K9me3 by the H3K9 methyltransferase SETDB1, rather than the loss of DNA methylation. 
In contrast, mutations in the zebrafish homologue were reported to result in ERV 





DNMTi in human, but through double-stranded DNA rather than dsRNA signalling 
(Chernyavskaya et al., 2017). There is, therefore, a lack of clarity regarding the role of UHRF1, 
what the cellular response to the loss of this important epigenetic regulator would be, what 
genes would be most affected and what the dependence, if any, of DNA methylation on the 
TTD-PHD domain would be during development.  
5.1.4 Stable knockdown of UHRF1 in hTERT-1604s global loss of methylation and de-
repression of ERVs 
The preliminary study carried out by the Walsh lab was carried out in a normosomic 
differentiated fibroblast cell line hTERT-1604 (described earlier in this thesis) which had been 
depleted of UHRF1 (UH4). The UH4s were generated in the same fashion as shown in the 
earlier research chapter for the D8, D10 and D16 cell lines (Figure 5.1A). The Walsh lab has 
previously confirmed the depletion of UHRF1 in this model (Figure 5.1B and C) and 
subsequent global loss of methylation similar to that of the depletion of DNMT1 (Figure 5.1D). 
In this investigation, Irwin et al (In Prep) implicated H3K9me3 in ERV de-repression in the 
absence of DNA methylation and showed that the PHD domain of UHRF1 plays an important 
role in the repression of ERVs in a human model (Figure 5.1E-G). The implication of the 
H3K9me3 binding was evident as cell lines rescued with the point-mutated UHRF1 (PHD1, 
PHD4, PHD10, TTD9) failed to repress the ERV’s but when the same UH4 cells were rescued 
with intact protein (WT10, WT18) repression occurred (Figure 5.1G). However, interestingly 
in this study by Irwin et al (In Prep), WT10 showed no recovery of methylation at the ERV 







Figure 5.1: Stable UHRF1 knockdown depletion results in a global loss of methylation and rerepression of ERVs in hTERT-
1604s. (A) The experimental approach is taken to generate and analyse the UHRF1-depleted hTERT-1604s. Transfection was 
carried out using an shRNA targeting UHRF1 and then cells grown in selective media until colonies appeared. Three separate 
clonally-derived cell lines were expanded (UH4, U5 and U10) and further analysed with methylation and transcription arrays 
and confirmed with wet-lab techniques. (B) Confirmation that UHRF1 expression is depleted in the UH4 cell line using the 
HT12 array and qPCR and (C) loss of protein using western blot. (D) UH4 and d16 show similar changes of methylation across 
all probes on the Infinium human 450k array: a βvalue of 1 equates to 100% methylation. Median values are indicated by 
the line and whiskers represent interquartile range. (E) The experimental approach is taken to generate rescue cell lines with 
UHRF1 proteins including proteins containing point mutations previously shown to affect binding (WT10, WT18, PHD (D334, 
E335) and TTD (Y188)) and colonies expanded. (F) All rescue cell lines fail to recover methylation and shows similar changes 
of methylation across all probes on the Infinium human 450k array. (G) qPCR shows derepression in UH4s in comparison to 
WT, while the rescue cell lines WT10 and WT18 repress the reactivation similar to WT levels, however, when UH4 is rescued 
with the point mutated proteins PHD1, PHD4, PHD10 and TTD9 the extent of repression is not re-established to the same 





It is clear that the loss of UHRF1 results in the rerepression of retrotransposable elements and 
loss of imprinted expression.  We hypothesize that a mutation within the PHD domain that is 
essential for the binding of UHRF1 to H3K9 will result in the rerepression of retrotransposable 
elements and loss of genomic imprinted expression without effecting the Uhrf1 expression. 
5.2 Aims  
The overall aim of this chapter is to provide more insight into the importance of the PHD 
domain in Uhrf1. Previously the Walsh lab had shown de novo methylation activity in hTERT-
1604 cells was sufficient to restore methylation to WT at some genes (O’Neill et al., 2018). 
We considered that these adult cells may instead lack other factors required for ERV DNA 
methylation which are only found earlier in development. Therefore, to examine the 
dependence of de novo methylation and ERV repression on an intact H3K9me3 binding 
domain in UHRF1, we generated mouse embryos containing mutations in the PHD domain 
matching those used in the hTERT-1604 UH4 cell line. We will further this investigation to 
include the genomic imprinted regions due to the overlapping similarities between 
transposable elements and the genomic imprinted regions using both the PHD mouse mutant 
embryo and hTERT-1604 models.  
• Firstly, we will generate a mouse model with a Uhrf1 loss of function PHD mutation to 
investigate the dependence of an intact H3K9me3 binding domain in UHRF1 for de 
novo methylation and retrotransposal repression during embryonic development. 
• Next, we will further explore the requirement of the PHD domain for the maintenance 
of genomic imprinted elements during mouse embryonic development. 
• Finally, we will investigate the consequence of the long-term depletion of UHRF1 has 
on the retrotransposal and genomic imprinted elements in a human chromosomally 






5.3 Materials and Methods 
Methylation analysis was carried out with the Infinium 450k beadchip array and 
pyrosequencing while expression analysis was carried out with qPCR as described in chapter 
2. Further investigations were carried out for methylation and expression using 
pyrosequencing, clonal analysis and in situ hybridisation.  
5.3.1 Pharmacological inhibition of DNMT1 
Cell culture was carried out as described in Chapter 2. For drug treatment, 5-Aza-2’-
deoxycytidine (5’Aza-dC; Sigma-Aldrich, Dorset, UK) was dissolved in DMSO and added to 
culture media; negative controls contained just DMSO.  Cells were washed twice with PBS 
before the addition of 10mls fresh complete media supplemented with 5-Aza-2’-
deoxycytidine (5’Aza-dC; Sigma-Aldrich, Dorset, UK) at a final concentration of 1μM.  Cells 
were then treated with 5-AZA-CdR at a final concentration of 300nM at 0 hours.  After 24 
hours the cells were washed with PBS and fresh media without drug was replaced.  Cells were 
grown for up to 36 days with the media changed every two days.  Cells were harvested at 72 
and 96 hours. 
5.3.2 CRISPR-Cas9 generation of Uhrf1 PHD D334/E335AA mutant mice 
Superovulation was induced in 5-week-old B6D2F1 female mice through intraperitoneal 
injection of pregnant mare’s serum gonadotropin (5 IU). 48 hours later the mice were injected 
with chorionic gonadotropin (p5 IU) then mated with male B6D2F1 mice overnight. After 
which zygotes at Embryo day (E) 0.5 were collected from the oviducts of female mice. To 
remove the cumulus cells zygotes were incubated in 1% hyaluronidase/M2 medium 
followed by washing with fresh M2 medium and recovery for 6h at 37 °C in a 5% CO2 
incubator. Microinjection containing a mixture of SpCas9 mRNA (100 ng/μl), Uhrf1-crRNA 
(50ng/μl) and 112-bp single-stranded oligodeoxynucleotide (ssODN, 10ng/μl), which was 
flanked by homologous arms corresponding to exon 7 of Uhrf1 was carried out using a 
FemtoJet microinjector, set to Pc = 10-15 hPa and Pi = 40-50 hPa. Zygotes that were 
successfully microinjected were then incubated for 72h in KSOM at 37 °C in a 5% CO2 





uteri of pseudopregnant female B6D2F1 mice. To confirm the CRISPR/Cas9 Uhrf1 mutation 
PCR using specific primers (Table 1) was carried out to amplify the genomic regions flanking 
the gRNA target. The PCR amplicons were ligated into the pClone007 vector and sequenced. 
5.3.3 Cloning 
The primers IAP-F 5’-ttg ata gtt gtg ttt taa gtg gta aat aaa-3’ and IAP-R 5’-caa aaa aaa cac cac 
aaa cca aaa t-3’ were used to generate a PCR product from bisulphite converted DNA 
following the pyro PCR protocol in chapter 2. The PCR product was cloned into the cloning 
vector pClone007 using the pClone007 Simple Vector kit according to the manufacturer’s 
instructions (Beijing Tsingke, Beijing, China). 1ul of vector plasmid was then used to chemically 
transform competent E.coli cells, by heat shocking the E.coli cells at 42⁰C for 45 seconds.  E. 
Coli cells were then incubated in Lennox broth (Sigma-Aldrich, St. Louis, Missouri, United 
States) for 1 hour then plated out on Luria-Bertani (LB)  agar (Shanghai shisheng Sibas 
advanced technology, Shanghai, Chin) agar plates containing 50mg/ml ampicillin (Shanghai 
shisheng Sibas advanced technology, Shanghai, China) for selection of transformants.  Plates 
were incubated overnight at 37⁰C. Agar plates containing colonies were then sent to Beijing 
Tsingke (Beijing, China) for plasmids to be extracted and sequenced.  
5.3.4 Bisulphite Sequencing 
The DNA sequence for the area of interest was obtained, bisulfite converted and aligned with 
sequencing results using the EMBL-EBI Clustal Omega Multiple Sequence Alignment tool; with 
sequences inputted as FASTA format.  The methylation status at each CpG site was confirmed 
by the retention of the cytosine of CG sites while the gain of thymine indicated the loss of 
methylation at the CG site when compared to the reference sequence.  
5.3.5 In situ IAP probe preparation  
 To label the IAP in mouse embryos an RNA probe was generated through in vitro 
transcription-based on previously used primer sequences (Walsh, Chaillet & Bestor, Nat Gen 
1998). An IAP probe template was generated using PCR, the PCR was set up using 25ul 2×Gflex 





‘GGGCCCAATACGACTCACTATAGGGAGGCCAGAATCTTCTACGGC’ which contains a T7 
promoter to transcribe the RNA probe containing DIG-labelled nucleotide in situ and B-17 
‘CTGTAAGCTTAAGGCCC’ at a final concentration of 0.3μM, 500ng of mouse embryo DNA 
template and 1 μl of Tks Gflex DNA Polymerase (1.25 units/μl) all reagents were sourced from 
Takara Bio (Shiga, Japan). PCR was carried out using the following conditions: 1 min at 94 °C 
followed by 35 cycles of 98°C for 10s, 60°C for 15s, 68°C for 35s and a final elongation step of 
68°C for 3min. The IAP template was then purified using the QIAquick Gel Extraction Kit 
(Qiagen, Crawley, UK) according to the manufacturer’s instructions. A DIG-labelled, single-
stranded RNA probe was then generated using the DIG RNA Labelling Kit (SP6/T7) (Roche, 
West Sussex, UK) by following the manufacturer’s instructions.  
5.3.6 Whole-mount in situ hybridization 
Embryos were prepared by fixing in 4% paraformaldehyde in phosphate buffer saline (PBS) at 
4°C overnight. After the overnight fixation embryos underwent washing with PBS/Tween 
(PBT) (1 × PBS plus 0.1% Tween) for 5 minutes with gentle rocking at 4°C. The embryos were 
subjected to a dehydration series using a methanol/PBT series of 25%, 50%, 75% and 100%, 
each stage lasted 5 minutes and was carried out at 4°C with gentle rocking. A final 100% 
ethanol step was carried out with the same conditions, once this was done the embryos were 
stored up to 1 month in the -20°C. The embryos were removed from storage and rehydrated 
to begin the hybridization, firstly rehydration was carried out with a series of methanol/PBT 
of 75%, 50% and 25% with the same conditions as the dehydration series. A bleaching step 
was conducted out with 6% hydrogen peroxide in PBT at 4°C for 1 hour. The embryos 
underwent to washing steps with PBT for 5 minutes with gentle rocking at room temperature. 
The embryos underwent proteinase K treatment at 10g/ml in PBT for 6 minutes at 4°C. Then 
followed up with a wash of 2mg/ml glycine in PBT for 5 minutes followed by another two 
washes with PBT for 5 minutes each. Afterwards, the embryos were washed in increasing 
concentrations of hybridization solution (50% formamide, 5 × SSC, pH 4.5 (citric acid to pH), 
1% SDS, 100 μg/ml yeast tRNA, 50 μg/ml heparin) and PBT mixture with the ratios of 1:3, 1:1, 
3:1, the embryos were washed for 5 minutes in each mixture, this was followed by a 10-
minute wash in the hybridization solution. The hybridization solution was replaced with fresh 





was replaced with fresh solution for a final time but also contained 200ng/ml of the IAP probe 
and incubated at 65°C overnight. Proceeding to the overnight incubation the embryos were 
washed in a 1:1 mixture of hybridization solution and  FA/SCC/Tween (FST) (50% formamide 
5 × SSC, 0.1% Tween and DEPC water; at pH 4.5) for 30 minutes then a 30-minute wash in FST 
at 65°C. The embryos were then allowed to cool down for 10 minutes at room temperature 
in a 1:1 mixture of FST and Tris-buffered/Saline/Tween (TBST)  (NaCL (FW 58.44), KCL (FW 
74.55), 1M Tris-HCl, Water; at pH 7.5). The embryos were blocked using a blocking reagent 
(Roche, West Sussex, UK) for 1 hour at room temperature, the blocking reagent is then 
replaced with fresh reagent with the addition Anti-Digoxigenin-AP Fab fragments (Roche, 
West Sussex, UK) (1:2500) and incubated at 4°C overnight. The next day the embryos were 
washed 3 times for 5 minutes in TBST, followed by 5 more times for 1 hour in TBST and then 
a final wash of TBST overnight at 4°C overnight with gentle rocking. After the overnight 
incubation in TBST the embryos were washed 3 times in NaCl/Tris–HCl/MgCl/Tween (NTMT) 
(100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl2, 0.1% Tween 2 mM (0.5 mg/ml) Levamisole; 
9.5pH) for 20 mins at room temperature. The NTMT was then removed and an NBT/BCIP stock 
solution (Roche, West Sussex, UK) made up with NTMT was added and left at room 
temperature for 40 minutes to allow for the colour to develop and was stopped by washing 
with PBS and then fixed using 4% paraformaldehyde/ 0.1% glutaraldehyde, before two final 
washes of PBS were carried out.  
Table 5.1 RT-qPCR primers used in this chapter  
Gene Primer Oligo sequence (5’-3’) 
Human 
GRB10 FWD GCACGAAGACAACCAGGTG 
 REV GAACGATCACTGCCTTACCC 





 REV GATTGCTGTTCCACCAAATCC 
NLRP2 FWD CGGCCGAGAGAGAAGCCTTATTAG 
 REV CAACACCTGGCCCTACTCGC 
UHRF1 FWD TGAGGACATGTGGGATGAGA 
 REV GTCCCTGGAGTTCATCTGGA 
IFI27 FWD TCTGTCCACCCTCTGCTTCT 
 REV GGCATGGTTCTCTTCTCTGC 
BST2 FWD AGGGAGGTGTCATCGTCAAC 
 REV CTCTTGTCTCCCACCCTGAG 
HERV-FC2 FWD TTTCCCACCGCTGGTAATAG 
 REV AGGCTAAGGATTCGGCTGAG 
STAT1 FWD CCCACTCTGATCAACTTTTGC 
 REV GGCCTGTTGAAGATGCTTGT 
Mouse 
H19 FWD CGATTGCACTGGTTTGGA 





Igf2 FWD GGATCCCAGAACCCGAGAAGA 
  REV GGGCGGCTATTGTTGTTCTCA 
 Grb10 FWD GTAAGCGGAGCACACGGATGAA 
  REV TACGAACGCCTTTGGATTACTCTG 




R    CTCTCACTGAGCCTACAGCCAAG 
 
 REV CTCTCACTGAGCCTACAGCCAAG 
 Table 5.2 Bisulphite primers used in this chapter  





 REV (Biotin) AAATCTAAACATCC 














 REV (Biotin) CCTTAAATAACATCACCCTATTCAACA 
 SEQ ATTGGTTTGAATTGTAGGA 
Mouse 
Grb10 FWD GGGGTTAGTGGATAGTTT 
 REV (Biotin) CTAAACTCCAAAACCCTTTTTCTA 
 SEQ GTTTTAGAATTAGGTAGTATTTAG 
Snrpn FWD GGTTAGAGGGATAGAGATTTTTGTATTG 
 REV (Biotin) TCCACAAACCCAACTAACCT 
 SEQ TATGTGTAGTTATTGTTTGGGA 
H19 FWD TTTTTTGTTGAATTTGGGGTATTTAAAG 
 REV (Biotin) CACATTTCTTAAATAACTCCTTCAATCTT 
 SEQ ATTTGGGGTATTTAAAGT 
KvDMR FWD AGGAGGGGGAGGTTATGA 





 SEQ GGGGGAGGTTATGAT 
Mest Qiagen 
Assay 
Mm_Mest_01_PM PyroMark CpG assay (PM00384230) 
5.4 Contributions  
For this chapter, the PHD mutant mouse was generated by Dr. Rachelle Irwin and Meiling Sun. 
I helped harvest embryos and carry out in situ. Cell lines were generated by Drs. Avinash 
Thakur and Rachelle Irwin. I revived lines from cryostorage, grew the cells and isolated nucleic 
acid for analysis. Primer sequences and PCR conditions for some human retrotransposable 
elements and immune genes were generated by Dr. Catherine Scullion. All genomic imprinted 
investigations were carried out by myself as well as the clonal analysis for the IAP elements 











5.5 Results  
5.5.1 Generation of a Uhrf1 PHD mutant mouse line 
Generation of a Uhrf1 PHD mutant mice required three rounds of injections due to low 
survival rate, suggesting that the PHD mutation had a highly lethal effect in development as 
described in Figure 5.2A. The morphology of the embryos at e8.75 and E9.5 looks relatively 
normal for the WT and HET mutant mice, but there are clear morphological abnormalities at 
E8.75 which is more extreme by e9.5 (Figure 5.2B). The mutation was confirmed using Sanger 
sequencing (Appendix Figure A1) and was observed with hypomethylation at the IAP 5’UTR 
at 2 individual E8.75 and E9.5 HOM embryos against a WT and HET embryo respectively 
(Figure 5.2B). Hypomethylation was then further observed at the IAP LTR at all 6 CG sites 
examined using pyrosequencing (Figure 5.2C). Methylation at the repetitive elements LINE-1 
and IAP 5’UTR show highly significant loss of methylation (Figure 5.2D).  Further to this, the 
Uhrf1 PHD mutation leads to derepression at the IAPez-GAG and musD elements, (Figure 
5.2E). A more in-depth transcriptional analysis confirmed derepression across several 
different retrotransposable elements (Figure 5.2F). While the Uhrf1 results in clear 
phenotypical defects during embryonic development and rerepression of the transposable 
elements, it is seen that the UHRF1 expression of the protein remains close to WT levels 
(Figure 5.2F). The Sanger sequence and sgRNA guide information can be seen in Appendix 
Figure A1. While generating the mice PHD mutants, the Walsh lab also attempted to generate 
2 human HEK293T cell lines with either a UHRF1 KO or a PHD mutation using CRISPR-Cas9 
(Appendix Figure A1). However, this proved to be lethal and resulted in no colonies growing 





Figure 5.2: Uhrf1 PHD mutation results in loss of methylation and derepression at several transposable elements during 
embryonic development. Mutation of the PHD domain of Uhrf1 in mouse embryos was carried out using CRISPR. (A) The 
Uhrf1 sgRNA were injected into C57BL/6 and DBA/2 embryos which were then implanted into a female surrogate. The first 
round resulted in embryo lethality and no offspring, the second round of injections were harvested at e8.75 and e9.5 to be 
used for investigations and finally the third round of injections resulted in a heterozygotic Uhrf1 PHD mutant. This HET mouse 
was then used as a founder for the Uhrf1 PHD mutation mouse line. (B) The mouse embryos for the WT and HET show normal 
morphology at e8.75 and e9.5 in which they have started turning, meanwhile, at the same age, the homozygous mutants 
appear smaller and less advanced than their WT and HET counterparts at the same ages. Overall levels of methylation were 





hypomethylated across all 6 CG sites investigated using pyrosequencing. (D) Significant loss of methylation was also observed 
at both the Line-1 and IAP transposable elements. (E) IAPez-GAG and musD both show derepression in homozygotic Uhrf1 
PHD mutants. (F) Further, in-depth transcription analysis of retrotransposons shows that a selection of different elements is 
derepressed in several different homozygotic Uhrf1 PHD mutants, with blue representing no change of expression and red 
representing large upregulation of element.  
5.5.2 Mouse Uhrf1 PHD mutant and IAP derepression  
To further investigate the derepression of the retrotransposable elements alternative 
methods were utilised. This included clonal analysis for a number of reasons: a) it could 
confirm methylation loss independently; b) if there was a mixed population of methylated 
and unmethylated transposons, this could be distinguished using this method; c) sites can be 
directly compared between clonal analysis and pyrosequencing, which is not always the case 
and d)since there are many IAP elements with different sequences due to mutations, we could 
get an impression of the extent to which methylation changes were linked to particular types.  
Figure A1 shows that all the IAP elements investigated using clonal analysis showed the 
expected heavily methylated CG sites in the WT mouse embryos E8.75 (Walsh et al., 1998).  
The IAP elements in the WT e8.75 mouse embryos contained 97% methylated CpG sites 
compared to the PHD mutant in which only 35.71% CpGs were methylated on average across 
all IAP elements investigated (Figure 5.3A-B). This confirms the loss of methylation from the 
pyrosequencing analysis with similar overall losses of methylation. To further gauge the effect 
on which the Uhrf1 PHD mutation has on IAP during embryonic development, an in-situ 
analysis was carried out for WT and HOM mutants at e8.75 and e9.5 using a probe specific for 
a recently active or young IAP. In Figure 5.3C it is clear that the signal is stronger in both e8.57 





Figure 5.3: Mouse embryos with homozygotic mutations in the PHD domain of Uhrf1 present with loss of methylation at 
IAP repetitive elements. IAP are repetitive elements found in mice, using bisulphite sequencing it is possible to measure the 
levels of methylation across the different repeats found throughout the genome. (A) Clonal analysis showing methylation 
across the IAP sequences, Black circles represent methylated CG sites while white circles represent unmethylated CG sites 
that have been converted to TG during bisulphite conversion. (B) Visual representation of the methylation from the clonal 
analysis. (C) Using a probe targeting IAP an in-situ hybridisation was carried out on mouse embryos at ages E8.75 and E9.5 
for both wildtype (WT) and homozygotic PHD mutations Uhrf1 (HOM). There was a clear IAP upregulation in the HOM 
embryos at both ages as shown by the darker colour. However, it is much more prominent in the E9.5 HOM suggesting the 





5.5.3 UHRF1 is important for the maintenance of imprinting 
Uhrf1 has been previously observed to play a role in the regulation of imprints during 
embryonic development, here we investigate the potential involvement of the PHD domain 
of Uhrf1 in maintaining the imprints during embryonic development. To investigate this, 
embryos were harvested at e8.75 and used to extract DNA and RNA. As expected, 
pyrosequencing technology indicated normal methylation (normally 45-55% in the mouse 
embryo (Thakur et al., 2016)) at the imprinted gDMRs in WT embryos. The PHD mutation, 
however, resulted in significant loss of methylation across the 4 imprinted DMRs investigated, 
with the H19 DMR just missing out on significance with a p-value of 0.0563 (Figure 5.4A). The 
loss of methylation at the H19 and Grb10 ICRs subsequently resulted in the loss of imprinted 
expression of H19 and Igf2, which are normally controlled by the H19 gDMR and Grb10 which 
is normally controlled by the Grb10 gDMR respectively (Figure 5.4B-D). However, only Grb10 






Figure 5.4: Mouse embryos with homozygotic mutations in the PHD domain of Uhrf1 present with loss of imprinting at 
E8.75. (A) Pyrosequencing confirms the loss of methylation at the imprinted DMRs in mouse embryos E8.75 with a 
homozygotic mutation at the PHD domain of Uhrf1 (HOM) when compared to a wild type (WT). This was then seen to have 
a functional effect with E8.75 HOM embryos which appear to lose imprinted expression at (B) H19, (C) Igf2 and (D) Grb10. 
Due to lack of embryonic material experiments were carried out in duplicate with biological replicates. Error bars indicate 
standard error of the mean. Significance carried out with a two-tailed T-test with the following key, *p < 0.05; **p < 0.01; 
***p < 0.001. 
5.5.4 5-aza-2′-deoxycytidine activates ‘viral mimicry’ response  
Initial investigations by the Walsh Lab noted that the UH4 cell line had upregulated expression 
of genes involved in ‘viral mimicry’ such as dsRNA sensors, transcription factors, anti-viral 
response, cell death and T-Cell signal (Figure 5.5A). Roulois et al (2015) have previously shown 
that the treatment of cells with low-dose 5-aza-2′-deoxycytidine (AZA) results in the activation 
of ‘viral mimicry’ in human colorectal cancer cells by inducing the expression of type III 
interferons (IFNs) and subsequent upregulation of interferon-stimulated genes (ISGs). We 





defence genes in STAT1 (Transcription factor), BST2 (Anti-viral response) and IFI27 (Cell death 
effects) (Figure 5.5B-D). 
Figure 5.5: Stable UHRF1 knockdown depletion results in upregulation of genes involved in viral mimicry like what is 
observed in low dose treatment of AZA in human colorectal cancer cells. (A) Average fold change from HT12 transcriptional 
array show expression of the viral defence genes vs WT cells Data generated by Dr. Catherine Scullion.  RT-qPCR expression 
analysis of HT29 human colorectal cancer cells treated as in 5-aza-2′-deoxycytidine (AZA) for (B) STAT1, (C) BST2 and (D) 
IFI27. qPCR was carried out in triplicate with technical replicates. Error bars indicate standard error of the mean. Significance 
carried out with a two-tailed T-test with the following key, *p < 0.05; **p < 0.01; ***p < 0.001. TFs; transcription factors, FC; 
fold change, DMSO; Dimethyl sulfoxide.  
5.5.5 Investigating the role of UHRF1 in imprinted maintenance in human  
By analysing the UHRF1-depleted cell line UH4 using the 450k Infinium beadchip array, it was 
clear that methylation was lost at a subset of imprinting gDMRs (Figure 5.6A). The DMRs 
GRB10 and SNURF showed the largest losses of methylation followed by the KvDMR, 
MKRN3_MIR4508 and ZNF597_NAA60 DMRs. The remaining DMRs analysed only observed 
small changes of methylation around +/-5%. Interestingly, rescuing the depleted hTERT-1604s 
with a plasmid containing UHRF1 (WT10) did not result in a recovery of methylation at the 





with pyrosequencing demonstrated a significant loss of methylation at both gDMRs in the 
UH4s and WT10 in comparison to the WT hTERT-1604s (Figure 5.6B). Loss of methylation 
observed at the UH4 imprinting DMRs GRB10 and SNURF resulted in significant loss of 
expression for both GRB10 and SNRPN in comparison to the WT hTERT-1604s. The imprints 
additionally failed to recover expression in the WT10 also showing a persistent significant loss 
of expression when compared to WT hTERT-1604s even more so than that in the UH4 cell line 
(Figure 5.6C).  
To further investigate the role of UHRF1 and implicate the PHD domain in the maintenance 
of genomic imprints, I attempted to generate an HCT116/HT29 KO and mutant cell line similar 
to the HEK293K mentioned above. As HCT116 appears to be more tolerable than that of the 
HEK293K counterpart, HCT116 and HT29 seemed like good models to attempt these edits for 
a second time (Liao et al., 2015; Rhee et al., 2000). Unfortunately, the PHD mutant had no 
clones grow from a single cell that contained the mutation, two HCT29 KO clones did show 
healthy growth and were seen with the KO CRISPR mutation. However, both clones did not 
show any signs of a successful KO during pyrosequencing and qPCR investigations (Appendix 







Figure 5.6: Depletion of UHRF1 in a differentiated human cell line results in loss of imprinting and failure to recover upon 
rescue. (A) Long term depletion of UHRF1 in the hTERT-1604 (UH4) cell results in loss of methylation at known imprinted 
DMRs as defined by Woodfine, Huddleston, and Murrell 2011 and Court et al. 2014 according to Infinium 450k beadchip 
array the UHRF1 rescue (WT10) failed to recover the loss of imprinting. (B) This loss of methylation was confirmed in GRB10 
and SNRPN in both the UH4 and WT10 cell lines using pyrosequencing. (C) The loss of methylation at the imprinted DMRs 
for GRB10 and SNRPN resulted in the loss of expression for the corresponding loci, however, these changes were unexpected 
for SNRPN (Glenn et al., 1996). On the other hand, the imprinting of GRB10 is more convoluted in human and has not been 
fully described but methylation at this homologous GRB10 DMR in mouse is linked with the repression of the gene (Hikichi 
et al., 2003). Pyrosequencing and qPCR experiments were carried out as duplicates with biological replicates. Error 
bars indicate standard error of the mean. Significance carried out with a two-tailed T-test with the following key, *p < 0.05; 





5.6 Discussion  
Here we showed that the mutation of the PHD domain of Uhrf1 in mouse embryos failed to 
gain methylation at the retrotransposable elements resulting in their subsequent activation, 
further contributing the current literature that suggests DNA methylation plays an important 
role for long term suppression of these elements. Further to this, we showed that in an adult 
human cell line that in a stable depletion of UHRF1 resulted in the derepression of the ERVs 
with repression upon the rescue of the WT UHRF1 protein. The PHD domain was then 
implicated further when the PHD mutant protein failed to rerepress the ERVs to the same 
extent of the WT protein. We then went on to be the first to show that a mutation at the PHD 
domain of Uhrf1 results in loss of imprinting at a subset of imprinted genes during embryonic 
development. Finally, we contribute to the current literature in regards to the recovery of 
imprinting in UHRF1 models by showing that UHRF1 and subsequent WT protein rescue does 
not result in the recovery of imprints in a chromosomally stable human adult fibroblast cell 
line.  
UHRF1 plays an essential role in maintaining methylation patterns throughout the genome. 
Since abnormal methylation patterns have long been associated with cancer, UHRF1, for this 
reason, is currently being actively researched as a potential therapeutic target for cancer  
(Baylin and Jones, 2016). AZA developed by Pískala and Šorm 1964 is a demethylating agent 
used in cancer therapy that is known to cause genome-wide promoter DNA hypomethylation 
and subsequent gene re-expression and anti-tumour changes in key cellular regulatory 
pathways (Tsai et al., 2012). AZA acts as a demethylating agent by incorporating into 
replicating DNA and covalently trapping DNMT1 and indirectly inhibiting it (Yoo et al., 2007). 
As well as anti-tumour changes in key regulatory pathways AZA is known to activate a ‘viral 
mimicry’ response targeting cancer-initiating cells by causing dsRNA expression (Roulois et 
al., 2015). Recent investigations from the Walsh lab found that the UHRF1 depletion in the 
hTERT-1604 also resulted in a viral mimicry state which is not shared by depletion of DNMT1 
in the hTERT-1604s. As mentioned in the introduction the Walsh lab previously carried out 
point mutation recovery experiments that implicated the PHD H3K9 binding, during this study 
we confirmed the stabilisation of the PHD mutation using a western blot. To further 





elements a PHD mutation was carried out in a mouse model using the same point mutation 
suggesting that the protein would still be stable. While the expression of Uhrf1 was normal it 
would be beneficial to confirm the stabilisation of the PHD mutant protein in the mouse 
model using a western blot. With the use of this model, it was possible to further show that 
the derepression of the retrotransposable element IAP occurs in mouse embryos at both 
e8.75 and e9.5 following mutations at the PHD domain of Uhrf1. Sequencing of the bisulphite 
converted DNA confirmed that the methylation lost was across several different IAP repeats. 
A knockout of SETDB1 carried out by Karimi et al (2011) in mESCs showed that ERVs lose 
H3K9me3 and results in their subsequent de-repression. This may help explain the loss of 
methylation caused by the PHD mutation as this domain is essential for the binding of Uhrf1 
to the H3K9me3 (Karagianni et al., 2008). Studies have shown a link between H3k9me3 and 
DNA methylation with some overlap being observed in mESCs (Karimi et al., 2011). However, 
in post-implantation, the correlation between DNA methylation and H3K9me3 is seen to be 
of greater importance (Wiznerowicz et al., 2007). Further studies have also noted that 
retrotransposon suppression in mice during preimplantation is mediated largely by SETDB1 
with DNA methylation having a greater role in post-implantation (Ecco et al., 2016; Matsui et 
al., 2010; Wiznerowicz et al., 2007). Previous studies have also revealed that KAP1 is recruited 
by the KRAB-ZNF transcription factor family to the ERV elements and plays an important role 
for their suppression (Ecco et al., 2016; Tie et al., 2018; Wiznerowicz et al., 2007). Further 
recruitment of the DNMT’s and SETDB1 have been observed to be partly dependent on KAP1 
(Ecco et al., 2016; Wiznerowicz et al., 2007).  
Similarly to the IAP elements, the methylated allele of ICRs is also normally associated with 
H3K9me3, which was observed to be selectively bound by ZFP57 and its cofactor KAP1 which 
co-immunoprecipitates with Uhrf1 (Quenneville et al., 2011). Therefore, this PHD mutation 
of Uhrf1 in mouse embryos proved to be an interesting model for a novel investigation into 
the role of the PHD domain in the maintenance of genomic imprints during embryonic 
development. Uhrf1 has been observed in playing a role in genomic imprinting and 
retrotransposable by being involved with both the maintenance and the de novo methylation 
at the genomic imprints as reviewed by Unoki (2019). This group showed that the loss of Uhrf1 
in fully grown oocytes only had a minuscule effect on the methylation at maternal ICRs except 





methylation at the ICRs in oocytes, the authors observed that Uhrf1 was involved with 25% 
of genome-wide de novo methylation in oocytes (Maenohara et al., 2017).  The KO of Dnmt1 
in oocytes only results in a small loss of methylation genome-wide and Uhrf1’s ability to 
interact with de novo Dnmt’s it is possible that Uhrf1 interacts with Dnmt3a during de novo 
methylation in oocytes (Maenohara et al., 2017; Meilinger et al., 2009; Shirane et al., 2013). 
However, preimplantation embryos lacking maternal Uhrf1 lost over 3/4s of their methylation 
at all ICRs examined. Interestingly the loss of maternal Dnmt1 in blastocytes had much less 
severe effect on the ICRs with only 50% of methylation being lost at the ICRs. Furthering this 
Maenohara et al (2017) witnessed large losses of methylation at the LINE1 and IAP elements 
in preimplantation embryos lacking maternal Uhf1. We furthered this work carried by 
implicating the PHD domain of Uhrf1 for the maintenance of retrotransposable elements and 
genomic imprinting during later stages of embryonic development.  
Furthering the de novo implication of Uhrf1 and recovery of methylation at a subset of gDMRs 
in Uhrf1 null mice rescued with the WT protein similar to the method later used by us for 
Dnmt3a2 (Qi et al., 2015; Thakur et al., 2016). Here we further explore the role of Uhrf1 in 
genomic imprinting by investigating the loss of imprinting in mouse embryos with PHD 
mutations at Uhrf1. While the loss of methylation is evident in the PHD mutation embryos the 
extent of the loss does not appear to be as severe as shown in mouse blastocysts lacking 
maternal UHRF1 in the study carried out by Maenohara et al (2017), suggesting that the 
complete loss of maternal UHRF1 is more severe to the maintenance of ICRs during early 
embryonic development. However, both the maternal knockout and PHD mutation of Uhrf1 
appear to have dramatic effects by presenting with partial preimplantation and embryonic 
lethality respectively (Maenohara et al., 2017). The worsened physiological effects observed 
in embryos at later stages could be due to the depletion of the maternal Uhrf1, as suggested 
in the case of DNMT1 mutants (Li et al., 1993): alternatively, the worsened abnormalities may 
also be caused by a domino effect of aberrant changes happening throughout the embryo 
developmental stages.  
To further understand the role of UHRF1 in genomic imprinting in humans, we studied the 
imprints in a UHRF1 depleted differentiated cell line named UH4. The UH4 cell model only 





and ZNF597_NAA60 DMRs. However, after rescuing the cells by transfecting a plasmid 
containing UHRF1 there was no recovery of methylation in the UH4s, unlike the somatic 
restoration of imprints as seen in mouse ESC  (Qi et al., 2015) suggesting it may not be possible 
in human. Secondly, the loss of methylation in the UH4s is not as widespread as what is 
observed in developmental models which may suggest that UHRF1 does not play as a vitally 
important role in maintaining imprinting status in differentiated cell models (Maenohara et 
al., 2017; Qi et al., 2015). While the depletion of UHRF1 appears to have a severe impact on 
the transposable elements as shown by Kong et al (2019),  the imprints may require a 
complete knockout in human cell models to cause a widespread loss of imprinting.  
The Walsh lab has previously attempted to generate two human cell model with (1) UHRF1 
knocked out and (2) a mutation at the PHD domain using the HEK293T cell line. However, this 
appeared to have lethal effects on the cells and no positive cells could grow from a single cell. 
Continuing from this we decided to use human colorectal cancer cell lines HCT116 and HT29 
as they have been previously reported to tolerate DNMT knock-outs which were observed to 
be lethal in hESCs suggesting they may have been a more suitable model for the UHRF1 
CRISPR edits (Liao et al., 2015; Rhee et al., 2000). However, after clonal expansion from 
mCherry positive single-cells separated using FACS, only two clonal HCT116 cell lines showed 
promise with single base-pair homozygotic frameshift mutations present within UHRF1 
resulting in altered expression of UHRF1. However, using LINE1 as a guideline of global 
methylation, the frameshift KO cells unexpectedly exhibited no loss of methylation at these 
repeats. Further investigations into the expression of genes known to be controlled by 
methylation and which have also been previously shown to be disrupted in UHRF1 depleted 
cell models exhibited no change of expression between the suspected frameshift mutant 
HCT116 cell lines and the WT HCT116.  Possible reasons for the false-positive effects observed 
in the HCT116 CRISPR edited cell lines could be that the UHRF1 locus could be aneuploid, 
which can be a common issue in tumour cell lines, additionally, the single base frameshift 
mutation may not have been sufficient to induce a phenotypical mutation (Barrangou et al., 
2015).   
We showed here that the PHD domain of UHRF1 plays a vital role in the maintenance of 





would have been valuable to further investigate the methylation at other imprinted DMRs 
and the expression of their respective imprinted genes. However, due to working with mouse 
embryos, the quantity of material was a limiting factor. Proceeding it may be beneficial to 
generate an mESC cell line from the PHD mutant mice if possible. This would not only remove 
the sample material limitation it would allow for further in-depth analysis. One such analysis 
could be to use CRISPR-CAS9 to correct the mutation at the PHD domain in an attempt to 
recover methylation and expression of the transposable elements and imprints which has 
been observed respectively by the Walsh lab and Qi et al (2015) in similar model systems. In 
an attempt to generate a true UHRF1 PHD mutant or KO in a human cell model, it may be 
beneficial to redesign the CRISPR-CAS9 sgRNA and plasmids and repeat the CRISPR to confirm 
that these edits are indeed lethal in these models. Further to this, it would be interesting to 
carry out other further UHRF1 domain edits using CRISPR to understand fully which domains 
are lethal when mutated in human cell models and the different effect they may have at 
methylation-dependent elements.    
5.7 Summary  
This chapter demonstrates that the PHD domain of Uhrf1 plays a role in maintaining 
retrotransposable elements and genomic imprinting during mouse embryonic development 
and appears to be highly lethal resulting in early embryonic termination around e9.5. Further 
to this, it could be seen that the depletion of UHRF1 causes loss of genomic imprinting at a 
small subset of imprints with failure to rescue upon recovery of UHRF1 in a human 
differentiated cell model. Finally, this chapter implies that mutations at the PHD domain of 
UHRF1 and/or the complete knock-out of UHRF1 is fatal to human developmental colorectal 
cancer cell models. It is clear that UHRF1 plays an important role in maintaining methylation 
at several different elements throughout embryonic development and in differentiated cell 
models, due to its implications shown here and in the literature it would be an interesting 
target for therapeutic interventions for diseases such as cancer and genomic imprinting 







Chapter 6- General Discussion  
6.1 Results Summary  
In this thesis, we have shown crosstalk across gametic and somatic DMRs in a long-term 
knockdown of DNMT1 in the chromosomally stable hTERT-1604s. This crosstalk to a certain 
extent shows a level of reprogramming in which the loss of methylation at a subset of gDMR 
leads to the gain of methylation at a corresponding sDMR at the same imprinted cluster. This 
unique mechanism hinted at a potential DMR at the promoter region of NLRP2, which upon 
further investigation showed preferential maternal expression and a potential paternal origin 
of methylation at the germline. Further to this, we demonstrated a possible statistical method 
in which to score ‘normal’ methylated DMRs against ‘abnormal’ by creating a methylation 
index. This methylation index was able to accurately flag disturbed regions in previously 
diagnosed patients and even identified a patient that was previously diagnosed with SRS as a 
misdiagnosis. Finally, we furthered the current understanding of UHRF1 in the maintenance 
of retrotransposable elements and genomic imprints using a mouse developmental model 
and a human differentiated model. The mutant mouse embryos indicated that the PHD 
domain of Uhrf1 plays a vital role in the repression of the retrotransposable elements as well 
as maintaining normal methylation and expression at the imprints during embryonic 
development. Consistent with this, the PHD mutant was observed to result in early 
termination in homozygotic mutant embryos. Furthermore, an shRNA depletion of UHRF1 in 
a human fibroblast cell line resulted in the loss of imprinting at a small subset of imprints with 
failure to recover upon the rescue of UHRF1. Finally, the CRISPR KO and PHD mutant of UHRF1 
appears to be lethal in human cell models due to the failure of establishing a true KO or 






6.2 Genomic Imprints 
6.2.1 DMR Hierarchy   
Somatic imprints are aptly named due to their unique establishment of the methylation mark 
after fertilisation. The mechanism for the de novo methylation at the sDMRs is still currently 
unknown, however, it is suggested that it may be guided by other epigenetic marks that were 
established during early development (John and Lefebvre, 2011). Further to this, the 
literature is heavily supportive that the establishment of methylation at the sDMR is very 
much dependent on the hierarchy interaction of the gDMR, as observed in a subset of 
imprinting clusters controlled by the gDMRs H19, KvDMR, IG-DMR and GNAS (Anwar et al., 
2012; Elli et al., 2018; Kagami et al., 2010; Srivastava et al., 2003). Figure 6.1 summarises our 
current understanding of the hierarchy system found between some gDMRs and their 
respective sDMRs. In the DNMT1 depleted hTERT-1604 cell model we showed a ‘methylation 
switch’ form of reprogramming at a subset of imprints which appears to be unique to the 
long-term knockdown of DNMT1. John and Lefebvre (2011) suggested that investigations into 
sDMRs may provide insight into de novo methylation outside gametogenesis and may help 
shed some light on the complicated mechanisms that are involved in gene silencing during 
embryonic development and differentiation.  
As mentioned sDMRs are relatively rare and correlate with gene promoters and transcription 
factor binding sites, higher-order chromatin structure, chromatin modifications and lncRNAs 
(Barlow and Bartolomei, 2014; Monk et al., 2019). It has been suggested that de novo 
enzymes targets sDMRs from epigenetic marks established in the germline, it has recently 
been proposed that H3K27me3 is responsible for this (Hanna et al., 2019). Once established 
the sDMRs are maintained by DNMT1,  in which DNMT1 is recruited to sDMR’s through an 
RNA-dependent mechanism to maintain the silencing of ubiquitously imprinted genes 
(Kanduri, 2016). This is interesting as it would be expected that the depletion of DNMT1 would 
result in the loss of this methylation, but using the hTERT-1604 DNMT1 and UHRF1 depleted 
models only the depletion of UHRF1 results in widespread loss of methylation at the sDMR 
while the DNMT1 depleted model either gains or maintains methylation at some sDMRs. The 





term depletion of DNMT1, this RNA dependent mechanism is still functionally active 
recruiting the remaining DNMT1 protein. Alternatively, the long-term loss of methylation 
originally caused by the DNMT1 depletion may result in epigenetic compensation such as 
histone modifications at the sDMRs re-establishing the mark to recruit de novo 
methyltransferases to the sDMRs (Barlow and Bartolomei, 2014). To investigate potential 
changes of epigenetic regulators such as histone modifications, binding of transcriptional 
factors, and continued binding of DNMT1 or recruitment of de novo enzymes at the sDMRs, 
would have to be investigated using tools like ChIP-Seq. Further to this to confirm whether or 
not the changes at the sDMR is dependent on the gDMR or epigenetic compensation would 
require further experimentation. However, understanding this mechanism may shed light 
into the complicated mechanism in gene silencing in embryonic development and 
differentiation.  
Figure 6.1: Schematic diagram describing the hierarchy of control of methylation at sDMR by the gDMR. As shown 
previously in a figure earlier in the thesis, the methylation at the gDMR is established in the germline, while the sDMR is 
established later during embryonic development. However, in this figure, it can be seen that one gDMR contains a hierarchal 
function over several sDMRs, with both the gDMR and sDMR being methylated on the paternal allele after birth. However, 
the loss of the gDMR before the establishment of methylation at the sDMR can lead to the loss of parental-specific 





Cross talk among primary and secondary DMRs has previously been associated in a number 
of patients with imprinting disorders with MLID: a study by Court et al (2013) observed 
changes of methylation at the gametic NESP-DMR were accompanied with loss of methylation 
at the nearby somatic GNAS-XL and GNAS-EX1A DMRs. We observed a similar hierarchal 
interaction between the H19 gDMR and the nearby sDMR IGF2_DMR0 in which all BWS 
patients with hypermethylation at the H19 gDMR were also observed to have 
hypermethylation at the IGF2_DMR0. Similarly, almost all SRS patients with hypomethylation 
at the H19 gDMR were observed with hypomethylation at the IGF2_DMR0. Moving forward 
it may be reasonable to suggest that altered methylation at the IGF2_DMR0 is a common 
disturbance in SRS and BWS patients and should be investigated using the normal MI. This 
interaction has been described previously in other studies in which the IGF2_DMR0 and 
IGF2_DMR2 were both seen gaining methylation along with the gametic H19 DMR in BWS 
patients and it has been suggested that the methylation for both IGF2 DMRs were established 
at the same time (Maeda et al., 2014).  Further confirming this interaction, it can be observed 
that the IGF2_DMR2 and IGF2_DMR0 are both hypomethylated in the DNMT1-depleted 
hTERT-1604s, following the same direction of loss of methylation at the gametic H19 DMR.  
While the IGF2_DMR2 has been associated with expression of Igf2 in mice, the function of 
IGF2_DMR0 remains unknown (Maeda et al., 2014; Murrell et al., 2001).  
Maintenance methylation and imprints 
In recent years it has been clear that DNMT1 is not sufficient for the maintenance of DNA 
methylation and requires all aspects of the PCNA/DNMT1/UHRF1 complex to faithfully 
maintain methylation, any disruptions to this complex has been observed to result in cancer-
specific methylation (Pacaud et al., 2014). Further to this interference with the UHRF1 
associated complex such as Histone deacetylase 1 (HDAC1), G9a and GLP also result in cancer-
specific methylation (Arzenani et al., 2011; Dong et al., 2008). As mentioned in the earlier 
chapters of this thesis UHRF1 plays a vital role in co-localizing DNMT1 to the hemimethylated 
DNA, so it is not a surprise that the interference with UHRF1 or its associated complex results 
in loss of maintenance methylation. However, while DNMT1 and UHRF1 work together to 
maintain methylation and result in a similar global loss of methylation when either protein is 





From previous work in the Walsh lab, it was observed that the depletion of UHRF1 in hTERT-
1604s resulted in a similar global loss of methylation in comparison to the DNMT1 depletion 
in the same cell model. However, the UHRF1 depletion resulted in a transcriptional state of 
‘viral mimicry’ due to a much greater upregulation at a few retroviral elements such as 
Interferon-Stimulated Genes (ISGs) than was observed in the DNMT1-depleted cell model. 
Similarly, the well-investigated imprinted DMRs such as GRB10, SNURF/SNRPN, KvDMR and 
H19 also appear to be more hypomethylated in the UHRF1 depleted hTERT-1604s than in 
their DNMT1 counterpart. As previously discussed this similar methylation response at the 
imprinted ICRs was reported in Uhrf1 null mouse embryos which were observed as having 
greater loss of methylation than was seen in Dnmt1 null mouse embryos (Maenohara et al., 
2017). 
6.2.2 Is the NLRP2 promoter region a novel DMR? 
The unique methylation pattern at the DMRs in the DNMT1-depleted hTERT-1604 model 
flagged the imprinted gene NLRP2 as having increased methylation at a previously described 
DMR and loss of methylation at the promoter region (Woodfine et al., 2011). As the promoter 
was not described previously as a DMR, further investigations were carried out at the NLRP2 
promoter region to verify its potential DMR status. While this investigation uncovered 
paternal specific methylation and maternal expression in aESC and phESCs, there were no 
other signs that this region was imprinted. A study by Baran et al (2015) claimed that NLRP2 
was a false positive due to picking up paternal and maternal monoallelic expression in their 
initial validation of imprinted genes in whole blood in the same tissues but across different 
samples, which I have termed as ‘unfaithful’. However, while Baran et al (2015) decided to 
write NLRP2 off as a false positive, it seems that the potential imprinting status of NLRP2 is 
more convoluted and potentially interesting than once believed. While not shown in the main 
body due to its conflicting nature with the parental ESC models, the promoter region of NLRP2 
in genome-wide uniparental disomic patients suggested paternal specific methylation. 
However, there was though no RNA-seq available to confirm if the expression had also 





It is hard to confirm whether this novel DMR present at the promoter region of NLRP2 is 
established in the germline or somatically without further testing. In support of the DMR 
being established in the germ-line, my study showed preferential methylation and expression 
bias in aESCs and phESCs which are believed to mimic levels of methylation seen in sperm and 
oocyte (Kim et al., 2007; Revazova et al., 2007). Furthering this, a study by Vértesy et al (2018) 
showed a higher expression in female germ cells than that observed in male, which would 
suggest that the promoter of NLRP2 in the male germ cells would contain higher levels of 
methylation and potential gametic establishment of the imprinted mark. However, this 
maternal specific expression only appears to persist into the early stages of pregnancy (Pilvar 
et al., 2019).  
6.2.3 non-canonical establishment of NLRP2 in the placenta 
A study carried out by Sanchez-Delgado et al in 2016 described a mechanism in which oocyte 
methylation survived past the blastocyst stage and persisted as transient DMRs. This would 
explain why Pilvar et al (2019) later detected monoallelic expression mostly during early-stage 
pregnancy but does not explain the ‘unfaithful’ monoallelic expression observed in somatic 
tissues (Baran et al., 2015). Interestingly NLRP2 appears to have a unique mechanism in which 
it can switch from biallelic expression to monoallelic expression during cellular 
reprogramming (Jeffries et al., 2016).  With this in mind if the monoallelic expression is lost 
after early pregnancy, later cellular differentiation may lead to reprogramming of a somatic 
DMR indiscriminately on one allele which would help explain the ‘unfaithful’ monoallelic 
expression described by Baran et al (2015). A similar model has recently been claimed to 
explain the establishment of a subset of sDMRs in which oocyte-derived H3K27me3 resulted 
in non-canonical and methylation-independent transient imprinting during preimplantation 
development (Figure 6.2). However, in the post-implantation extra-embryonic lineages a 
differential methylation mark I.E an sDMR is established as seen in Figure 6.2 (Hanna et al., 
2019). Figure 6.2 contains a graphical abstract that explains the loss of H3K27me3 and the 
gain of biallelic methylation or the maternal methylation in the embryonic and extra-
embryonic lineages respectively. Interestingly, H3K27me3 is lost on both alleles and 
methylation is the main repressor at these stages, however, the active H3K4me3 histone mark 





activation, widespread depletion of H3K27me3 occurs, suggesting that a similar imprinting 
model may be occurring in human as observed in mouse (Xia et al., 2019). Supporting this 
type of model for the novel NLRP2 DMR is an expression analysis study which showed a 
gradual decrease of expression in NLRP2 after fertilization and a gradual increase at day 5 
(Zhang et al., 2008). However, Hanna et al (2019) observed that these non-canonical imprints 
were localised to the retroviral elements such as endogenous retrovirus-K (ERV-K) and long 
terminal repeats which is not seen at this novel NLRP2 DMR, but a DNA repeat is present. 
Another possible explanation for its distorted imprinting status could be that it is polymorphic 
which may be due to an SNP leading to parental specific methylation pattern based on the 
parent it is inherited from. Whether or not these suggestions are plausible, or the region 
contains a mechanism not yet explored, further investigations are surely required if we are to 









Figure 6.2 Noncanonical establishment of somatic differentially methylated regions in early development. In the 
preimplantation embryo, the sDMR containing the retroviral element ERVK is hypomethylated and is expressed in a 
monoallelic fashion from the paternal allele with the repressed maternal allele being observed with enrichment of the 
repressive histone mark H3K27me3 while the paternal allele is enriched with the active H3K4me3 mark. However, the 
maternal H3K27me3 mark is gradually lost throughout preimplantation development and is completely lost at post-
implantation. However, in extra-embryonic lineages methylation is established only on the maternal allele resulting in 
repression of ERVK, while the paternal allele shows monoallelic expression of ERVK and is hypomethylated with H3K4me3 
histone enrichment. In the embryonic lineages, DNA methylation is established on both the maternal and paternal alleles 
and loss of the H3K4me3 mark resulting in the repression of the ERVK element. 





6.2.4 Imprinting disorders and diagnosis 
As the use of genome-wide technology increases in the investigation of imprinting disorders 
so does our understanding. One study investigating the prevalence of imprinting disorders in 
Estonia between 1998-2016 observed an increased prevalence of all imprinting disorders over 
this period, with an increased incidence of rare imprinting disorders in recent years which the 
authors suggest is due to advances in diagnostics and physician awareness (Yakoreva et al., 
2019). Similarly,  as research laboratories increasingly use genome-wide technologies during 
their investigations into imprinting disorders it is starting to become clear that there is a 
growing number of patients with imprinting disorders that suffer from MLID, rather their 
diagnosis being limited to one disease-specific locus (Eggermann et al., 2014; Eggermann et 
al., 2015c). One current issue with the investigation of DMRs as described by Monk et al 
(2018) is the definition of what is loss or gain of methylation. Along with this, the authors 
stated many points that would need to be answered which are (1) the statistical cut off (2) a 
number of controls required to define the ‘normal’ range (3) complications with mosaic 
epimutations (4) methylation variance at the CpGs within the DMR and (5) the reproducibility 
of the molecular techniques used. When investigating the possibility of using the Infinium 
bead-chip array as a tool for diagnosis of imprinting disorders, in doing so we defined a 
statistical cut-off for a normal range of methylation for a large set of DMRs. The MI defined 
in chapter 4 of this thesis for a set of ‘normally’ defined imprints in 100 samples answers the 
issues set by Monk et al in 2018 and was able to accurately score epimutations in previously 
diagnosed imprinting disorder patients as well as describing a potential misdiagnosis, 
presented in Figure 6.3. The MI I have described is dependent on the normal variability of 
methylation at each individual DMR across 100 patients, this means that with this MI would 
identify abnormal methylation that was completely dependent on the DMR. As an example, 
in Figure 6.3 has a normal variability between ~54% and ~63% at the H19 DMR, if a patient 
were presenting with H19 DMR methylation at 40% would be classed as abnormal using this 
MI. However, using the general characteristic of 35-65% this would still be within ‘normal 
methylation’ for an imprinted DMR. This is important as this would be a decrease of ~13% in 
methylation when compared to the normal blood sample with the lowest methylation value 
at the H19 DMR which is quite a steep decrease. It is also worth to note that another study 





supporting the fact that the DMR though within the normal characteristic range may still be 
abnormally methylated (Gicquel et al., 2005). However, on the other hand 40% would be 
classed as normal methylation for the PEG10 DMR as seen in Figure 6.3. It is easy to generalise 
imprinted regions with a generic methylation range of 35-65% due to the monoallelic 
methylation mechanism that they possess, while this range is suitable for initial 
characterisation of imprinted regions it is imperative that each region is investigated as 
individual regions. 
Figure 6.3: Graphical representation of the methylation index across select DMRs in blood. Using 100 patient blood samples 
the average methylation for each DMR was examined for viability. As the methylation at the DMRs across the samples was 
not normally distributed we settled on using the median and IQR to create a methylation index (MI). Using the 1.5 x IQR rule 
to find outliers we created the upper and lower limits which was applied to the commonly disrupted DMRs linked with 
imprinting disorders. The methylation inside the MI for each region highlighted green on the figure would be classed as 
normal variability, while outside the upper and lower MI highlighted red on the figure and labelled with ID (Imprinting 
disorders) would be classed as an outlier of normal variability for the region and therefore can be used to identify abnormally 
methylated DMRs. The MI was extended further with an extra + or -5% added to the upper and lower limit respectively to 
detect potential multiple-locus imprinting disturbances (MLID). This more stringent limit was implemented as these regions 
are not fully described in their functionality or implication within imprinting disorders and therefore we wanted to only 
identify more ‘extreme’ changes of methylation to increase the likelihood that the region is implicated with the imprinting 






Imprinting disorders are usually caused by aberrant methylation patterns present at the ICR 
of the imprinted loci. However, a sub-group of imprinting disorder patients are observed with 
epimutations at other loci which have been discussed as potentially altering gene expression 
at multiple imprinted loci, resulting in additional clinical features (Begemann et al., 2018). Due 
to these complications with MLID, research must focus on understanding the physiological 
effects that these epimutations outside the disease-causing loci cause and the mechanism for 
how they occur. Multiple studies have called for an urgent need for multi-locus imprinting 
disorder testing and improved diagnostics in general for imprinting disorders, with the bead 
chip array being discussed as a potential future diagnostic tool (Eggermann et al., 2014; 
Eggermann et al., 2016; Grafodatskaya et al., 2016).  
6.2.5 Multi-locus imprinting disorders 
As genome-wide analyses of imprinting disorders become more prominent patients with 
imprinting disorders are presenting with additional disturbances at imprinted regions outside 
the disease-causing loci, however, it is not known if and to what extent which MLID may or 
may not be affecting the phenotype of the imprinting disorder (Sanchez-Delgado et al., 
2016a). Maternal effect mutations in members of the subcortical maternal complex (SCMC) 
such as the PADI6, NLRP5 and NLRP2 have been observed in MLID (Demond et al., 2019; 
Meyer et al., 2009; Qian et al., 2018; Sparago et al., 2019). The SCMC in oocytes and 
preimplantation embryos has long been speculated to be involved in the establishment and 
maintenance of maternal imprints during early development. Maternal mutations in many of 
the members that make up the SCMC have been observed to cause loss of imprinting and or 
early embryonic termination. However, further investigations are required to fully 
understand the role of the SCMC in genomic imprinting (Monk et al., 2017). Interestingly as 
NLRP2 is one of the components of this complex it could help further support a role for the 
novel DMR in which the non-canonical imprinting mark being established at post-
implantation extra-embryonic ectoderm stage helps to control the gene dosage of NLRP2 






As mentioned NLRP2 has been associated with MLID: one mother contained a homozygous 
(Arg493SerfsTer32) variant of NLRP2 and had suffered 3 miscarriages and gave birth to two 
children, both afflicted with BWS and MLID. Both children were heterozygotes for the NLRP2 
variant (Begemann et al., 2018). Within the same study the authors discussed a mother with 
a predicted deleterious mutation in the TTD domain of UHRF1 (Val172Met), this mother gave 
birth to discordant monozygotic twins both with the UHRF1 variant. However, only one 
suffered from SRS with MLID while the co-twin was epigenetically normal. 
6.2.6 Retroviral elements and imprinting  
In the previous chapter, the role of the PHD domain of Uhrf1 was investigated in the 
repression of the retroviral element IAP in mouse embryos. This investigation along with 
previous investigations into Uhrf1 carried out by the Walsh lab agrees with much of the 
literature which describes a clear role for UHRF1 in the repression of transposable elements 
(Chernyavskaya et al., 2017; Kong et al., 2019; Sharif et al., 2007). The experiments carried 
out previously by the Walsh lab in the hTERT-1604 UH4 and recovery models, along with the 
results from the experiments carried out in this thesis, heavily implicates the H3K9 binding 
function by the PHD domain of UHRF1 in the repression of transposable elements and 
silencing of the inactive allele at genomic imprinted regions. However, one study by Sharif et 
al 2016 contradicts the implication of UHRF1 in the repression of the transposable elements, 
suggesting that in the absence of Dnmt1, Uhrf1 actually blocks Setdb1 from binding to the 
transposable elements and therefore blocks methylation-independent repression of the 
elements in mouse embryos. In support of Sharif et al 2016, a mouse liver regeneration model 
with a hepatic KO of Uhrf1 resulted in even further repression of IAP-d-int due to epigenetic 
compensation of H3K27me3 from active promoter regions to the transposable elements in 
Uhrf1HepKO mice (Wang et al., 2019). Wang et al (2019) carried this out by using flox sites 
flanking exons 6–10 which when recombined resulted in a stop codon, deleting the nuclear 
localization signal and all the domains required for DNA methylation. These mice were then 
crossed with mice expressing the Cre recombinase under the liver-specific albumin promoter 
backcrossed onto the Uhrf1fl/fl background to generate Uhrf1HepKO mice. The deletion of 
Uhrf1 resulted in the loss of methylation at the TE’s and epigenetic compensation of 





in further repression of IAP-d-int in comparison to quiescent Uhrf1hepKO Liver. However, 
while being the direct opposite that is observed in studies carried out by the Walsh lab and 
others this could be explained due to the difference in the experimental design of these 
studies. For example, one major factor which would not be affected in these two studies but 
would in our model system is maternal Uhrf1 in the mouse embryos, which plays a vital role 
in maintaining methylation in preimplantation embryos (Maenohara et al., 2017). A recent 
study has shown that Uhrf1 is important for the repression of retrotransposons in male germ 
cells in mice and that the cKO of Uhrf1 in germ cells also resulted in the upregulation of the 
imprinted loci Dlk1 and Gtl2 (Dong et al., 2019). 
 It was theorised by Denise Barlow in 1993 that the development of imprinting may have been 
due to the host defence system, a theory that has held up for a subset of imprinted loci as 
recently discussed by Ondičová, Oakey and Walsh, 2020. A recent study showed that parental-
specific methylation at 17 human-specific imprinted gDMRs is a consequence of transcription 
of the loci initiating in promoters of nearby lineage-specific endogenous retroviruses (ERVs) 
leading to de novo methylation in the oocyte (Bogutz et al., 2019). As briefly discussed above, 
retroviral elements have been observed which overlap with imprinting transcription start 
sites that have inherited oocyte H3K27me3. This histone mark was then gradually lost in the 
preimplantation embryo along with the rest of the genomic H3K27me3, then later methylated 
maternally in extraembryonic lineages, establishing sDMRs for the investigated imprinted 
regions (Hanna et al., 2019; Zheng et al., 2016b). Hanna et al (2019) later reviewed 
unexplained factors from their study which was that the (1) associated imprinted gene 
expression of the ERV elements was regulated? by the methylation, (2) why sDMRs were 
established at the regions instead of the maintenance or re-establishment of the H3K27me3 
and (3) the possible existence of unknown factors involved with either marking the inactive 
allele for methylation or protecting the active allele from methylation (Hanna, 2020). From 
recent studies, a subset of imprints has a clear overlap with retroviral elements and would 







6.3 Future direction  
6.3.1 Further characterization of the beadchip array and diagnosis of imprinting disorders 
Through the online bioinformatic software USEgalaxy, we have described a very bioinformatic 
friendly method to score imprinted DMRs in blood using the highly reproducible 450k array 
beadchip array, matched with the bespoke workflow designed by Thursby et al (2020). We 
have already made progress to investigate the more updated 850k epic array and seen a 
similar trend for scoring the imprinted DMRs in saliva. However, this was with a small sample 
size of 20 patients and may not be statistically representative as would be required for this 
type of work. Firstly, it would be paramount to greatly increase the sample numbers for the 
saliva investigation to get a large representation to ensure that the variability at each DMR is 
accurately accounted for. The reason for doing this in saliva over blood would be to create a 
non-invasive method to accurately diagnose imprinting disorders and fully investigate any 
underlying epimutations that may also have present as part of their disorder. Firstly, an 
accurate MI will have to be developed as described above. Once this has been completed and 
the DMRs and the defined MI is within the expected ranges it would have to be tested for its 
ability to identify epimutations in patients suffering from imprinting disorders. To do this, we 
would have to recruit a number of patients that have been previously diagnosed with an 
imprinting disorder and an epimutation at the disease-causing loci. The recruitment could 
also include a small subset of patients that have been diagnosed based on symptoms with no 
underlying epimutation at the known disease-causing loci to see if the saliva samples when 
analysed using the 850k epic array can identify epimutations in patients previously 
molecularly undiagnosed similar to the SRS study carried out by Prickett et al (2015).  
While being a powerful tool for the investigations of imprinting disorders and the potential 
use as a diagnostic tool for imprinting disorders as shown in this thesis. The increase used of 
the 850k beadchip array for diagnostic, would not only provide a reproducible and 
informative diagnostic test hopefully reducing the risk of misdiagnosis of imprinting patients 
due to overlapping features. It will also open up opportunities to further investigate the 
genome-wide impact at the methylation level and increase our current knowledge in patients 





lead to more effective treatment options. One aspect of imprinting disorders which will 
benefit greatly from a genome-wide methylation tool for diagnostics would be MLIDs if used. 
This would help to accurately represent the percentage of imprinting disorder patients that 
suffer from multiple epimutations, further allowing for researchers and clinicians to 
investigate and treat the patient based on the true extent of their methylome rather than just 
the disease-causing loci.  
6.3.2 Reprogramming of methylation at imprints  
As the recent research in the Walsh lab and the literature have both confirmed recovery of 
methylation at imprinted DMRs in mESCs models with the knockout and rescue of Dnmt3a2 
and Uhrf1 it is clear that under the right conditions methylation at the imprints are susceptible 
to imprinting outside the germline (Qi et al., 2015; Thakur et al., 2016). While UHRF1 KO and 
rescue did not have the same effects in our human cells and it was subsequently not explored 
in this thesis further, investigations into the recovery of methylation in the Dnmt3a2 rescue 
cell lines would provide vital information for understanding reprogramming of imprints in 
somatic tissues. Qi et al (2015) showed that there was no correlation between the recovery 
of methylation and common histone marks. However, as clearly shown in this thesis the 
knockout of Uhrf1 and Dnmts can have highly variable effects at the same loci. Therefore, this 
would be an opportunity for further exploration to confirm if histone marks are implicated in 
the recovery of methylation in our model system. Further to this, it would also be 
advantageous to rescue the Dnmt3ab KO mESC with clinically relevant point mutations in 
different domains of Dnmt3a2, this would help confirm what regions are required for the 
recovery of methylation at the imprinted DMRs. Keeping on the same direction if possible we 
could generate an mESC cell line from the Uhrf1 PHD mutant mice and rescue the mutant 
Uhrf1 and investigate whether the loss of imprinting can be recovered as observed in the 
article by Qi et al (2015). A further novel investigation that if successful could provide exciting 
data would be to attempt to differentiate the Dnmt3a2 rescued mESCs into a neurological cell 
line to see (1) if it is possible, (2) would the neuralization process recover methylation at DMRs 
that failed to gain methylation and (3) will the imprinted loci at the DMRs that did recover 
methylation but showed insignificant changes of expression between the KO and rescue cell 





While the novel switch of methylation between gametic and somatic DMRs in a human cell 
model with a long-term depletion of DNMT1 does not entail recovery of methylation at DMRs, 
it does appear to be a novel model describing possible cross-talk between DMRs within the 
same imprinted cluster. As already mentioned, wet lab investigations should be carried out 
at other imprinted loci that show the unique trend observed in this model. The model should 
also be further explored by examining the gametic and somatic DMRs for changes in histone 
modifications that may be occurring with the loss and gains of methylation at these DMRs. As 
this appears to be unique to the long-term depletion of DNMT1 in the hTERT-1604 these 
explorations into the histone modifications should also be carried out for the long-term 
depletion of UHRF1 and transient depletion of DNMT1 hTERT-1604 models for direct 
comparisons in an attempt to explain the differences in the models.  
6.3.3 Human model for imprinting  
While the hTERT-1604 cell line had benefits over other cell models used for human, such as 
being chromosomally stable etc, it is still restrictive in terms of being an accurate model due 
to experimental immortality. While the unique mechanism of gains of methylation at the 
sDMR is an exciting investigation observed in the DNMT1 depleted model, the hTERT-1604s 
do not appear to show expected changes of expression when methylation is lost at the DMRs 
in either the UHRF1 or DNMT1 depleted models, causing an obvious concern in terms of 
applying it to human imprinting disorders. Further to this more investigations will be required 
to fully understand the mechanism occurring at these sDMRs, for example confirming were 
the remaining DNMT1 protein in the depleted models are binding throughout the genome, 
this could be carried out using CHIP-seq analysis. Further to this CHIP-seq analysis may be 
carried out on the de-novo methyltransferases to see if de novo methyltransferases are 
responsible for the gains of methylation at the sDMRs. The Walsh lab has attempted to create 
UHRF1 KO/PHD mutant cell model in human ESCs and then in human colorectal cancer cells, 
however, it appears that these genomic edits by CRISPR in both cases appeared to have a 
lethal impact to the cells. A more suitable model would allow for more clinically relevant 
experiments to be carried out and help further the understanding behind imprinting and 
imprinting-like disorders in human. One way to carry this out would be to use primary blood 





examine how the imprints respond to the siRNA treatment and how they respond after 
several days once treatment has stopped. A further model which would not have time 
restrictions which would be imposed by the primary cell models would be to use human ESCs. 
This would allow for long term depletions to be carried out with an shRNA if tolerated, like 
that used in the hTERT-1604 models. If the depletion does not appear to be lethal this would 
be a good model to see if the long-term depletion of DNMT1 mimics the methylation pattern 
observed at the DMRs which was observed in the hTERT-1604 model. Further to this, a UHRF1 
depletion and rescue, if tolerated, would be a further model to investigate if recovery of 
methylation at the imprints could occur outside the germline in a chromosomally stable 
model, specifically in human.  
6.4.4 Characterizing the novel NLRP2 DMR 
The novel NLRP2 DMR, if indeed it is a true imprinted DMR, seems to have very complicated 
regulation, but it may have a similar mechanism of establishment as described by Hanna et al 
(2019), due to role NLRP2 plays in the SCMC and its expression pattern in the early embryo. 
As of now this thesis only describes a methylation bias at the NLRP2 promoter region using 
aESC and phESCs along with the unclear monoallelic expression described throughout the 
literature. However, while we indicate potential explanations, it would require intensive 
research to confirm these claims. Unfortunately, while NLRP2 is present in mouse it does not 
appear to be imprinted meaning no mouse models could be utilised (Kuchmiy et al., 2016).  
The promoter region of NLRP2 does not contain H3K27me3 in hESCs according to the UCSC 
histone modifications track, which is aligned with the model that this histone mark is lost and 
replaced with methylation as an sDMR in the post-implantation tissue (Hanna et al., 2019). 
Xia et al (2019) showed a pattern of transcription and asymmetric H3K27me3 marking 
occurring after fertilization in human. Using the extensive dataset published on the Gene 
Expression Omnibus (GEO) with accession number GSE124718, it would be possible to 
confirm if maternal H3k27me3 is inherited from oocyte after fertilization and is then slowly 
depleted at the novel DMR. This can then be matched to methylation at each stage using the 
dataset under GSE81233 which contains single-cell methylome data for both male and female 
gametes and methylome data from the 2-cell to post-implantation stage. Finally, using the 





single-cell RNA-seq from oocyte until late-stage blastocyst, one could link NLRP2 expression 
to any epigenetic changes observed in the previous datasets.  
6.4 Concluding remarks  
Using both wet-lab and bioinformatic techniques, I was able to investigate the loss of 
maintenance methylation of enzymes in normal adult cells as well as in mouse embryos in 
regards to genomic imprinting with the latter model also being used to investigate genomic 
retroviruses. My results add to the current knowledge of crosstalk among DMRs which can be 
observed at imprinting domains regulated by the hierarchical model. Further to this, I have 
described a methylation index to score normal methylation levels at several imprinted DMRs 
which can identify abnormal methylation at imprinted DMRs that are normally disturbed in 
imprinting disorders. Furthermore, here I showed that the PHD domain of Uhrf1 plays an 







Imprinted DMR Est MO Chr Start End Blood TS 
MI     
Upper 
MI   
Lower 
KvDMR1 G M chr11 2719948 2722259 57.98 27.91 66.04 49.04 
IGF2_DMR2 S P chr11 2153834 2155112 49.52 42.08 58.39 40.61 
IGF2_DMR0 S P chr11 2168333 2170145 57.18 53.46 66.15 48.39 
H19 G P chr11 2018812 2024740 59.20 55.83 63.95 54.29 
MEG3 S P chr14 101290524 101293978 59.58 18.20 64.79 53.90 
MEG8 G M chr14 101370741 101371419 68.89 84.56 80.09 56.03 
NDN G M chr15 23931451 23932759 50.99 52.52 62.15 37.88 
Table A1 showing methylation at chromosome 14 imprinted DMRs in a Temples syndrome patient sample similar to the 
misdiagnosed SRS patient. Methylation across imprinted DMRs associated with the respective diseases, methylation values 
with red underlining text showing gains of methylation outside the defined methylation index (MI) while blue underlined 
text shows loss of methylation outside the defined MI. The patient shows clear hypermethylation at the MEG8 DMR and 
hypomethylation at the MEG3 DMR, suggesting possibly mUPD14, there is also significant hypomethylation at the KvDMR 
which was also observed in the original study which the dataset (GSE78956) was generated. The blood sample displays the 
median methylation of the average methylation of the DMR across 100 control blood samples, while disease sample display 
mean methylation at the DMR as an individual sample. MO, Methylation Origin; Chr, Chromosome; Est, Established; G, Germ-














Imprinted DMR Est MO Chr Start End Blood 
TNDM 1 
MI     
Upper 
MI   
Lower 
FAM50B U M chr6 3849082 3850359 58.02 55.57 66.41 48.06 
PLAGL1 G M chr6 144328078 144329888 63.66 9.88 68.48 58.34 
PEG10 G M chr7 94284759 94287960 43.14 41.18 46.70 39.41 
HTR5A G M chr7 154862719 154863382 56.08 57.13 65.35 46.47 
GRB10g G M chr7 50848726 50851312 61.75 58.43 70.59 52.79 
MEST G M chr7 130130122 130134388 63.44 58.15 69.33 56.40 
KvDMR1 G M chr11 2719948 2722259 57.98 56.37 66.04 49.04 
Table A2 showing an expected epimutation at the PLAGL1 DMR in a Transient neonatal diabetes mellitus 1 patient 
samples. Methylation across imprinted DMRs associated with the respective diseases, methylation values with red 
underlining text showing gains of methylation outside the defined methylation index (MI) while blue underlined text shows 
loss of methylation outside the defined MI. The patient shows clear hypermethylation at the PLAGL1 which is the disease-
causing epimutation for this disorder. This matches the original study from which this dataset (GSE78956) was derived. The 
blood sample displays the median methylation of the average methylation of the DMR across 100 control blood samples, 
while disease sample display mean methylation at the DMR as an individual sample. MO, Methylation Origin; Chr, 
Chromosome; Est, Established; G, Germ-line; M, Maternal, P; Paternal; MI, Methylation Index; DMR, Differentially 






Figure A1: CRISPR models of UHRF1 PHD mutant models in both human embryonic kidney cells (HEK293) and mice. (A) 
PHD mutation introduced in the HEK293 cells, through CRISPR was successfully carried out resulting in mCHERRY expression. 
However, single-cell colonies would not grow suggesting lethality. (B) Figure as seen in 5.1. (C) sgRNA targeting the PHD 
domain of mouse Uhrf1. (D) DNA sequence trace from the tail DNA of a living WT, heterozygotic and homozygotic mouse 







Figure A2: UHRF1 KO clones do not show loss of methylation or changes of expression at methylation-controlled regions. 
The human colorectal cancer cell lines HCT116 and HT29 were used to try and generate a UHRF1 knockout (KO) differentiated 
human cell line model through the CRISPR-CAS9 technique. (A) After incubation with the plasmid to induce the UHRF1 KO, 
cells were identified using mCherry and separated using fluorescence-activated cell sorting (FACS). Cells were grown from a 
single cell, resulting in two HCT116 KOs containing a homozygotic gain (KO 14 (+1bp)) and loss (KO 23 (-1bp)) of a single base 
pair when the genomic sequence was analysed. (B) Using LINE1 as an indicator of genome-wide methylation there was no 
sign of loss of methylation for either KO14 and KO23 in comparison to the HCT116 WTs using pyrosequencing. In contrast, 
UHRF1 depletion resulted in a clear loss of methylation at the LINE-1 elements in UH4 compared to the hTERT-1604 WT. (C) 
Gene expression analysis using qPCR showed overexpression of UHRF1 when compared to the WT. However, IFI27 and 
GRB10 which are observed to be controlled by methylation show no alterations to their expression. As both clonal cells did 
not appear to cause any significant changes of methylation or expression no repeats were carried out and therefore statistical 
analysis for pyrosequencing assay was carried out using the value of each CpG site for 1 assay. Similarly, the qPCR, only 1 run 
was completed so the analysis was carried out on the results from the triplicate samples. Significance carried out with a two-
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